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Transcriptome analysis of amoeboid and ramified microglia isolated from 
the corpus callosum of rat brain: Microglia, the resident immune cells of the 
central nervous system (CNS), have two distinct phenotypes in the developing 
brain: amoeboid form, known to be amoeboid microglial cells (AMC) and 
ramified form, known to be ramified microglial cells (RMC). The AMC are 
characterized by being proliferative, phagocytic and migratory whereas the 
RMC are quiescent and exhibit a slow turnover rate. The AMC transform into 
RMC with advancing age, and this transformation appears to be indicative of 
the gradual shift in microglial functions. Both AMC and RMC respond to 
CNS inflammation, and they become hypertrophic when activated by trauma, 
infection or neurodegenerative stimuli. The molecular mechanisms and 
functional significance of morphological transformation of microglia during 
normal development and in disease conditions are not clear. It is hypothesized 
that AMC and RMC are functionally regulated by a specific set of genes 
encoding various signaling molecules and transcription factors. To address 
this, a cDNA microarray analysis of AMC and RMC isolated by laser capture 
microdissection from frozen tissue sections of the corpus callosum (CC) of 5-
day and 4-week old rat brain respectively, was carried out. The global gene 
expression profiles of both microglial phenotypes were compared and the 
differentially expressed genes in AMC and RMC were clustered based on their 
functional annotations.  
This genome wide comparative analysis identified genes that are 
specific to AMC and RMC. AMC showed expression of genes required for 
cell proliferation, differentiation and migration whereas the RMC expressed 
genes required for maintenance of synaptic integrity and neuronal maturation. 
Further, the gene expression profiles of both AMC and RMC showed high 
similarity to that of hematopoietic stem cells (HSCs) than to neural stem cells 
(NSCs) and embryonic stem cells (ESCs). The highlight of the expression 
profile is that the expression of inflammatory cytokines and chemokines by 




Expression and role of Sirtuin 3 in microglia: A high expression of Sirtuin 3 
(Sirt3), an aging-associated gene was identified in the AMC. Sirt3 is a protein 
deacetylase implicated in regulating cellular reactive oxygen species (ROS) 
levels. It has been shown that Sirt3 lowers cellular ROS levels by 
deacetylating forkhead box O 3a (Foxo3a), a transcription factor which 
becomes activated and transcribes antioxidant genes catalase (Cat) and 
manganese superoxide dismutase (mnSod). 
 The present study revealed that Sirt3 immunoreactivity was localized 
in the AMC distributed in the CC of the early postnatal rat brain and became 
hardly detectable in the RMC in the CC of the adult rat brain. Knockdown of 
Sirt3 mRNA expression in microglia was found to increase cellular and 
mitochondrial ROS and to decrease the expression of antioxidant, mnSod 
which is indicative of the importance of Sirt3 in ROS regulation. Additionally, 
Sirt3 overexpression led to increase in the expression of the transcription 
factor Foxo3a and the antioxidant Cat. It was observed that Foxo3a binds to 
the promoter of Cat and mnSod genes in microglia. These results suggested 
that Sirt3 regulates ROS by increasing the expression of antioxidants via 
Foxo3a-mediated antioxidant defense mechanism. In the in vivo traumatic 
brain injury rat model, Sirt3 expression was markedly induced in the activated 
microglia on the injured side of the brain as opposed to its hardly detectable 
expression in the ramified microglia on the non-injured side. In contrast, the 
expression of Sirt3 remained low in microglia of AD rat brains. This is 
indicative of the absence of Sirt3-mediated ROS attenuation in activated 
microglia thereby leading to aging-associated neurodegenerative diseases such 
as AD. The above results point to an antioxidant defense mechanism provided 
by Sirt3 in activated microglia. Hence, targeting Sirt3 may therefore prove to 













































The central nervous system (CNS) constitutes neurons and glia which include 
the macroglia i.e. astrocytes and oligodendrocytes, and microglia. The 
astrocytes and oligodendrocytes provide structural and metabolic support for 
the nervous tissue and myelinate the axons respectively, and the microglia 
protect the CNS from pathological stimuli. Microglia, the smallest of all the 
glial cell-types are the prime immune-effector cells of the CNS and make-up 
about 5 to 12% of the total glial cell population (Ling and Leblond 1973). 
Microglia were first identified by Nissl in 1889 (Nissl 1889). Thereafter, the 
origin, morphology and role of microglia in health and disease were 
elaborately described by Rio-Hortega in 1939 (Rio-Hortega 1939). Microglia 
are morphologically heterogeneous and broadly classified as amoeboid, 
ramified and activated based on their shape and function. The amoeboid 
microglial cells (AMC), which are abundant in the periventricular white 
matter, namely the corpus callosum (CC) of the brain, function as 
macrophages in the developing brain. It has been well demonstrated that AMC 
gradually transform into ramified microglial cells (RMC) with advancing age 
(Ling and Wong 1993). The time course of development of microglia differs 
in different regions of the brain (Orlowski et al. 2003). In the CC, AMC 
preponderate a week before birth in mice and rats (Leong and Ling 1992; 
Brockhaus et al. 1996; Hirasawa and Kohsaka 2007) and actively 
phagocytose the cellular debris and refine axonal connectivity during the first 
postnatal week (O'Leary et al. 1981; Innocenti et al. 1983; Hristova et al. 
2010). This is followed by the gradual transition into RMC, which survey the 
brain parenchyma with their fine and non-overlapping ramifications, thereby 
monitoring chronic and acute insults (Nimmerjahn et al. 2005). Upon 
activation by trauma, infection or neurodegenerative stimuli, microglia retract 
their ramifications, transform into amoeboid or spherical shape, produce pro-
inflammatory cytokines, present antigens to T-cells and phagocytose the 
cellular debris (Ling et al. 2001). These microglia are termed as ‗activated‘ or 
‗reactive‘. Once thought to be in a quiescent state, RMC in the healthy adult 
brain have now been shown to be highly dynamic and implicated in 
performing novel functions, some of which include re-modeling of synapses 




1.1 The origin of microglia 
Three different sources for microglial origin have been proposed: 1. 
Neuroectodermal 2. Mesodermal 3. Monocytic (Kaur et al. 2001). Of these, 
the latter two sources are now widely accepted. The proposal of  mesodermal 
origin of microglia suggests that primitive macrophages or precursor cells that 
develop in the yolk sac invade the brain parenchyma through the mesoderm 
(pial surfaces) between embryonic day 8.5 and 9.5 just before blood 
circulation is established (Kaur et al. 2001; Ginhoux et al. 2010). On the 
contrary, Ling (1979) demonstrated that the circulating blood monocytes 
transform into AMC which in-turn transform into RMC (Ling 1979; Ling and 
Wong 1993). A series of experiments showing the expression of monocyte-
specific enzymes (Ling et al. 1982; Kaur et al. 1984) and surface antigens 
(Perry et al. 1985; Ling et al. 1990) in microglia offered support to the 
monocytic origin of microglia. Furthermore, injection of cortisone or 
dexamethasone which reduces the production of monocytes in postnatal rats, 
led to decrease in the numbers of AMC in the brain (Ling 1982; Kaur et al. 
1994). Thus, it is clear that a first wave of microglial cell population arises 
from the yolk sac progenitors prior to establishment of blood circulation. This 
may be followed by the infiltration of circulating monocytes derived from the 
bone marrow into the brain parenchyma to form a transient microglial 
population i.e. AMC which later transform into adult microglia or the RMC. 






1.2 Functions of microglia 
 
1.2.1 Proliferation of microglia 
AMC have a high proliferative capability during the first two postnatal weeks 
in the developing rat brain (Imamoto and Leblond 1978; Ling and Wong 
1993).  This initial surge of microglial population in the CNS is followed by a 
gradual decline in their numbers as they begin to differentiate into RMC. It 
was estimated that about one-third of the total AMC transform into RMC and 
the rest of them undergo apoptosis (Imamoto and Leblond 1978; Ling and 
Wong 1993). In neuropathological conditions such as ischemia (Lalancette-
Hébert et al. 2007) and Alzheimer‘s disease (AD) (Gomez-Nicola et al. 
2013), activated microglia proliferate rapidly. Additionally, microglial 
proliferation is evident before the onset of disease symptoms in autoimmune 
disorders such as multiple sclerosis (Ponomarev et al. 2005).  
 A vital signaling event that regulates microglial proliferation is through 
the binding of colony stimulating factor (CSF1) to its receptor CSF1R. It has 
been shown that CSF1 is upregulated in the brain of an AD transgenic mouse 
model (Murphy Jr et al. 2000) and promotes the proliferation of microglia by 
binding to the CSF1R, which is solely expressed by microglia in the CNS 
(Erblich et al. 2011). A recent study showed the absence of microglia in the 
brain of mouse deficient in CSF1R (Ginhoux et al. 2010). CSF1R is in turn 
regulated by the C/EBPα-PU.1 transcription factors (Zhang et al. 1994; 
Zhang et al. 1996; Gomez-Nicola et al. 2013). Furthermore, silencing the 
expression of PU.1 in primary human microglia in vitro reduced the viability 
of microglia (Smith et al. 2013). These studies clearly established the 
importance of C/EBPα-PU.1 and CSF1-CSF1R signaling events in microglial 
proliferation. Other factors that promote microglial proliferation include 
interleukins such as IL-6 (Klein et al. 1997) and IL-1, and TNF-α (Kloss et al. 
1997), whereas one that strongly inhibits microglial proliferation is TGF-β 
(Jones et al. 1998).  
RMC in a healthy adult brain are quiescent and have a low turnover 




proliferative capacity of AMC, RMC and activated microglia is worth 
investigating to identify those key cell cycle regulating genes that are 
differentially expressed in these three forms of microglia. 
 
1.2.2 Production of cytokines, chemokines and other factors by microglia 
Cytokines and chemokines are signaling molecules that bind to their 
respective receptors on the cell surface for mediating cell-cell communication 
(Borish and Steinke 2003). Microglial cells upon activation can release, as 
well be targeted by cytokines and chemokines from neighboring cells 
(Hanisch 2002). Cytokines function as either pro- or anti-inflammatory. Pro-
inflammatory cytokines are mainly associated with activation and recruitment 
of microglia and peripheral immune cells in neuropathological conditions. 
Anti-inflammatory cytokines are released in order to dampen the 
inflammatory process and assist in tissue growth and repair (Hanisch 2002). 
Interleukin (IL)-1 is a pro-inflammatory cytokine which is produced by 
microglia during injury, infection and stroke, and mediates the CNS 
inflammatory mechanism (Rothwell 1991). However, excessive production of 
IL-1 by activated microglia has been a major concern in the pathology of 
several neurodegenerative disorders. Release of IL-1α and IL-1β by activated 
microglia has been shown to promote AD pathology (Li et al. 2003). 
Furthermore, in acute injury and ischemia, microglia-derived IL-1 binds to its 
receptor on neurons and glial cells, thereby causing cell death through 
activation of numerous cellular signaling cascades (Rothwell 2003). Tumor 
necrosis factor alpha (TNF-α), another widely studied pro-inflammatory 
cytokine released by activated microglia, is known to possess functions similar 
to IL-1 (Nakamura et al. 1999). TNF-α binds to its receptor, TNFR and 
promotes inflammatory process and influx of perivascular leukocytes into the 
CNS (Seabrook and Hay 2001). Microglia-derived TNF-α mediates neuronal 
death (Guadagno et al. 2013) and activation of nuclear factor kappa B (NF-
κB) pathway which upregulates the expression of several other cytokines 
including IL-1 (Aloisi 2001). Excessive TNF-α production by activated 




process such as AD (Weitz and Town 2012). On the other hand, anti-
inflammatory cytokines such as transforming growth factor beta (TGF-β) 
secreted by activated microglia reduces inflammation (Dheen et al. 2007). 
TGFβ suppresses microglial proliferation, and production of neurotoxic 
superoxides, TNF-α and IL-1β, in response to LPS or any other 
neuropathological stimuli (Pratt and McPherson 1997).  
Chemokines are molecules required for the chemotaxis or movement of 
immune cells to site of injury or infection (Luster et al. 2005; Krumbholz et 
al. 2006; Ubogu et al. 2006). Chemokines released by microglia help in the 
recruitment of peripheral immune cells such as T-cells and macrophages for 
the augmentation of the inflammatory process in the CNS (Babcock et al. 
2003). Subfamilies of chemokines include the CXC (CXCL8/IL-8, 
CXCL9/MIG, CXCL10/IP-10, CXCL12/SDF-1α), CC (MCP-1, MIP-1α/β and 
RANTES) and CX3C (CX3CL1/fractaline) and their receptors (Rock et al. 
2004). In addition to recruitment of peripheral immune cells, chemokines 
released by neurons promote the migration of microglia to the injury site 
(Yang et al. 2011). Cytokines such as TNF-α have also been shown to activate 
microglial cells to produce an array of chemokines and chemokine receptors 
(McManus et al. 1998).  
Microglia are capable of secreting a variety of other factors such as matrix 
metalloproteinases (MMPs) (Del Zoppo et al. 2007), cathepsins (Kingham 
and Pocock 2001), plasminogen activator (Nakajima et al. 1992), glutamate 
(Takeuchi et al. 2006) and growth factors (Thored et al. 2009). Factors such 
as MMPs and cathepsins are required for the dissolving or clearance of the 
extracellular matrix to facilitate the migration of activated microglia in CNS 
pathology (Lively and Schlichter 2013). A few cathepsins secreted by 
microglia are also involved in the breaking down of Aβ into harmless 
peptides, thus reducing the progression of AD (Mueller-Steiner et al. 2006). 
Microglia secrete neurotrophic factors such as insulin-like growth factor (IGF) 





1.2.3 Migration of microglia 
Microglia migrate during CNS development and injury (Nolte et al. 1996; 
Rezaie and Male 1999; Stence et al. 2001). The increase in microglial 
numbers around the injury site is mainly due to microglial proliferation and 
migration. Microglial movement is activated by chemokine molecules 
(chemotaxis) and facilitated by re-arrangement of microglial cytoskeleton and 
release of enzymes to degrade the extracellular matrix (Lively and Schlichter 
2013). The microglial motility in disease states has been shown to be regulated 
by the Rho family of small GTPases (Barcia et al. 2012). Recent studies have 
also identified novel structures called ‗podosomes‘ on microglial surfaces 




Microglia function as macrophages that phagocytose cellular debris and 
pathogens during CNS development, injury, infection, and aging. There are 
two types of cell surface receptors in microglia that trigger phagocytosis: the 
toll-like receptors (TLRs) that recognize infectious substances and the 
receptors that identify apoptotic signals from dying or injured neurons 
(Neumann et al. 2009). Microglia actively phagocytose unwanted synaptic 
connections during CNS development through the complement receptor C3 
expressed on their surface (Stevens et al. 2007). During CNS injury, 
microglial major histocompatibility complex (MHC-I) is involved in the 
phagocytosis of injured neurons (Cullheim and Thams 2007). Even in the 
absence of inflammation, microglia are active in recognizing and 
phagocytosing apoptotic neurons through the TREM-2 receptor (Takahashi et 
al. 2005). In an aging-associated neurodegeneration such as AD, microglial 
CCR2 (a chemokine receptor) aids in the recognition and clearance of amyloid 
beta (Aβ) aggregates (El Khoury et al. 2007). Phagocytosed debris by 
microglia are broken down in lysosomes, which are more acidic in activated 





1.3 Gene expression profiling using DNA microarray 
technology 
Gene expression profiling refers to the study of changes in the levels of 
mRNA transcripts to comprehend the functioning of a particular cell-type or 
tissue in a time-dependent or region-wise manner. Generation of mRNA 
profiles of different biological systems and disease states through the use of 
DNA microarray technology holds promise for the translation of lab-based 
research into development of new drugs and therapies (Copland et al. 2003).  
 
1.3.1 Principle of DNA microarray technology 
A microarray chip consists of thousands of DNA fragments attached to a solid 
surface through covalent bonding. Each fragment, also called a probe, 
represents a unique section of a gene. Total RNA extracted from the sample to 
be profiled is converted into cRNA or cDNA and tagged with biotin or 
fluorescence molecules. Labeled cRNA or cDNA is then allowed to sit on the 
microarray chip for a certain period of time. During this time, hybridization 
occurs between the cRNA or cDNA of the sample and their complementary 
probes on the chip. Any non-hybridized cRNA or cDNA is washed away from 
the chip. Hybridization intensity of cRNA or cDNA from the sample with the 
DNA fragments on the microarray chip is then measured using laser scanners. 
The raw hybridization intensities are interpreted as changes in the expression 
levels of specific genes leading to generation of gene expression profiles 
(Heller 2002; Murphy 2002).  
 DNA microarrays have single or two channel detection system. In a 
two-channel microarray, two different samples (control and test) can be 
profiled on the same chip by labeling the cDNA from the two samples with 
two different fluorescence probes (such as cy3 and cy5). The relative 
intensities of the two fluorescence labels reveals the upregulation or 
downregulation of genes in the test sample when compared with control 
(Shalon et al. 1996). In the case of single-channel microarrays, only one 




particular gene in test sample-treated chip versus control sample-treated chip 
reveals its upregulation or downregulation. Oligonucleotide microarrays 
developed by Affymetrix contain 11 pairs of oligonucleotides for every gene. 
Each pair, also called a probe set, has a perfect match (PM) and a mismatch 
(MM) probe. The PM probe is 100% complementary to the sequence of a 
particular gene. The MM probe differs from the PM only at the 13
th
 nucleotide 
which is substituted with another base. The inclusion of the MM probe is to 
eliminate signals due to non-specific hybridization (i.e. noise) (Lockhart et 
al. 1996). 
 
1.3.2 Generation of gene expression profiles 
Once the microarray experiment is performed, raw intensity files (DAT and 
CEL) generated from the microarray scanner contains intensity values for 
every probe on the chip. The location of the probe on the chip and its details is 
contained in a library file (CDF). These files are essential to carry out the data 
analysis. The data analysis involves the following steps: (1) background 
correction to eliminate noise, (2) data normalization using statistical methods 
such as robust multiarray average (RMA) and MAS 5 (Irizarry et al. 2003) 
and (3) statistical analysis such as t-test or ANOVA are applied to the 
normalized data to obtain gene lists with p values and fold change values. The 
gene list (gene expression profile) is subsequently used to determine gene 





1.4 Gene expression profiling in microglia 
Microglia undergo functional and morphological changes during development 
and in CNS pathologies (Olah et al. 2011). These phenotypic changes in 
microglia are believed to be regulated by a specific set of genes. Therefore, 
gene expression profiles of different microglial phenotypes are essential to 
identify as well as understand the function of various underlying genes in 
regulating this phenotypic transformation of microglia. Gene expression 
profiles of primary cultured microglia and microglial cell lines treated with 
different stimuli such as LPS, interferon-gamma and prion protein have so far, 
unraveled the genes important for the function of activated microglia. 
However, these profiles do not entirely represent the gene expression profile 
of activated microglia in vivo in various neuropathological conditions (Hurley 
et al. 1999). Furthermore, it should be noted that, the expression profiles from 
whole brain tissues reported in current literature may not represent the 
expression profile of microglial cells exclusively. This is due to the fact that 
these profiles also reflect the gene expression of other cell-types (neurons, 
astrocytes, oligodendrocytes) in the brain. Hence it is necessary to isolate and 
compare the gene expression profiles of different phenotypes of microglia in 
vivo in order to gain a holistic understanding of the molecular mechanisms that 
regulate microglial transformation and activation. Techniques such as laser-
capture microdissection (LCM) can be used to isolate microglia alone with 






1.5 Role of microglia in CNS disorders 
 
1.5.1 Microglia in aging-associated neurodegeneration 
Aging process causes priming of microglia and the primed microglial cells in 
aging rodent brains exhibit exaggerated inflammatory response when exposed 
to an external stimulus such as LPS or injury (Conde and Streit 2006; Luo et 
al. 2010). This leads to microglial senescence due to repeated proliferation of 
microglia (Flanary et al. 2007). Microglial senescence is also caused by 
persistent microglial activation over the years making them dystrophic, that is, 
incapable of self-renewal and phagocytosis (Streit 2006; Luo et al. 2010). A 
number of aging-associated neurodegenerative diseases involving memory and 
cognitive impairments have also been partially attributed to this microglial 
senescence (Schematic figure 1) (Streit 2006; Lucin and Wyss-Coray 2009). 
Studies in human post-mortem brains indicate that microglial senescence is 
associated with the progression of aging-related neurodegenerative disease 
such as AD (Streit 2006). In AD, chronic activation of senescent microglia 
mediated by the accumulation of non-phagocytosed amyloid beta (Aβ) 
augments neurodegeneration due to excessive production of cytotoxic 
substances such as reactive oxygen species (ROS) and TNF-α, a pro-
inflammatory cytokine by microglia (Qin et al. 2002; Dheen et al. 2005). 
Similarly, in Parkinson‘s disease (PD), aggregates of non-phagocytosed α-
synuclein and neuromelanin released from the dying dopaminergic neurons 
could potentiate microglia in releasing excessive amounts of ROS and pro-
inflammatory cytokines (Zhang et al. 2005). On the whole, aging brains 
contain senescent microglia, which are phenotypically different from those in 
healthy younger brains and appear to have lost their ability of effective 
clearance of toxic protein aggregates. The toxic protein aggregates either by 





















Schematic figure 1. The aging-associated neurodegenerative process 
perpetuated by chronically activated microglia (Conde and Streit 2006; 
Streit 2006; Dheen et al. 2007; Flanary et al. 2007; Lucin and Wyss-Coray 
2009; Luo et al. 2010). 
 
1.5.2 Microglia in brain injury 
Brain injury is characterized by cascades of several biochemical events 
resulting in long-term neurological impairments (Werner and Engelhard 
2007; Park et al. 2008). One of the biochemical events is persistent 
inflammation due to chronic activation of microglia which may last several 
years after the initial damage (Ramlackhansingh et al. 2011). Whether 
persistent microglial activation is beneficial or detrimental in brain injury is 
yet to be fully clarified. Some studies have shown that persistent microglial 
activation is useful for tissue repair in brain regions distant from the site of 
injury as these microglia secrete brain-derived neurotrophic factor (BDNF), a 
protein known to aid neuronal growth and survival (Nagamoto-Combs et al. 
2007). However, it has also been shown that chronic oxidative stress and 




































are known to be the prime cellular sources of reactive oxygen species (ROS) 
in the injured CNS (Dohi et al. 2010). 
 
1.5.3 Microglia in cerebrovascular disorder 
Stroke, caused by vascular blockade (ischemia) or hemorrhage in the brain 
involves excessive oxidative stress and inflammation brought about by 
activated microglia (Wood 1995). As in brain injury, microglia in stroke have 
been shown to exhibit both neuroprotective and neurotoxic functions. In an 
experimental model of ischemic stroke, activation of microglia leads to 
neuronal apoptosis by overproduction of TNF-α which is mediated by a 
transcription factor, NF-κB (Kaushal and Schlichter 2008). On the other 
hand, microglia have also been shown to promote neurogenesis in the 
ischemic brain by producing insulin-like growth factor-1 (IGF-1) which 
influences the differentiation of neural stem cells in the subventricular zones 
(SVZ). The microglia found in the penumbra region of the ischemic brain 
displayed a reduced inflammatory phenotype as opposed to those around the 
infarct zone, which appeared amoeboid and activated after stroke (Thored et 
al. 2009). 
 
1.5.4 Microglia in developmental disorders 
Involvement of microglial activation in CNS damage is not only limited to 
adult brain disorders, but also neonatal brain disorders. White matter damage 
in the developing brain of neonates due to reduced supply of oxygen (hypoxia) 
results in the death of oligodendrocytes causing disrupted or delayed axonal 
myelination, (Volpe 2001; Baud et al. 2004), thereby leading to epilepsy or 
cerebral palsy. Recent studies have shown the activation of microglia in the 
periventricular white matter of rat neonates exposed to hypoxia and suggested 
that these microglia could cause damage to oligodendrocytes via production of 
pro-inflammatory cytokines and reactive oxygen intermediates (ROI) (Deng et 





1.5.5 Microglia in CNS infections 
A variety of infectious agents such as bacteria (eg.Streptococcus pneumoniae) 
and virus (eg.Enterovirus) induce meningitis (Nau and Brück 2002) and 
neurodegeneration which is associated with overproduction of 
proinflammatory cytokines and ROS by microglia (Koedel and Pfister 1999; 
Rock et al. 2004). Microglia identify these infectious agents via their cell 
surface toll-like receptors (TLRs) such as TLR-4 and engulf them by 
phagocytosis (Lehnardt et al. 2002; Ribes et al. 2010). Identification of 
infectious agents by microglial TLR-2 prevents microglia-mediated 
neurodegeneration in neonatal meningitis. TLR-2 mediated caspase-8 
activation in microglia causes them to undergo apoptosis, and hence keeps a 
check on excessive inflammatory processes (Lehnardt et al. 2007). 
Microglial activity is also a prominent feature in HIV-associated 
dementia (HAD) since microglia have been shown to be the main cellular 
targets of HIV in the brain (Price et al. 1988). Furthermore, they harbor the 
virus and increase the viral load in CNS (Persidsky and Gendelman 2003). 
HIV is capable of entering microglia via the microglial CD4 and CCR3/5 
receptors (He et al. 1997) leading to formation of microglial nodules 
(Minagar et al. 2002). HIV-infected microglial cells produce an array of 
neurotoxic substances which include NO, TNF-α, and glutamate causing 
neuronal damage. However, it is important to note that, during early stages of 
HAD, activated microglia are neuroprotective as they clear the excess 
glutamate and produce antioxidants such as glutathione (Vallat-Decouvelaere 
et al. 2003). 
 
1.5.6 Microglia in other CNS disorders: Genetic and autoimmune diseases 
The severity of Huntington‘s disease (HD), a genetic disorder causing motor, 
cognitive and psychiatric defects is directly linked to the extent of microglial 
activation (Tai et al. 2007) and the density of reactive microglia, suggesting 
microglial toxicity in HD (Sapp et al. 2001). Similarly, microglia are 
implicated to cause neurodegeneration in familial amyotrophic lateral sclerosis 




express a mutant form of antioxidant protein, superoxide dismutase-1 (SOD-
1), leading to inefficiency in scavenging ROS (Boillée et al. 2006). Microglia 
themselves exacerbate oxidative damage in ALS by producing ROS mediated 
by their cell surface enzymes, NADPH oxidases (NOX) (Boillée and 
Cleveland 2008). 
 A characteristic feature of multiple sclerosis (MS), an inflammatory 
demyelinating disease, is the presence of lesions or scars, which contain 
activated microglial cells that promote myelin degradation (Li et al. 1996; 
Trapp et al. 1999). These microglial cells undergo oxidative bursts leading to 
production of peroxynitrite, highly reactive oxygen intermediate (ROI) which 





1.6 Drugs that attenuate microglial activation 
 
1.6.1 Retinoic Acid 
Retinoic acid (RA), a metabolite of retinoids, plays an important role in the 
development, functioning and regeneration of CNS (Drager 2006; Maden 
2007). RA functions by binding to its nuclear receptors namely, the RAR and 
RXR (subtypes: α, β and γ) which are expressed by microglia. RAR and RXR 
form heterodimers either with each other or with other nuclear receptors such 
as the peroxisome-proliferator activated receptor (PPAR) and bind to the RA 
response elements (RARE) in the promoter region of target genes for either 
transactivation or transrepression (Lane and Bailey 2005). It has been shown 
that the expression of RA receptors in microglia decreases with normal aging 
process suggesting a role for RA in microglia-mediated aging related 
neurodegenerative diseases (Enderlin et al. 1997). 
 Administration of RA to microglial cultures has been shown to 
attenuate microglial activation and thereby its inflammatory responses (Dheen 
et al. 2005). It has been shown that all-trans RA inhibits the production of 
TNF-α and inducible nitric oxide synthase (iNOS), an enzyme responsible for 
the production of NO in activated microglia by significantly suppressing the 
NF-κB activity (Dheen et al. 2005). A recent study showed that all-trans RA 
is effective in reducing Aβ accumulation, preventing neuronal loss and 
reducing microglial toxicity in an AD animal model (Ding et al. 2008). 
9-cis RA (another form of RA) binds to the RXR receptor and has been 
shown to suppress the expression of pro-inflammatory cytokines and NO by 
activated microglia (Xu and Drew 2006). A combined treatment of PPAR 
agonists and 9-cis RA inhibited the activation of microglia and prevented the 
progression of experimental autoimmune encephalomyelitis (EAE), an animal 
model of MS (Xu et al. 2005). However, use of either 9-cis RA or PPAR 
agonists alone was not as effective as the use of a combination of both in 
ameliorating EAE (Diab et al. 2004). Therefore, it seems that RA effectively 
inhibits microglial activation, when it is administered with drugs that can form 






Glucocorticoids (GCs) are immunosuppressive steroid hormones that function 
via binding to glucocorticoid receptors (GRs) present in the cytosol of target 
cells. GRs have been identified on microglia and the GC-GR complex is 
known to suppress the inflammatory response of microglia by acting on 
transcription factors such as NF-κB and activator protein-1 (AP-1) (Nissen 
and Yamamoto 2000; Bladh et al. 2005) and mitogen activated protein 
kinase (MAPK) pathways such as ERK-1/2, p38 and JNK (Kassel et al. 2001; 
Wang et al. 2008). GCs regulate a repertoire of microglial functions such as 
proliferation, migration, inflammation and production of ROS. GCs have been 
reported to inhibit the proliferation of amoeboid microglia in early postnatal 
rat brain and to promote their premature differentiation into the resting 
ramified morphology (Kaur et al. 1994). Dexamethasone, a synthetic 
glucocorticoid, effectively suppresses the expression of chemokine, MCP-1 
which assists the recruitment of microglia to the inflammatory sites, (Zhou et 
al. 2007), and Nox2-dependent ROS production from activated microglia 
(Huo et al. 2011). The expression of iNOS and NO production have also been 
shown to be inhibited in activated microglia exposed to GCs (Lieb et al. 
2003).  
On the other hand, the immunosuppressive effects of GC on microglia 
seem to be dependent on the dosage and duration of exposure. Several studies 
reported that a prolonged exposure to GCs promote microglial activation and 
inflammation. Activated microglia in vitro produced excessive quantities of 
pro-inflammatory factors if exposed to GCs for a longer durations (more than 
48 hours) (Brooke and Sapolsky 2002). Elevated levels of GCs can also 
promote proliferation of microglia via activation of N-methyl D-aspartate 
(NMDA) receptors (Nair and Bonneau 2006). A recent study demonstrated 
that microglial GRs play a pivotal role in PD pathogenesis. A selective 
knockout of microglial GRs led to a persistent activation of microglia and 
death of dopaminergic neurons which could not be rescued even upon 




understand the effectiveness of GCs in inhibiting microglial activation, future 
studies must be directed towards a collective understanding of the role of 
microglial GRs and effect of GCs on them. 
 
1.6.3 Minocycline 
Minocycline is a semi-synthetic bacteriostatic antibiotic which exhibits anti-
inflammatory properties. There are several modes of action of minocycline on 
microglia, one of them being via inhibition of MAPK pathway. In cultured 
microglia, minocycline inhibits p38 MAPK (Tikka and Koistinaho 2001). 
Minocycline has also been shown to reduce oxidative stress by directly 
neutralizing peroxynitrite (Schildknecht et al. 2011). Overall, minocycline 
scavenges ROS produced by microglia. On the other hand, recent studies 
reported that minocycline may be detrimental if administered after the onset of 
a CNS disease. After the onset of ALS, administration of minocycline 
promoted microgliosis (Keller et al. 2011). In a PD animal model, though 
minocycline administration led to reduction of microglial activation, it could 
not prevent neuronal death as minocycline could not limit the expression and 
function of TNF-α and its receptors (Sriram et al. 2006). Taken together, 
although minocycline could limit microglial activation to a certain extent, its 
toxicity following the onset of a CNS disorder becomes a major concern. 
 
1.6.4 Dimethylsphingosine 
Sphingosine kinase-1 (Sphk1) is involved in the phosphorylation of 
Sphingosine into Sphingosine-1-phosphate (S1P), which regulates a number of 
cellular functions (Taha et al. 2006). SphK1 is expressed in microglia and has 
been shown to be involved in inflammatory response of microglia (Nayak et 
al. 2010). Dimethylsphingosine (DMS) is an inhibitor of Sphk1 and the DMS-
mediated inhibition of Sphk1 in activated microglia suppresses the expression 
of pro-inflammatory cytokines such as TNF-α, IL1β and the production of NO 
(Nayak et al. 2010). It was further demonstrated that DMS-mediated 
inhibition of Sphk1 reduces microglial activation via inhibiting the activity of 




involvement of sphingolipid pathway molecules in microglial activation could 
be useful in identifying new drug targets that could regulate microglia-
mediated inflammation in the brain. 
 
1.6.5 Plant extracts 
Plant extracts such as costunolide, curcumin and resveratrol have been shown 
to be effective in inhibiting microglial activation. Costunolide (Cos), a 
sesquiterpene lactone extracted from Costus speciosus root exhibits anti-
inflammatory properties by inhibiting an array of microglial pro-inflammatory 
cytokines such as TNF-α, IL1, IL6, MCP-1 and enzymes such as COX-2 and 
iNOS via  inhibition of NF-κB and induction of MKP-1 (Rayan et al. 2011). 
Curcumin (1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-di-one), 
a principal constituent of turmeric has also been shown to inhibit microglial 
activation via downregulation of iNOS, COX-2 and MCP-1 by suppressing the 
JAK-STAT pathway (Kim et al. 2003). Resveratrol, (3, 4′, 5-trihydroxy-trans-
stilbene), a non-flavonoid polyphenol, is present in red wine and grape seeds. 
Resveratrol is an active ROS inhibitor which reduces oxidative stress in 
microglia by upregulation of Sirt1 (a gene known to be anti-aging and a 
member of the class III Histone deacetylase) and inhibition of MAPK 
pathways (Zhang et al. 2010). Pre-treatment of microglia with Ginsenoside 
Rg1 (Rg1), a component of the chinese herb, Panaxnotoginseng led to 
attenuation of LPS-induced microglial activation. It has been shown that Rg1 
can effectively activate microglial phospholipase C-γ1 signaling thereby 
inhibiting the production of an array of neurotoxic and proinflammatory 
molecules (Zong et al. 2012). Effectiveness of these plant extracts in 
controlling microglia-mediated neuroinflammation needs to be further 
established in animal models of neurodegeneration and neuroinflammation as 





1.7 Microglia and oxidative stress 
 
1.7.1 Reactive oxygen species and antioxidants 
‗Oxidative stress‘ is referred to as ‗an imbalance between the production and 
usage of reactive oxygen species (ROS), and the cell‘s ability to readily 
neutralize them. ROS are important for cell signaling as well as defense 
against invading pathogens (Babior et al. 1973; Esplugues 2002; Bokoch 
and Knaus 2003). However, excessive production of ROS by cells is 
detrimental as it can cause severe and irreversible damage to proteins (Berlett 
and Stadtman 1997), lipids (Halliwell and Chirico 1993) and DNA 
(Wiseman and Halliwell 1996) leading to death of neighboring cells. ROS 
are highly reactive molecules which include superoxide (O2
-
), hydrogen 
peroxide (H2O2), Nitric oxide (NO), peroxynitrite (ONOO
-
), hypochlorous 
acid (HOCl) and hydroxyl ions (OH
-
) (Nordberg and Arner 2001).  
Superoxide is generated by transfer/leakage of electrons to molecular oxygen 
from the respiratory chains of mitochondria and endoplasmic reticulum 
(Jastroch et al. 2010). It has been suggested that macrophages including 
microglia generate superoxide as a part of their defense mechanism for killing 
pathogens. Enzymes that belong to the nitric oxide synthase (NOS) family 
produce NO through the catalytic conversion of L-arginine to L-citrulline 
(Michel and Feron 1997). NO by itself is a useful signaling molecule as it has 
been shown to act as a gaseous neurotransmitter and also functions in the CNS 
as a neuroprotectant (Sinz et al. 1999, Esplugues 2002). However, in cells 
that are in a pro-oxidative state, NO can combine with other oxygen 
intermediates to form peroxynitrite which causes lipid oxidation. These toxic 
ROS are implicated to worsen CNS disease conditions (Calabrese et al. 
2007).  
ROS is neutralized by enzymes called ‗antioxidants‘. Antioxidants 
such as catalase, glutathione peroxidase and superoxide dismutase are 
activated upon cell stress due to increase in ROS which in turn neutralize them 
(Mates et al. 1999). Manganese superoxide dismutase (mnSod) is localized in 




peroxide. Hydrogen peroxide is then converted to water and oxygen either by 
catalase or glutathione peroxidase. Lack of cooperation between antioxidants 
could lead to reaction of hydrogen peroxide with NO to form peroxynitrite 
(Dringen 2005). 
 
1.7.2 ROS production by activated microglia 
Age-related build-up of oxidative stress is one of the major risk factors for the 
onset of several neurodegenerative disorders (Dröge and Schipper 2007) and 
microglia are the primary sources of reactive oxygen species (ROS) in the 
CNS following injury (Dohi et al. 2010), infection (Marques et al. 2008) and 
aging-associated degeneration (Wilkinson and Landreth 2006; Block et al. 
2007). Microglial cells in the aging brain produce excessive levels of 
mitochondria- and lysosome-derived ROS (Nakanishi and Wu 2009). 
Overproduction of ROS by activated microglia can cause detrimental effects 
on healthy neurons in their vicinity thereby leading to neurodegenerative 
diseases such as AD and PD (Block et al. 2007). Activated microglia also 
produce NO, superoxides generated by the NADPH oxidases (NOX), such as 
NOX-2 which is localized to the cell membrane and NOX-4 which is localized 
to the endoplasmic reticulum (Li et al. 2009; Huo et al. 2011). Treatment of 
microglia with LPS in vitro as well as in vivo led to upreguation of NOX-2 
and iNOS in microglia (Huo et al. 2011). Activated microglia were also found 
to produce excessive amount of NOX-dependent ROS following traumatic 
brain injury (Dohi et al. 2010). Schematic figure 2 summarizes the sources of 































Schematic Figure 2. Cellular sources of ROS in microglia (Adapted from Li 
et al. 2009; Nakanishi and Wu 2009; Huo et al. 2011). 
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Sirtuins are histone deacetylating enzymes (HDACs) that belong to class III 
HDACs. Sirtuins catalyze the removal of an acetyl group from a histone/ 
protein in the presence of nicotinamide (NAD
+
) (Schematic figure 3). Sirtuins 
comprise seven mammalian homologues: Sirt1-Sirt7. Earlier reports on the 
role of sirtuins in lower organisms such as Saccharomyces cerevisiae, 
Caenorhabditis elegans and Drosophila revealed that these proteins function 
as important regulators of life-span (Tissenbaum and Guarente 2001; 
Hekimi and Guarente 2003; Rogina and Helfand 2004). It is now known 
that sirtuins are localized to different sub-cellular organelles and are 
implicated in metabolic regulation, DNA repair, and regulation of cellular 
stress in mammals (Haigis and Guarente 2006). Knockout of any of the 
seven homologues of sirtuins leads to premature aging and/or reduced lifespan 
in mice (Finkel et al. 2009) suggesting that sirtuins are key regulators of life-





Schematic figure 3. Histone/ protein deacetylation catalyzed by Sirtuins in 
the presence of NAD
+
 (Adapted from Lavu et al. 2008).  
 
1.8.1 Functions and cellular localizations of sirtuins 
Each of the seven mammalian sirtuin homologues exhibits distinct spatial 
cellular expression and specific functions.  
 
1.8.1.1  Nuclear Sirtuins 
Sirt1, Sirt6 and Sirt7 are localized in the nucleus (Haigis and Guarente 
2006). Sirt1, the most well studied of all the sirtuins, functions as an important 
regulator of oxidative stress and longevity by catalyzing the deacetylation of 
forkhead box proteins (FOX), p65 (a component of NF-κB) and p53 activity 












Sirt1 regulates glucose homeostasis by promoting insulin secretion from the 
pancreatic β cells (Moynihan et al. 2005). Further, it promotes the nuclear 
translocation of Foxo1, which activates genes required for glucose synthesis 
during stress in the liver hepatocytes (Frescas et al. 2005). In the CNS, Sirt1 
is known to be important for the survival of neuronal cells. Both in AD and 
PD, Sirt1 upregulation in neurons is found to be neuroprotective (See 
Schematic figures 4 & 5) (Chen et al. 2005; Knutson and Leeuwenburgh 
2008; Lu et al. 2008). Sirt1 inhibits pro-apoptotic proteins such as p53 and 




Schematic figure 4. Sirt1 when over-expressed in neurons inhibits the Aβ-
mediated activation of NF-κB and thereby promotes neuroprotection in AD 







Schematic figure 5. Sirt1 when activated by resveratrol inhibits MPTP-
mediated loss of dopaminergic neurons in PD (Adapted from Knutson and 















Sirt6 monitors DNA damage and telomere dysfunction since cells 
lacking Sirt6 displayed chromosomal abnormalities (Mostoslavsky et al. 
2006, Cardus et al. 2013). It has also been shown that Sirt6 regulates glucose 
metabolism via insulin-like growth factor-1 (IGF-1) since mice lacking Sirt6 
became hypoglycemic with age and had low levels of IGF-1 in their blood 
(Mostoslavsky et al. 2006). Since IGF-1 is a neurotrophic factor important for 
learning and memory (Zhao et al. 2004), lack of Sirt6 in the neurons may lead 
to cognitive disorders. Sirt7 is localized in the nucleolus and is predominantly 
involved in the rRNA metabolism (Ford et al. 2006). Sirt7 expression is 
undetectable in tissues that have low proliferative capacity such as brain 
(Haigis and Guarente 2006). 
 
1.8.1.2  Cytosolic Sirtuin 
Sirt2 is localized in the cytosol and deacetylates cytoskeletal proteins such as 
tubulin. During cell cycle, it has been found to interact with chromatin and 
deacetylate histone H4 (Vaquero et al. 2006). In the CNS, Sirt2 was found to 
inhibit differentiation of oligodendrocytes (Li et al. 2007). A recent study has 
shown that neuronal Sirt2 may be implicated in age-related neurodegenerative 
disorders since its expression increases in neurons in the aging brain (Maxwell 
et al. 2011). 
 
1.8.1.3  Mitochondrial Sirtuins 
Sirtuins such as Sirt3, Sirt4 and Sirt5 are localized in the mitochondria 
(Huang et al. 2010). Sirt4 and Sirt5 have been shown to have a weak 
deacetylase activity and function as ADP-ribosyl transferases required for 
metabolic processes (Huang et al. 2010). The function of Sirt4 is similar to 
that of Sirt1, as it is involved in glucose homeostasis in liver and pancreas. 
The role of Sirt5 is still elusive in the context of mammalian cell-types. 
 
1.8.1.3.1 Sirtuin 3 (Sirt3) 
Sirtuin3 (Sirt3) was the first sirtuin to be localized to the mitochondrial matrix. 




Glatt et al. 2007; Halaschek-Wiener et al. 2009; Lescai et al. 2009). A 
number of studies identified the presence of Sirt3 polymorphisms as an 
important factor for lifespan extension and healthy aging in people who are 
over 90 years old (Glatt et al. 2007; Halaschek-Wiener et al. 2009). 
Furthermore, the expression of Sirt3 is high in metabolically active tissues 
such as the heart, brain, liver, and kidney (Jin et al. 2009). In the 
cardiomyocytes, Sirt3 was found to lower oxidative stress by deacetylation 
and subsequent nuclear translocation of forkhead box o3a (Foxo3a) 
transcription factor (Sundaresan et al. 2009). Foxo3a binds onto promoters of 
antioxidant genes, such as catalase (Cat) and manganese superoxide dismutase 
(mnSod) to promote their transcription (Sundaresan et al. 2009).  
Overexpression of Sirt3 reduces ROS production in the mitochondria of 
brown adipocytes (Shi et al. 2005). Sirt3 deacetylates and activates complex I 
of the mitochondrial respiratory chain, aiding in electron transfer and the 
subsequent synthesis of ATP. The absence of Sirt3 leads to leaking of 
electrons by the inactive complex I to molecular oxygen causing the 
generation of superoxides and hydrogen peroxide (Ahn et al. 2008). Recently, 
it has been shown that Sirt3 is a mitochondria-localized tumor suppressor and 
its absence induces mammary tumors in mouse models (Kim et al. 2010).  
Sirt3 is known to exist in two different forms: the long form and short 
form. The long form of Sirt3 is a 42 kDa protein and has an N-terminal 
peptide of 142 amino acids which is cleaved-off to generate the 28 kDa Sirt3 
functional enzyme (Onyango et al. 2002). Sirt3 is not exclusively 
mitochondrial as it was also found to reside in the nucleus and cytosol. Both 
long and short Sirt3 forms were found to be localized to nucleus in normal 
growth conditions and upon cellular stress, they translocate to the 
mitochondria (Scher et al. 2007). Though its function in the nucleus has 
remained elusive, Sirt3 can deacetylate histone H4 in vitro (Scher et al. 2007). 
In the context of microglia, the expression, cellular localization and function 





1.9 Animal models of neuropathology 
 
1.9.1 Traumatic brain injury rodent model 
Traumatic brain injury (TBI) occurs due to an external mechanical force such 
as an impact, penetration of an object or blast waves from an explosion, 
leading to primary and secondary brain damage (Maas et al. 2008). Primary 
damage involves shearing of white matter tracts (diffuse axonal injury), focal 
contusions and hematoma. This could be followed by a secondary damage, 
which involves a cascade of biochemical processes such as inflammation, 
oxidative stress, neuronal death and failure of ATP production due to 
mitochondrial dysfunction.  The secondary damage may last for days, months 
or even years after the initial insult and eventually cause temporary or 
permanent neurological deficits (Maas et al. 2008).  
In order to study the pathophysiology of TBI, four different rodent 
models of TBI have been developed: the fluid percussion injury (FPI), 
controlled cortical impact (CCI), weight-drop injury and blast injury (Xiong et 
al. 2013). Of all these models, the FPI and CCI are highly reproducible and 
can be used to produce both diffuse as well as focal injury (Xiong et al. 2013). 
In the FPI model, a pendulum held at a particular height is released to hit a 
piston leading to discharge of a fluid onto the brain surface (intact dura). The 
resulting fluid pressure on the brain surface leads to a focal injury on the 
cortical and subcortical (hippocampus and thalamus) regions. The pendulum 
release point may be adjusted to produce a mild, moderate or severe injury. 
Neuronal injury in the subcortical regions is initiated within minutes after the 
FPI and can persist for over a year. TBI is known to cause cognitive 
dysfunction in humans which is also observed in the FPI rodent model (Smith 
et al. 1991). 
 
1.9.2 Alzheimer’s disease rodent model 
Alzheimer‘s disease (AD) is an aging-associated neuropathological disorder 
characterized by the presence of neurofibrillary tangles (NFTs) or 




to cause loss of neurons in cortical and some sub-cortical regions 
(hippocampus) leading to memory and cognitive impairments (Querfurth and 
LaFerla 2010). NFTs are generated due to hyperphosphorylation of the 
neuronal cytoskeletal protein tau and Aβ is produced from the processing of 
amyloid precursor protein (APP) by β and γ-secretase enzymes. Both NFTs 
and Aβ can lead to AD through numerous biochemical events such as 
inflammation, failure of synaptic transmission, oxidative stress, mitochondrial 
dysfunction and loss of neurotransmitter production (Querfurth and LaFerla 
2010).      
 Several different transgenic AD rodent models have been developed to 
replicate and study the pathophysiology of AD. Transgenic AD models 
overexpressing APP displayed over 5 times the accumulation of Aβ in 
comparison to control animals. These animals had smaller hippocampus and 
corpus callosum; and displayed memory deficits when subjected to behavioral 
tests (Kobayashi and Chen 2005). Another type of AD animal model 
contained mutations in the enzyme presenilin 1 (PS1), which controls the 
activity of γ-secretase enzyme. These animals also showed a high build-up of 
Aβ peptides but did not display any behavioral deficits (Spires and Hyman 
2005). Similarly, AD transgenic models displaying NFTs have also been 
developed to study the pathology of AD (Götz et al. 2001). 
 Apart from its genetic basis, AD also develops sporadically without 
any familial basis and accounts for more than 95% of AD cases (Lecanu et al. 
2005). Chemically-induced sporadic AD rat model was developed by the slow 
release of ferrous sulfate heptahydrate, LButhionine-(S,R)-sulfoximine, and 
Aβ into the left ventricle of rats. These rats developed AD pathology rapidly in 
about 4 weeks and displayed Aβ plaques, hyperphosphorylated tau, neuronal 





1.10 Use of BV-2 microglia for in vitro experiments 
BV-2 cell-line was developed by immortalizing neonatal mouse microglia. 
Upon activation, both BV-2 cells and primary microglia displayed a similar 
inflammatory gene expression profile (Henn et al. 2008). Further, they show 
similarity to in vivo microglial cells and express receptors required for 
microglia-neuron and microglia-T cell communication. They also produce 
factors that enable them to communicate with other glial cells such as 
astrocytes (Henn et al. 2008). Difficulties in transfecting primary microglial 
cells for gene functional analyses led to their replacement with BV-2 cell line 





1.11 Use of lipopolysaccharide (LPS) for activation of 
microglia 
Lipopolysaccharide (LPS), an endotoxin is the cell-wall component of gram-
negative bacteria and a potent activator of microglia. LPS has been widely 
used to study the inflammatory response of microglia both in vivo and in vitro 
(Dheen et al. 2007). LPS binds to the TLR-4 receptor on microglia surface 
and activates the NF-κB pathway (Lu et al. 2008). This leads to binding of 
NF-κB onto promoters of several inflammatory genes such as TNF-α and 






1.12 Scope of the study 
The present work was aimed at studying the functions of AMC, RMC and 
activated microglia by: (a) Identifying the functional differences between 
AMC and RMC in the developing rat brain and (b) Exploring the 
developmental regulation and function of Sirtuin 3 (Sirt3) in the microglia. 
Until recently, microglia were viewed only as macrophages of the CNS. 
Further, microglia in the adult brain were thought to be resting, which act only 
when there is a pathological insult to the CNS. Recent studies have shown that 
both AMC and RMC have numerous diverse functions apart from protecting 
the CNS from injuries and invading pathogens. Some of these functions 
include development and maintenance of CNS and synaptic integrity and 
repairing worn-out neural tissue. The functional significance of the 
morphological transformation of AMC into RMC in the developing CNS is 
also not fully understood. In addition, the gene expression profiles of both cell 
types had not been elucidated systematically. It is hypothesized that 
morphological differences in postnatal AMC and adult RMC are 
functionally distinct and are regulated by a specific set of genes.  
In the current literature, microarray profiles of microglial cells exposed to 
different pathological stimuli in vitro only highlight the genes that are 
involved in the immune response of microglia. Additionally, the gene 
expression profiles of in vitro microglia do not entirely represent that of 
microglia in the healthy CNS. In order to address this gap in literature, AMC 
from 5-day old rat brain and RMC from 4-week old rat have been isolated 
using laser-capture microdissection (LCM), with minimal contamination from 
other cell-types in the brain, and analyzed by cDNA microarray in the present 
study. The significantly up- and down-regulated genes have been examined 
using pathway analysis software and compared with monocytic and stem-cell 
gene expression profiles to delineate the functions of AMC and RMC in the 
developing rat brain.   
In the event of pathology, microglia transform into an activated (reactive) 
phenotype and become the primary cellular sources of ROS in the CNS. Sirt3, 




However, the function of Sirt3 in microglial ROS regulation is not known. It 
is hypothesized that Sirt3 regulates ROS production in activated 
microglia. In view of this, expression and functional analysis of Sirt3 in 
activated microglia was carried out. Sirt3 expression has also been analyzed in 
microglia in vivo using healthy and neuropathological rat models. In vitro 
analysis using BV-2 microglial cell line has been performed to study the 
function of Sirt3 in regulating ROS production by activated microglia.   
The overall findings would provide novel insights into the mechanism of 
microglial function in the healthy developing brain as well as provide 
candidate targets to ameliorate excessive activation and ROS production by 





1.13 Aims of the current study 
1.13.1 To perform a transcriptome analysis of AMC and RMC isolated from 
the corpus callosum (CC) of 5-day and 4-week old rat brain 
Microglial cells exist in various phenotypes during development, in adulthood, 
in aged brain and disease. In the developing rat brain, microglia appear as 
rounded/ spherical cells until postnatal day 14 and thereafter become flattened 
cells with highly motile processes. The functional significance of 
morphological transformation of microglia during development is not clear. In 
addition, the gene expression profiles of both cell types had not been studied 
systematically. The main objectives of this study are as follows: 
 
1.13.1.1 To identify the genes that are differentially expressed in the 
AMC and RMC 
It is hypothesized that morphological differences in amoeboid and ramified 
microglia are functionally relevant and are regulated by a specific set of genes. 
To address this: 
a) Microarray analysis was carried out using laser-captured AMC and 
RMC from the corpus callosum (CC) of 5-day and 4-week old rat brain 
frozen sections respectively.  
b) The gene expression data was analysed using bioinformatics tools to 
identify significantly up- and down-regulated gene clusters in both 
AMC and RMC. 
 
1.13.1.2 To elucidate functions for AMC and RMC based on the 
transcriptome profiling 
Previous studies have shown the functional dissimilarities between AMC and 
RMC (Tremblay et al. 2011). AMC is proliferative and migratory whereas 
RMC is quiescent and maintains the homeostasis in the adult nervous tissue. 




a) Functional pathways enriched in AMC and RMC have been identified 
using pathway analysis software. 
b) AMC and RMC profiles were compared with gene expression profiles 
of circulating monocytes and stem cells. 
 
1.13.1.3 To identify and validate novel genes specific to AMC and 
RMC in vivo   
Several novel genes such as Runt-related transcription factor-1 translocated to-
1 (Runx1t1), Septins, doublecortin (Dcx) and Sox have been identified from 
the transcriptome profiling and validated using immunohistochemistry and 
qRTPCR in microglia in vivo. 
 
1.13.2 To characterize the function of Sirt3 that was found to be 
upregulated in the AMC in comparison to the RMC 
Sirtuin 3 (Sirt3) is known to be involved in life-span extension and regulation 
of ROS. The expression and function of Sirt3 was studied in microglia since, 
microglia are the primary cellular sources of ROS in the CNS (Dohi et al. 
2010; Marques et al. 2008; Wilkinson and Landreth 2006; Block et al. 2007). 
Specifically: 
a) The temporal expression pattern of Sirt3 from early postnatal to adult 
stages of rat brain was studied.  
b) Both in vivo and in vitro expression of sirt3 in microglia activated by 
lipopolysaccharide (LPS) was examined 
c) Functional analysis of Sirt3 was carried out in BV-2 microglial cells 
using siRNA-mediated knockdown and overexpression approach to 
study its effect on microglia-mediated reactive oxygen species (ROS) 
production.  
Lastly, the expression of Sirt3 in an acute brain injury model i.e. traumatic 
brain injury rat model and chronic neurodegenerative disease model i.e. 


































Wistar rats aged 1, 3, 5, 7, 14, and 21-day, 4-week and 2-month old were used 
in this study. They were purchased from Comparative Medicine (CM), 
National University of Singapore (NUS). While handling and treatment of 
animals, guidelines set by the Institutional Animal Care & Use Committee 
(IACUC), NUS were adopted (IACUC protocol # 059/11 and 080/10). The 
numbers of rats used in this study are listed in table provided below. 
 
Age Number Experiment 
5-day N = 3 Laser capture microdissection of 
microglia 
4-week (28-day) N = 3 Laser capture microdissection of 
microglia 
1, 3, 5, 7, 14, 21 and 
28-day 
N = 21 Temporal expression pattern of Sirt3 
5-day N= 6 LPS treatment 
4-week (28 day) N = 6 LPS treatment 
3-day  N=24 Primary microglia culture 
2-month N = 9 Traumatic brain injury (TBI) 
Total 72  
 
2.1.1 Collection of fresh brain samples 
5-day and 4-week old Wistar rats were anaesthetized by injecting 
pentobarbitone (Nembutal, 50mg/kg body wt) intraperitoneally (i.p.). The 
animals were tested for responsiveness by pinching their toes. Once animals 
were completely unresponsive, their heads were decapitated. An incision was 
made along the midline of the head to remove the skin. The skull was cut open 
and the whole brain was removed carefully and washed twice in sterile ice-
cold 0.1 M phosphate buffered saline (PBS). Whole brain was then placed in 




tilting, rapidly frozen in liquid nitrogen and stored at -80ºC freezer for long-
term tissue preservation. 
 
2.1.2 Treatment of animals with drug 
2.1.2.1  Materials 
Lipopolysaccharide (LPS) extracted from E. coli serotype O26:B6 (Cat No. 
L2762; Sigma-Aldrich‚St. Louis, MO, USA) 
 
2.1.2.2  Procedure 
Two injections of LPS (1mg/kg diluted in 250μl of saline per injection) were 
given to the 5-day and 4-week old rats intraperitoneally (i.p.) at an interval of 
6h. LPS injections were replaced by saline injections (250μl per injection) in 




2.1.3.1  Principle 
To perform immunohistochemical analysis, it is important to preserve the 
intact structure of tissues or organs. Fixatives such as aldehydes or alcohols 
are helpful in stabilizing cellular structures, nucleic acids and proteins thereby 
protecting them from damage and denaturation (Jamur and Oliver 2010). 
Fixation through the transcardiac perfusion is advantageous as the animal to 
be fixed does not die until the fixation process is complete allowing the heart 
to pump the fixative throughout the entire body including the brain (Paul et al. 
2008). 
 
2.1.3.2  Materials 
Paraformaldehyde (PF) (Cat. No. P001, TAAB Laboratories, UK)   
0.1M sodium di-hydrogen phosphate 





2.1.3.3  Preparation of Fixative 
In order to prepare 1000 ml of 0.1 M phosphate buffer, 800 ml of 0.1M di-
sodium hydrogen phosphate was slowly mixed with constant stirring to 200 ml 
of 0.1M sodium di-hydrogen phosphate and pH was adjusted to 7.4. 4% 
fixative solution was prepared by adding 40g of PF to 1000 ml of phosphate 
buffer by heating until the PF had completely dissolved. The fixative solution 
was then cooled by placing the container on ice and was stored in 4ºC. 
 
2.1.3.4  Transcardial perfusion of rats 
A cannula with a needle (23 gauge size) was attached to two containers filled 
with ringer‘s solution and fixative. The rat to be perfused was restrained and 
anaesthetized with pentobarbitone (i.p., 30mg/kg body wt). The anaesthetized 
animal was placed on the work surface, with its ventral surface facing upward. 
A toe-pinch response test was performed and once the animal was completely 
unresponsive, its position was secured by pinning the fore- and hind paws to 
the work surface.  Using a scalpel, an incision was made along the thoracic 
and abdominal midline. The diaphragm was cut and the ribcage was carefully 
reflected without causing any injury to the lungs. Ringer‘s solution was 
allowed to drip through the needle which was inserted into the left ventricle of 
the heart. Immediately, the right auricle was snipped using fine scissors. Once 
the flow from the right auricle was free of blood and the liver appeared pale, 
the ringer‘s solution was replaced with fixative. Following perfusion, the brain 
tissue was removed and placed in fixative for post-fixation for a period of 2h 
to 3h at 4ºC. The post-fixed tissue was then transferred to 15% sucrose 
solution (in 0.1 M phosphate buffer) overnight at 4ºC. 
 
2.1.4 Traumatic brain injury (TBI) rat model 
Wistar rats were anesthetized with Ketamine (75mg/kg) and Xylazine 
(10mg/kg) intraperitoneally (i.p.) prior to the surgical procedure. The 
anesthetized animal was mounted and restrained in a stereotaxic frame. A 
5mm hole was made at a location 4.5mm bregma and left lateral 3.0mm on the 




guide cannula. The bone was removed and bleeding was arrested. A head 
cannula was fixed rigidly with crynaoacrylate glue (dental cement) over the 
hole until the cannula abuts the dural surface. The head cannula was filled 
with sterile saline, making sure there are no bubbles. A pendulum was held at 
a specific height and released to strike a piston attached to the head cannula. 
Rapid injection of small volume of saline into the closed cranial cavity led to a 
severe focal damage in the ipsilateral cerebral cortex and hippocampus, 
generating a brief displacement and deformation of neural tissue. The pressure 
pulse was measured in atmospheres (ATM) by an extracranial transducer and 
recorded on a digital storage oscilloscope. Sham-operated animals received 
anesthesia and surgery, but were not subjected to trauma treatment. 
 
2.1.5 Alzheimer’s disease (AD) rat model 
Chemically-induced sporadic AD rat model which was developed by the slow 
release of ferrous sulfate heptahydrate, L-Buthionine-(S,R)-sulfoximine, and 
Aβ into the left ventricle of rat brain was kindly gifted by Taconic farms 
(USA). The rat brain supplier assessed the model by identifying the presence 
of Aβ plaques, hyperphosphorylated tau, neuronal loss, gliosis and memory 
loss. In order to check for neuronal degeneration, cresyl violet staining was 
performed to view nissl granules on hippocampal tissue sections of sham-
operated control and AD rat brains. 
 
2.1.6 Histology 
2.1.6.1  Preparation of gelatinized slides 
2.1.6.1.1 Materials 
Gelatin (Merck, Germany) 
Chrome alum (Chromium(III) potassium sulfate (Merck, Germany) 







Gelatin solution was prepared by addition of 9g of gelatin to 600 ml distilled 
water. This solution was heated with constant stirring until gelatin had 
completed dissolved. The solution was allowed to cool to room temperature. 
Meanwhile, the slides to be coated with gelatin were immersed in absolute 
ethanol and allowed to dry in a fume hood. Once the gelatin solution had 
cooled, 0.9g was added and the solution was stirred. The solution was filtered 
using Whatman‘s filter paper. Slides were then immersed for 1 minute in the 
gelatin solution and allowed to dry in a fume hood. The gelatinized slides were 
stored in a 37ºC incubator. 
 
2.1.6.2  Cryosectioning of brain tissues 
2.1.6.2.1 Materials and equipment 
Cryostat (Leica CM 3050, Leica-Microsystems, Wetzlar, Germany) 
MMI Membrane slides (Cat. No. 50103, Molecular Machines & Industries, 
Switzerland) 




The fixed and dehydrated brain tissue was trimmed to remove unwanted 
portions such as cerebellum and brain stem. A thin layer of embedding matrix 
was applied to a metal chuck and was frozen to a semi-solid state by 
immersing a portion of the chuck in liquid nitrogen. The brain tissue was then 
placed on the chuck and covered with embedding matrix. The tissue was 
rapidly frozen by immersing the tissue completely in liquid nitrogen. The 
frozen tissue sample was placed in the cryostat with a chamber temperature 
(CT) of -15ºC and an object temperature (OT) of -10ºC.  
The fresh forebrain embedded in OCT was sectioned coronally through 
the corpus callosum (CC) at 5μm thickness and mounted on metal slides for 




in -80ºC. The fixed brain tissue embedded in embedding matrix was sectioned 
coronally through the corpus callosum (CC) at 30μm thickness and mounted 
on gelatinized glass slides for performing immunohistochemistry. These slides 
were allowed to dry in room temperature and then stored in -20ºC. 
 
2.1.6.3  Microtome sectioning of AD rat brain tissues 
2.1.6.3.1 Materials and instrument 
Microtome (Model No. RM2165, Leica, Germany) 




Clearene (Cat. No. 3803600, Leica Biosystems, USA)  
Proteinase K (Cat. No. 21627, Chemicon international, MA, USA) 
Tissue processor (Model No. ATP700, Histo-Line Laboratories, Italy) 
 
2.1.6.3.2 Procedure 
10% formalin fixed sham-operated and AD rat brains were provided by 
Taconic Farms, USA. These brain tissues were paraffinized in a tissue 
processor. The paraffinized tissue blocks were sectioned coronally through the 
hippocampus at 7µm thickness in a microtome and mounted on silane-coated 
glass slides. For preparation of silane solution, 6ml of silane was mixed with 
294ml of 100% ethanol. Glass slides were cleaned in 100% ethanol and 
immersed in silane solution for 2 minutes. Thereafter the slides were dried at 
60ºC for 1h in an incubator. The dried silane-coated slides were stored in room 
temperature. 
 For immunohistochemistry, the slides were de-paraffinized by 
immersing them in 3 changes of clearene for 5min each. This was followed by 
immersing the slides in a graded series of ethanol and finally washed 
thoroughly in deionized water. For antigen retrieval, tissues were incubated 




2.1.6.4  Immunohistochemistry 
2.1.6.4.1 Principle of immunohistochemistry 
Immunohistochemistry is the process of detecting a particular antigen 
(protein) using a primary antibody specifically raised against the antigen. A 
secondary antibody (tagged with an enzyme such as alkaline phosphatase or 
horseradish peroxidase) specifically raised against the primary antibody is 
incubated on the tissue for a certain period of time. The resultant antigen-
antibody complex is detected by incubating the tissues in a chromogenic 
substrate such as diaminobenzidine (DAB) yielding a brown color on the 
tissue wherever the antigen is present (De Matos et al. 2010). In fluorescence 
immunohistochemistry, the secondary antibody is tagged with a flurochrome 
such as fluorescein isothiocyanate (FITC) or Cyanine (Cy3/ Cy5). The 
antigen-antibody complex can be visualized upon illuminating the tissue under 
laser light at specific excitation and emission wavelengths and can be viewed 
under a confocal microscope (Fritschy and Härtig 2001). 
 
2.1.6.4.2 Materials and instrument 
Diethylpyrocarbonate (DEPC)-treated water 
0.1M Phosphate buffered saline (PBS; PB0344, Vivantis, Malaysia) (pH 7.4) 
Peroxidase conjugated isolectin (1:50; Cat. No. L5391, Sigma-Aldrich, MO, 
USA)   
DAB solution 
30% Hydrogen peroxide (H2O2) solution 
MMI isolation caps (Cat No. 50202, Molecular Machines &Industries, 
Switzerland) 
MMI CellCut (Molecular Machines & Industries, Glattbrugg, Switzerland) 
Rabbit anti-Sirt3 antibody (1:100; Cat. No.sc-99143, Santacruz 
Biotechnologies, CA, USA) 
Mouse anti-OX42 antibody (1:50; Cat No. CBL1512, Millipore, MA, USA) 





FITC-conjugated goat anti-mouse IgG (1:100; Cat No. 5024, Millipore, MA, 
USA) 
4‘, 6- diamidino-2-phenylindole dihydrochloride (DAPI; Cat. No. D3571, 
Molecular Probes, Invitrogen, Carlsbad, CA, USA) 
Fluorescent Mounting Medium (Cat No. S3023, Dako, Carpinteria, CA, USA) 
Normal goat serum (Cat. No. S1000, Vector labs, CA, USA) 
 
2.1.6.4.3 Procedure for staining microglia on fresh brain sections 
The frozen sections prepared for laser capture microdissection, were washed 
in PBS three times for less than a minute. The sections were then fixed in 75% 
ethanol for 1min and incubated with peroxidase conjugated isolectin for 
15min. The sections were then dehydrated by a graded series of ethanol and 
xylene. The sections were placed in a jar containing DAB solution and 
incubated until a brown color developed which was indicative of the 
localization of lectin positive microglia in the tissue sections. The entire 
procedure was completed in less than an hour to minimize denaturation of 
RNA.  
 For laser-capture microdissection of microglia, the slides were placed 
on the microscope stage of MMI CellCut. The isolation caps (for collection of 
laser-cut cells) were placed right above the CC region where microglial cells 
are found in abundance. Lectin-stained microglia cells (AMC from 5-day and 
RMC from 28-day old rat brain CC) were selected and cut by laser and 
collected into the isolation caps. Extra care was taken to minimize the 
contamination of materials from other cell types while laser dissecting 
microglia from the CC. 
 
2.1.6.4.4 Procedure for immunofluorescence staining of microglia on 
fixed brain tissues 
Fixed frozen tissue sections were washed in PBS and blocked with 5% normal 
goat serum at room temperature for 1h. A primary antibody cocktail of anti-
OX42 (1:50) and anti-Sirt3 (1:100) was prepared in PBS. Tissue sections were 




tissue sections were washed in PBS and incubated with a secondary antibody 
cocktail of anti-mouse FITC (1:100) and anti-rabbit Cy3 (1:100) for 1h. After 
this, the sections were washed in PBS and incubated with DAPI (1:5000) to 
stain the nucleus. The sections were washed with PBS and mounted in 
fluorescent mounting medium. The slides were protected from light and later 
viewed under a confocal laser-scanning microscope (Model Fluoview FV-





2.2 Microarray analysis of laser-captured microglia 
2.2.1 Principle of microarray experiment 
A microarray experiment is performed to identify gene expression changes on 
a high-throughput basis. This procedure involves the basic principle of nucleic 
acid hybridization. A microarray chip is made up of thousands of 
oligonucleotides attached onto a solid surface. RNA is extracted from the 
sample to be profiled and converted to cDNA by reverse transcription. The 
cDNA is converted to cRNA by in vitro transcription with fluorescence or 
biotin tags. The biotin-labeled cRNA is spotted on the microarray chip for 
hybridization for a certain period of time and the non-hybridized cRNA is 
washed away. Finally, the microarray chip is scanned under laser light and the 
images obtained are analyzed (Heller 2002; Murphy 2002). 
 
2.2.2 Procedure 
2.2.2.1  Extraction of RNA from laser-captured microglia 
2.2.2.1.1 Principle of RNA extraction 
The traditional method for the isolation of total RNA from tissues and cells 
utilizes guanidium isothiocyanate for lysis of proteins and inhibition of 
RNases and the phenol-chloroform method for separation RNA from DNA 
into aqueous and organic phases (Chomczynski and Sacchi 2006). The 
RNeasy kit developed by Qiagen is an incorporation of guanidine-
isothiocyanate lysis methodology and a silica-membrane based purification 
process. 
2.2.2.1.2 Material 
QIAzol Lysis Reagent (Cat. No. 79306, Qiagen, Germany) 
RNeasy mini kit (Cat. No. 74106, Qiagen, Germany) 







Firstly, the laser-captured microglial cells were lysed using a 
phenol/guanidine-based QIAzol Lysis reagent which inhibits RNases from 
denaturing RNA. The lysate was mixed with 70% ethanol and applied to the 
RNeasy silica-membrane spin column as ethanol sets-up the appropriate 
binding conditions. RNA longer than 200bp was bound to the silica membrane 
aided by application of a high-salt buffer. Unnecessary substances were 
washed away. Finally, RNA was eluted in 20µl of nuclease-free water. After 
extraction, RNA quality and concentration was determined using a 
sphectrophotometer before proceeding for cDNA conversion. The absorbance 
ratio (A260/A280) within a range of 1.8 to 2 indicates good quality RNA with 
minimum or free of contamination. 
 
2.2.2.2  Synthesis and clean-up of double stranded cDNA 
2.2.2.2.1 Materials 
GeneChip® HT One-Cycle cDNA Synthesis Kit (Cat. No. 900431, 
Affymetrix, CA, USA): 
50µM T7-Oligo(dT) primer:  
5X 1st strand reaction mix  
0.1M Dithiothreitol (DTT) 
10mM dNTP mix  
SuperScript™ II reverse transcriptase (200 units/µl) 
5X 2nd strand reaction mix 
E.coli DNA polymerase I (10 units/µl) 
E.coli DNA ligase (10 units/µl)  
RNase H (2 units/µl) 
T4 DNA polymerase (5 units/µl) 
0.5M Ethylenediaminetetraacetic acid (EDTA)  
5X T4 DNA polymerase buffer 
 





cDNA Cleanup Spin Columns 
cDNA Binding Buffer 
cDNA Wash Buffer 
cDNA Elution Buffer 
1.5 mL Collection Tubes (for elution) 
 
2.2.2.2.2 Procedure 
In order to synthesize cDNA from RNA, 5µg of total RNA was mixed with 
2µl of T7-Oligo(dT) primer and the mixture was incubated at 70ºC for 10min 
in a water bath. The tube was centrifuged briefly to collect the entire liquid at 
the bottom of the tube. Then this mixture was added with 4µl of first strand 
reaction mix, 1µl of dNTP mix and 2µl of DTT and incubated at 42ºC for 
2min. Further, 1µl of superScript™ II reverse transcriptase was added to the 
mixture which was again incubated at 42ºC for 1h to synthesize first strand 
cDNA. 
 For the second strand cDNA synthesis, the 1
st
 strand cDNA synthesis 
mixture was mixed 3µl of dNTP, 1µl of E.coli DNA ligase, 4µl of E.coli DNA 
polymerase I, 1µl of RNase H and 30µl of 5X 2nd strand reaction mix and the 
mixture was made up to a total volume of 150µl with DEPC-treated water. 
This mixture was incubated at 16ºC for 2h, then added with, 2µl of T4 DNA 
polymerase and incubated for 5min at 16 ºC. Finally, the reaction was stopped 
by adding 10µl of EDTA.  
162µl of cDNA synthesized from total RNA was added to 600µl of 
cDNA binding buffer and mixed by vortexing. This mixture was transferred to 
a spin column and centrifuged at a speed > 10,000 rpm for 1min.The flow-
through was discarded and 750µl of cDNA wash buffer was added to the spin 
column. The column was centrifuged at > 10,000 rpm for 1min. The flow-
through was discarded and the spin column was centrifuged at 13,000rpm for 
5min by keeping the cap open. A new 1.5ml collection tube was placed under 
the spin column and 14µl of cDNA elution buffer was added to the center of 





2.2.2.3  Synthesis of biotin-labeled cRNA 
2.2.2.3.1 Materials 
200 units of T7 RNA polymerase (Cat. No. 2085, Ambion, CA, USA) 
GeneChip® IVT Labeling Kit (Cat. No. 900449, Affymetrix, CA, USA): 
In vitro transcription (IVT) labeling enzyme mix 
10X IVT labeling buffer 
Biotin-labeled ribonucleotides (Bio-UTP and Bio-CTP) 
 
2.2.2.3.2 Procedure 
10 to 12µl of cDNA template was mixed with 4µl of 10X IVT labeling buffer, 
12µl of biotin-labeled ribonucletides, 4µl of IVT labeling enzyme mix, 1µl of 
T7 RNA polymerase and the mixture was made up to a total volume of 40µl 
with nuclease-free water. This mixture was vortexed and the reagents were 
collected at the bottom of the tube by a brief centrifugation. This mixture was 
incubated at 37ºC for 4h. The biotin labeled-cRNA was either stored in -70ºC 
or cleaned-up and quantified. 
 
2.2.2.4  Clean-up and quantification of biotin-labeled cRNA 
2.2.2.4.1 Materials and instrument 
RNeasy mini kit (Cat. No. 74106, Qiagen, Germany) 
100% Ethanol 
β-mercaptoethanol 




Nuclease-free water was added to biotin-labeled cRNA to scale-up the volume 
to 100µl. The cRNA (100µl) was mixed with 350µl of RLT lysis buffer 
(supplemented with 10μl β-mercaptoethanol per ml of RLT buffer) and 250µl 
of absolute ethanol and this mixture was applied to the spin column. The 




discarded and the column was washed with RPE buffer by centrifugation at 
13,000rpm for 15sec twice. The collection tube was replaced with a new one 
and 50µl of nuclease-free water was added to the column. The column was 
centrifuged at 13,000rpm for 1min and the flow-through containing purified 
cRNA was collected. 
  After extraction, RNA quality and concentration was determined using 
a sphectrophotometer before proceeding for cDNA conversion. The 
absorbance ratio (A260/A280) within a range of 1.8 to 2 was considered to be 
indicative of good quality RNA with minimum or free of contamination. Since 
some amount of cRNA remains unlabeled, it was essential to calculate the 
adjusted cRNA yield using the formula given below (provided in the 
manufacturer‘s manual): 
 
Adjusted cRNA yield = RNAm - (total RNAi) (y) 
Where,  
RNAm = amount of cRNA measured after IVT (μg)  
total RNAi = starting amount of total RNA (μg) 
y = fraction of cDNA reaction used in IVT 
 
2.2.2.5  Fragmentation of cRNA 
2.2.2.5.1 Materials 
5X Fragmentation Buffer (available with GeneChip Sample Cleanup Module, 
Cat. No. 900371, CA, USA, Affymetrix)   
RNase-free water 
2.2.2.5.2 Procedure 
Full-length cRNA was broken down into 35 to 200bp sized RNA fragments 
for better hybridization on microarray chip. 15µg of cRNA was mixed with 
6µl of 5X fragmentation buffer and was incubated at 94ºC for 35min. 





2.2.2.6  cRNA hybridization on microarray chip 
2.2.2.6.1 Materials 
1X, 2X Hybridization buffer 
GeneChip Rat Genome 230 2.0 Array (6 arrays) 
10mg/ml Herring Sperm DNA (Cat. No. D1811, Promega, WI, USA) 
50mg/ml Bovine serum albumin (BSA; Cat. No. W384A, Promega, WI, USA) 
GeneChip Eukaryotic Hybridization Control Kit (Cat. No. 900299, 
Affymetrix, CA, USA): 
Control oligonucleotide B2 (3 nM) 
20X Eukaryotic hybridization controls (bioB, bioC, bioD, cre) 
 
2.2.2.6.2 Procedure 
10µg of labeled and fragmented cRNA was mixed with 10µl of 20X 
hybridization controls (bioB, bioC, bioD, cre), 3.3µl of control oligonucleotide 
B2 (3 nM), 2µl of herring sperm DNA, 2µl of BSA, 20µL of DMSO, 100µl of 
2X hybridization buffer and nuclease-free water to achieve a total volume of 
200µl. This hybridization mixture was incubated at 99ºC for 5min, then at 
45ºC for 5min and then centrifuged at a high speed (>10,000 rpm) for 5min to 
eliminate insoluble material from the hybridization mixture. . During this time, 
the probe array was filled with 160µl of 1X hybridization buffer and incubated 
at 45ºC for 10min with rotation. The 1X hybridization buffer was removed 
from the probe array and hybridization mixture was added carefully without 
adding any insoluble material. The probe was incubated at 45ºC in an oven for 
16h.  
 
2.2.2.7  Probe array washing, staining and scanning following hybridization 
2.2.2.7.1 Materials and instruments 
Fluidics Station 450 (Cat. No. 00-0079, Affymetrix, CA, USA) 
GeneChip® Scanner 3000 (Cat. No. 00-00212, Affymetrix, CA, USA) 
Wash Buffer A (Cat. No. 900721, Affymetrix, CA, USA) 




Streptavidin Phycoerythrin (SAPE) stain solution: 
2X MES Stain Buffer: 600µl 
50mg/ml BSA (Cat. No. 15561-020, Invitrogen, CA, USA): 48µl 
1mg/ml SAPE (Cat. No. S-866, Invitrogen, CA, USA): 12µl 
DEPC-treated water: 540µl 
Antibody mix: 
2X MES stain buffer: 300µl  
50mg/ml BSA (Cat. No. 15561-020, Invitrogen, CA, USA): 24µl 
10mg/ml Goat IgG Stock (Cat. No. I5256, Sigma, MO, USA): 6µl   
0.5mg/ml Anti-streptavidin antibody (goat), biotinylated (Cat. No. BA-0500, 
Vector Labs, CA, USA): 3.6µl  
DEPC-treated water: 266.4µl 
 
2.2.2.7.2 Procedure 
Following 16h of hybridization of cRNA on the probe arrays, the 
hybridization mixture was removed and 160µl of wash buffer A was added 
without introducing any bubbles. The probe arrays were then inserted into the 
fluidics station and the fluidics protocol was carried out. The fluidics protocol 
involved following steps: 10 cycles of 2 mixes with wash buffer A at 30ºC and 
6 cycles of 15 mixes with wash buffer B at 50ºC. The probe arrays were 
stained first with 600µl of SAPE solution at 35ºC for 5min. The arrays were 
washed again with wash buffer A at 30ºC. This was followed by addition of 
600µl of antibody solution and finally 600µl SAPE solution. The probe arrays 
were washed with wash buffer A at 35ºC and were finally filled with wash 
buffer A and maintained at 25ºC.  
 Probe arrays were scanned in the Genechip scanner 3000 at a 
wavelength of 570nm and pixel value of 3µm. The probe array image files 
(.DAT) were analyzed in the Affymetrix GeneChip® operating software 
(GCOS) and scaled to an average chip intensity of 500. To assess the quality 
of the microarray data, control B2 oligonucleotide and biotinylated control 
cRNAs were added into the hybridization mix. These controls bind to their 




sample hybridization on the microarray. In addition, signal intensity of 
housekeeping genes such as GAPDH and β-actin was used for the assessment 
of RNA integrity, cDNA synthesis and in vitro transcription of cRNA. The 
3‘/5‘ intensity ratio of GAPDH and β-actin probes is usually less than 3. 
 
2.2.2.8  Microarray data analysis 
The 6 microarray image files (.DAT): 3 different samples for AMC (from 5 
day old rat brain) and 3 different samples for RMC (from 28 day old rat brain) 
were converted into .CEL files containing the intensity calculations on the 
pixel values of the .DAT file. The .CEL files were loaded into Affymetrix® 
Expression Console™ 1.1 (Affymetrix, CA, USA) and the robust multiarray 
average (RMA) normalization procedure involving background correction of 
perfect-match (PM) probe intensities, quantile normalization and computation 
of expression measure for each probe on each microarray chip was performed 
(Irizarry et al. 2003).  
 The normalized probe intensities were processed in the Bioinformatics 
toolbox
TM
 in MATLAB R2009a (MathWorks, MA, USA) using the demo 
script- ‗Exploring Gene Expression Data‘. The data was filtered for removing 
genes with low expression values and low variance across chips. Further, t-test 
was performed to retain genes with p values less than 0.05 and a volcano plot 
was generated to identify the two-fold differentially expressed genes. The 
microarray data was MIAME (minimum information about a microarray 
experiment) compliant and was deposited in NCBI‘s Gene Expression 
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/ webcite). The entire 
microarray dataset is accessible through GEO Series accession number 
GSE29885. 
 More stringent criterion was applied to the normalized data and gene 
lists were generated using GeneSpring GX 7.3 software (Agilent 
Technologies, CA, USA). All the six chips were globally normalized and the 






2.2.2.9  Pathway analysis performed using gene lists generated from 
microarray data 
Agglomerative average-linkage hierarchical clustering of the AMC and RMC 
profiles was obtained for selected groups of genes with GeneSpring GX 7.3 
software (Agilent Technologies, CA, USA) with standard correlation used as 
the similarity matrix. The gene lists obtained was fed into Pathway Studio 6 
software (Ariadne, MD, USA) to generate pathways for identifying 
interactions between the genes for validation purposes.  
 The gene list generated from MATLAB was used to identify functional 
groups enriched in the AMC and RMC using DAVID Bioinformatics 
Database (Dennis et al. 2003; Huang et al. 2008). To identify the ‗Stemness‘ 
of AMC and RMC, gene lists of AMC and RMC were compared to gene lists 
of embryonic, neural and hematopoietic stem cells (Ramalho-Santos et al. 
2002). Since the data were accumulated from a different microarray platform, 
orthologs of genes pertaining to the Rat 230 2.0 platform were found using the 
online NetAffyx application (Affymetrix, CA, USA). For comparison of gene 
expression data of AMC and RMC to that of peripheral blood monocytes (Liu 
et al. 2008), the raw CEL files of monocyte expression data were downloaded 
from NCBI GEO (Gene Expression Omnibus) and the orthologs pertaining to 
the Rat 230 2.0 platform were identified using the online NetAffyx 
application. These files were RMA normalized in Affymetrix Expression 
Console Version 1.1 (Affymetrix, CA, USA) as described in section 3.6.2.6 
and subsequently the average expression values of the monocyte genes were 





2.3 Cell Culture 
2.3.1  Primary microglia culture 
2.3.1.1  Materials 
Dulbecco‘s Modified Eagle‘s Medium (DMEM; Cat. No. SH30022.01, 
Hyclone, UT, USA) 
Fetal bovine serum (FBS) (FBS; Cat. No. SV30160.03, Hyclone, UT, USA) 
0.1M Phosphate buffered saline (PBS; PB0344, Vivantis, Malaysia) (pH 7.4) 
Trypsin-EDTA solution (TE; Cat. No. T9285, Sigma-Aldrich, MO, USA) 
Antibiotic antimycotic solution (100X; Cat.No. A5955, Sigma-Aldrich, MO, 
USA)  
Deoxyribonuclease I (Cat.No. D4527, Sigma-Aldrich, MO, USA)  
70µm nylon cell strainer (Cat. No. 352350, BD Biosciences, NJ, USA) 
Ethylenediaminetetraacetic acid (EDTA) (10X; Cat. No. E-7889, Sigma-
Aldrich, MO, USA) 
Insulin (Cat. No. I0516, Sigma-Aldrich, MO, USA) 
 
2.3.1.2  Procedure 
Before beginning the primary culture, 5ml of antibiotics, 50ml of FBS, 5ml of 
non-essential amino acids, and 625µl of insulin were added to 450ml of 
DMEM to make complete medium. Brain cortices were removed from 3 day 
old rat pups and were cleaned in sterile, ice-cold PBS twice in a 100mm dish. 
The meninges were carefully peeled off and the tissues were transferred to a 
50ml centrifuge tube and enzymatically digested with TE and DNase. The cell 
suspension was dissociated in 75cm
2
 culture flask at 37ºC for 15min at 
250rpm. The dissociated cell suspension was filtered through a 70µm cell 
strainer and were seeded in complete medium containing 75cm
2
 culture flask 
at 37ºC incubator with 5% CO2 and 95% air. Mixed glial cultures were 
cultured for 10 to 12 days with medium change every alternate day. In order to 
purify microglia from the mixed glial cultures, the cultures were washed twice 
in sterile PBS and mild trypsinization was performed. The cells were 




EDTA) in 39ml of DMEM for 5min. Membrane of astrocytes and 
oligodendrocytes detached from the surface was discarded. The flask was left 
with microglial cells which were cultured for 2 days in complete medium and 
harvested thereafter for further analyses. 
 
2.3.2  Maintenance and subculture of BV-2 cell line 
2.3.2.1  Materials 
Dulbecco‘s Modified Eagle‘s Medium (DMEM; Cat. No. SH30022.01, 
Hyclone, UT, USA) 
Fetal bovine serum (FBS) (FBS; Cat. No. SV30160.03, Hyclone, UT, USA) 
0.1M Phosphate buffered saline (PBS; PB0344, Vivantis, Malaysia) (pH 7.4) 
Trypsin-EDTA solution (10X TE; Cat. No. T9285, Sigma-Aldrich, MO, USA) 
Lipopolysaccharide (LPS) extracted from E. coli serotype O26:B6 (Cat No. 
L2762; Sigma-Aldrich‚St. Louis, MO, USA) 
 
2.3.2.2  Procedure 
The murine microglia cell line, BV-2 cells were seeded in 75cm
2 
culture flasks 
and maintained in complete medium, Dulbecco‘s Modified Eagle‘s Medium 
(DMEM) supplemented with 10% fetal bovine serum. The cells attained 
maximum confluency two days after they were seeded in culture flasks. In 
order to subculture, TE working solution was prepared by mixing 1 ml of TE 
concentrate in 9 ml of 0.1M sterile PBS. The cells were washed twice in warm 
PBS and incubated with TE for 5min in an incubator at 37℃ with 5% CO2 
and 95% air. The culture flask was then gently rocked and tapped at the 
bottom to aid cell detachment. The TE was then neutralized by addition of 
complete medium. The cell suspension was collected in a 50 ml centrifuge 
tube and the cells were pelleted by centrifugation at 1000rpm for 5min at 4℃. 
Supernatant was carefully discarded and the pellet was re-suspended in fresh 
complete medium. Cells were counted using a hemocytometer and seeded in 
new culture dishes or flasks. For activation, BV-2 microglia were treated with 





2.3.3  Measurement of total intracellular ROS production in BV-2 
microglia 
2.3.3.1  Principle of intracellular ROS production using flow cytometry 
The dye: 5-(and 6)-chloromethyl-2', 7'-dichlorodihydrofluorescein diacetate 
(CM-H2DCFDA) is used for measurement of ROS. This dye is capable of 
passively diffusing into cells, where it is hydrolyzed to DCFA and trapped 
inside the cells. Oxidation of DCFA by intracellular ROS leads to formation of 
a fluorescent product called 7‘-dichlorofluorescein (DCF).The fluorescence 
intensity of DCF can be measured using a flow cytometer with laser light with 
excitation at 492 to 495nm and emission of 517 to 527nm. 
 
2.3.3.2  Materials and instrument   
0.1M phosphate buffered saline (PBS) 
5-(and 6)-chloromethyl-2', 7'-dichlorodihydrofluorescein diacetate (CM-
H2DCFDA; Cat. No. C6827, Molecular Probes, Invitrogen, CA, USA). 
Dimethyl sulfoxide (DMSO; Cat. No. 196055, MP Biomedicals, CA, USA) 
Flowcytometer (CyAn ADP, DakoCytomation, USA) 
 
2.3.3.3  Procedure 
CM-H2DCFDA working solution was freshly prepared prior to ROS 
measurement. CM-H2DCFDA (50 μg) was mixed with 87μl of DMSO to 
prepare stock solution. This stock solution was further diluted in pre-warmed 
sterile PBS to arrive at a final concentration of 10μM. The working solution 
was protected from light. 
 One day prior to ROS measurement, BV-2 cells were plated in 6-well 
plates and grown overnight in an incubator at 37ºC with 5% CO2 and 95% air. 
The following day, BV-2 cells were subjected to LPS treatment and detached 
by addition of TE for 5min at 37ºC. TE was inactivated by addition of DMEM 
supplemented with 10% FBS. The cells were collected in a 15ml centrifuge 
tube and pelleted by centrifugation at 1000rpm for 5min at 4ºC. The pellet was 




5min at 4ºC). The supernatant was then discarded and cells were resuspended 
in either 500μl of CM-H2DCFDA dye working solution or 500μl PBS (for 
negative control). The cells were incubated in the dye for 30 to 45min at 37ºC 
incubator and were protected from light. The fluorescence intensity of the 
oxidized product was measured in a flow cytometer by setting the excitation 
wavelength at 488nm and emission wavelength of 535nm. Intensity data 
obtained from the flow cytometer was analyzed using the Summit V4.2 
software. The amount of intracellular ROS produced was directly proportional 
to the fluorescence intensity of the oxidized dye. 
 
2.3.4 Measurement of mitochondrial ROS production in BV-2 microglia 
2.3.4.1  Principle of mitochondrial ROS measurement by confocal laser 
microscopy 
Mitochondria are the site for the electron transport chain, where energy in the 
form of ATP is generated. However, electrons from the transport chain may 
leak and interact with molecular oxygen to form superoxides as observed in 
neuropathologiessuch as PD (Adam-Vizi 2005). MitoSOX red reagent is a 
live-cell permeable dye specifically targeted to the mitochondria and oxidized 
by superoxides produced in the mitochondria alone.  
 
2.3.4.2  Materials 
0.1M phosphate buffered saline (PBS) 
MitoSOX red mitochondrial superoxide indicator for live imaging (Cat. No. 
M36008, Molecular Probes, Invitrogen, CA, USA). 
Dimethyl sulfoxide (DMSO; Cat. No. 196055, MP Biomedicals, CA, USA) 
 
2.3.4.3  Procedure 
MitoSOX reagent stock (50µg) was mixed with 13µl DMSO to make a 5mM 
reagent solution. A 5µM working solution was prepared in warm DMEM. BV-
2 cells were grown on poly-L-lysine coated coverslips in a 24-well plate 




PBS and incubated with the working solution for 10min at 37ºC. Following 
this, the cells were washed thrice with warm PBS, viewed and photographed 
under a laser confocal microscope (Fluoview 1000, Olympus, Tokyo, Japan). 
 
2.3.5  RNA isolation and quantitative real-time RT-PCR (qRTPCR) 
2.3.5.1  Isolation of total RNA 
2.3.5.1.1 Materials and instrument 
RNeasy mini kit (Cat. No. 74106, Qiagen, Germany) 
70% ethanol 
β-mercaptoethanol 




Protocol provided by the manufacturer was strictly followed. Following 
treatment of BV-2 microglia with LPS, 600µl of RLT lysis buffer 
(supplemented with 10μl β-mercaptoethanol per ml of RLT buffer) was added 
to each well (of a 6-well plate) kept on ice. After 5 to 10min of lysis, cells 
were scrapped and the lysate was transferred to a 1.5ml centrifuge tube. The 
lysate was thoroughly homogenized with a 1ml syringe fitted with a 20-gauge 
needle. The lysate was mixed with an equal volume of 70% ethanol, 
transferred to the RNeasy spin column and centrifuged at a speed > 10,000rpm 
for 1min at room temperature. The flow-through was discarded and RW1 and 
RPE buffers were added into the spin columns in the subsequent steps to 
eliminate contaminating materials. The RNA bound to the spin column was 
eluted in 20µl of nuclease-free water. The concentration of RNA was 





2.3.5.2  Reverse transcription of RNA into cDNA 
2.3.5.2.1 Materials 
Moloney murine leukemia virus reverse transcriptase (M-MLV; Cat. No. 
M1701, Promega, WI, USA) 
dNTP mix (Cat. No. 18427-013, Invitrogen, CA, USA) 
Oligo(dT) primer (Cat. No. C1101, Promega, WI, USA) 
RNase inhibitor (Cat. No. N2111, Promega, WI, USA) 
 
2.3.5.2.2 Procedure 
2μg of total RNA from each sample was added to 1μl of oligodT primer 
(500μg/ml) in a microfuge tube and heated at 70ºC for 5min for first-strand 
synthesis. The tube was then cooled in ice for 5min. 1μl of M-MLV reverse 
transcriptase enzyme (200 units), 1.25μl of dNTP mix (10mM), 0.035μl of 
RNase inhibitor (40units/μl) and nuclease-free water were added to the tube to 
make it at a final volume of 25μl. This mixture was incubated at 42ºC for 1h 
for the reverse transcription of RNA to cDNA. The reaction was halted by 
performing a final incubation for 5min at 95ºC. The cDNA product was stored 
at -20ºC.  
 
2.3.5.3 Quantitative real time RT-PCR 
2.3.5.3.1 Principle 
Quantitative real time RT-PCR (qRTPCR) is used to amplify a certain region 
of cDNA using forward and reverse oligonucleotides (primers) specific to that 
region. The amplified double-stranded DNA is quantified by measuring the 
amount of fluorescence dye, such as SYBR green, that intercalates with the 
DNA.  
Firstly, the two strands of DNA are separated to form two template 
strands by heating at a high temperature for a brief period of time. This is 
followed by amplification process during which the primers bind to the 
template strands and the enzyme, taq DNA polymerase extends the specific 




complementary only to one specific region of the DNA which represents a 
particular gene of interest. Each amplification cycle has alternating 
temperature to allow the sequential process of primer binding, extension and 
denaturation. After several cycles of amplification, adequate copies of cDNA 
are made.  
 During the amplification process, SYBR green fluorescence dye 
intercalates with double stranded DNA and the qRTPCR instrument quantifies 
the fluorescence intensity of the intercalated dye and provides a numerical 
value called the cycle threshold (Ct) value (Bustin 2000). The 2
-[ΔΔCt]
 method 
is used to calculate the relative expression of a particular gene in experimental 
groups when compared with control groups (Livak and Schmittgen 2001). 
 
2.3.5.3.2 Material and instrument 
Fast SYBR® green master mix (Cat. No. 4385612, Applied Biosystems, CA, 
USA) 
Fast real-time PCR system (Model No. 7900HT, Applied Biosystems, CA, 
USA) 
MicroAmp® Optical 96-Well Reaction Plate with Barcode (Cat. No. 4306737 
Applied Biosystems, CA, USA) 
 
2.3.5.3.3 Procedure 
5µl of fast SYBR green master mix (containing ROX dye and dNTPs) was 
added to 2µg of cDNA, 0.5µl each of forward and reverse primer (0.5µM 
each) and topped-up with nuclease-free water to a final volume of 10µl. The 
mixture was added to a well of the 96-well PCR plate. Genes investigated in 
this study were Cat, mnSod, Runx1t1, Sept9, Sept4, Mbp or Dcx. β-actin or 
Gapdh were used as internal control for quantification. The primer sequences 
of these genes are listed in the table below. A common PCR thermal profile 
was set-up for all the primers according to the Fast SYBR® green master mix 
protocol. After pre-incubation at 95°C for 20s, 45 cycles of polymerase chain 
reaction (PCR) was performed as follows: denaturation at 95°C for 1s, 




and melting curves were displayed as output file and used for calculation of 
relative gene expression. 
 
Gene Forward Primer (5’ - 3’) Reverse Primer (5’ - 3’) 
Sirt3 tttctttcacaaccccaagc agggatcccagatgctctct 
mnSod ttaacgcgcagatcatgca ggtggcgttgagattgttca 
Cat tgagaagcctaagaacgcaattc cccttcgcagccatgtg 
Cd11b (OX42) aacaccaaggacaggctgcg tgcgcctgagtatgccgttc 
Gfap ggtgtggagtgccttcgtat tacgatgtcctgggaaaagg 
Vim aatgcttctctggcacgtct gctcctggatctcttcatcg 
CNPase acggcgtggcgactagactgt ccgggcttcagcttcttcagg 
Gapdh acatgccgcctggagaaacctgcca tgccagccccagcatcaaaggtgga 
Mbp (mouse) cagggagccataatgggtag gcttctttagcggtgacagg 
Dcx ccaagagagaacagcaaacca tccagtcagcaaaggtaagga 
β actin ggattccatacccaagaagga gaagagctatgagctgcctga 
Runx1t1 acgaacagctgcttctggat tgcttggatgttctgagtgc 
Sept9  aaccatgtccctcgaacttg aagagagaggggacacgaca 
Sept4 ctcatccgggagaaagatga gagctgatgcagggaag 
Mbp (rat) tacttggccacagcaagtacc gggtgtacgaggtgtcacaat 
 
2.3.6 Agarose gel electrophoresis 
2.3.6.1 Principle 
Agarose gel electrophoresis is used to separate DNA based on their size on a 
matrix of agarose. Since DNA carries a net negative charge, it runs through 
the agarose matrix towards the positive electrode. Based on their size, DNA 
molecules run at different speeds through the matrix. Molecules of larger size 
run slower and are retained closer to the negative electrode. Smaller DNA 
molecules run faster and farther and are retained closer to the positive 
electrode on the gel. Ethidium bromide (EtBr) added to the gel intercalate with 





2.3.6.2 Materials and instrument 
Agarose powder (Cat. No. A2790, Sigma-Aldrich, MO, USA) 
100bp DNA ladder (Cat. No. G6951, Promega, WI, USA) 
6X DNA loading dye (Cat. No. G1881, Promega, WI, USA) 
Tris acetate EDTA buffer (TAE; PB0940, Vivantis, Malaysia) (pH 8.0) 
Ethidium bromide (EtBr) 
GeneGenius (Syngene, UK) 
 
2.3.6.3 Procedure 
2% agarose gel was prepared by boiling 2g of agarose in 100ml TAE buffer in 
a microwave oven. The agarose solution was cooled until vapors disappeared, 
mixed with 5μl of EtBr and casted on a gel-tray. Gel-comb was placed to form 
wells in the gel. 2μl loading dye was added to 10μl of DNA and was loaded 
onto wells in the agarose gel. In one well, 5μl DNA 100 bp marker mixed with 
1μl of loading dye was loaded. The DNA molecules in the gel were separated 
by electrophoresis and visualized in a UV illuminator and gel images were 
obtained in Gene Genius gel documentation system. 
 
2.3.7 Immunofluorescence Staining 
2.3.7.1 Material 
4% paraformaldehyde (4% PF) 
Rabbit anti-Sirt3 antibody (1:100; Cat. No.sc-99143, Santacruz 
Biotechnologies, CA, USA) 
Tomato (Lycopersicon esculentum) lectin: (Sigma-Aldrich, St. Louis, MO, 
USA; Cat. No. L0401) 
Cy3-conjugated sheep anti-rabbit IgG (1:100; Cat. No.C2306, Sigma-Aldrich, 
MO, USA) 
4‘, 6- diamidino-2-phenylindole dihydrochloride (DAPI; Cat. No. D3571, 
Molecular Probes, Invitrogen, Carlsbad, CA, USA) 
Fluorescent Mounting Medium (Cat No. S3023, Dako, Carpinteria, CA, USA) 




Normal goat serum (Cat. No. S1000, Vector labs, CA, USA) 
 
2.3.7.2 Procedure 
To study the expression of Sirt3, BV-2 cells were trypsinized and seeded onto 
poly-l-lysine coated cover slips in a 24-well plate. After treatment of cells with 
LPS, the cells were washed in PBS and fixed with 4% PF for 20min. The cells 
were then washed for 15min (3 changes of PBS for 5min each) and blocked 
with 5% serum for 1h.  After blocking, the cells were incubated overnight with 
rabbit anti-Sirt3 antibody (1:100) at 4ºC in a cold room. The following day, 
the cells were washed with 3 changes of PBS for 15min and incubated with 
FITC-conjugated lectin (1:300) for 1h at room temperature. The cells were 
again washed with 3 changes of PBS for 15min. Next, the cells were incubated 
with Cy3-conjugated anti-rabbit antibody (1:200) for 1h at room temperature. 
Cells were subjected to 3 changes of PBS washing and counterstained with 
DAPI (1:5000). The cover slips were carefully mounted on clean glass slides 
using fluorescence mounting medium and stored at 4ºC. The slides were 
viewed and images were captured under a laser confocal microscopy 
(Fluoview 1000, Olympus, Tokyo, Japan). 
 
2.3.8 Western blotting 
2.3.8.1 Principle 
Western blotting or immunoblotting is a technique used for separation and 
quantification of proteins from a tissue or cell lysate. Specific antibodies 
raised against the protein of interest can be used to detect the protein which is 
separated on a SDS-polyacrylamide gel and then transferred to a 
polyvinylidene difluoride (PVDF) membrane. Secondary antibodies raised 
against the primary antibody are tagged with horseradish peroxidase (HRP) 
which emits a signal upon reaction with a chemiluminiscent substrate (Kurien 





2.3.8.2 Extraction of total protein and quantification 
2.3.8.2.1 Materials 
Mammalian Protein Extraction Reagent (M-PER; Cat. No. 78501, Thermo 
Fisher Scientific, MA, USA) 
Protease Inhibitor Cocktail Kit (Cat. No. 88665, Thermo Scientific, MA, 
USA) 
Bio-Rad Protein Assay Dye Reagent Concentrate: (Cat. No. 500-0006, Bio-
Rad, CA, USA) 
Microplate reader (Spectramax M5; Molecular Devices, CA, USA) 
 
2.3.8.2.2 Procedure 
Total protein was extracted from the BV-2 microglial cells. BV-2 cells were 
seeded in 6-well plates one day prior to the extraction process. After treatment 
of cells with LPS, the cells were washed twice in sterile PBS and lysed by 
incubating them with 150 to 200μl of MPER reagent containing protease 
inhibitor cocktail for 5min on ice. After cell lysis, the cells were scrapped, 
transferred to a 1.5 ml centrifuge tube and pelleted by centrifugation at 
13,000rpm at 4ºC for 20min. The supernatant containing the protein lysate was 
immediately transferred to a fresh microfuge tube and stored at -80ºC.  
 Quantification of proteins was done using the Bradford calorimetric 
assay (Bradford 1976). The color of Coomassie brilliant blue in the assay 
reagent changes upon its binding with the proteins in the sample. The change 
in the color depends upon the protein concentration and could be detected by 
measuring the absorbance values in a calorimeter at 595nm. A standard curve 
was drawn using serial dilutions of a standard protein and the protein 
concentration of an unknown sample was determined by extrapolation method. 
10μl of the sample to be quantified was added to 200μl of assay reagent in a 
96-well plate. The plate was read in a microplate reader at 595nm. The 





2.3.8.3 Extraction of nuclear and cytosolic proteins 
2.3.8.3.1 Materials 
Nuclear extraction kit (Cat. No. 2900, Chemicon international, MA, USA) 
Trypsin-EDTA solution (10X TE; Cat. No. T9285, Sigma-Aldrich, MO, USA) 
 
2.3.8.3.2 Procedure 
Before starting the protein extraction procedure, buffer solutions were 
prepared as instructed by the manufacturer. 10X cytoplasmic extraction buffer 
was diluted to 1X using deionized water and  1X cytoplasmic extraction buffer 
was mixed with nuclear extraction buffer, protease inhibitor (PI; 1:1000) and 
dithiothreitol (DTT; 1:2000). The cells were seeded one day prior to the 
extraction process in a 6-well plate. After treatment with LPS, the cells were 
washed with pre-warmed and sterile PBS twice and trypsinized with TE. The 
cells were collected in a 1.5 ml tube and centrifuged at 250g for 5min at 4ºC. 
The pellet was washed twice in PBS, centrifuged at 250g for 5min at 4ºC and 
mixed with 150µl of 1X cytoplasmic extraction buffer. The tubes were 
inverted 15 to 20 times, then incubated on ice for 5min and centrifuged at 
250g for 5min at 4ºC. The pellet was resuspended in 100µl of 1X cytoplasmic 
extraction buffer and mixed well by repeated drawing and ejecting using a 
syringe fitted with 27G needle. The tube was centrifuged at 8000g for 20min 
at 4ºC. The supernatant containing the cytoplasmic protein extract was 
transferred to a new tube and stored immediately at -80ºC. The remaining 
pellet was resuspended in the nuclear extraction buffer. The suspension was 
drawn and ejected back into the tube using a syringe fitted with a 27G needle 
and this process repeated 10 times. The nuclear fraction was disrupted by 
placing the tubes on a low-speed rotor for 1h at 4ºC. The tubes were 
centrifuged at 16,000g for 5min at 4ºC to obtain the nuclear protein extract in 





2.3.8.4 Sodium dodecyl sulfate-Polyacrylamide gel electrophoresis (SDS-
PAGE) 
2.3.8.4.1 Materials 
SDS-PAGE (Resolving gel + Stacking gel) 
For 10% resolving gel (15ml): 
H2O: 5.9ml 
30% acrylamide mix: 5ml 
1.5M Tris buffer (pH 8.8): 3.8ml 
10% SDS: 150µl 
10% ammonium persulfate (APS): 150µl 
T.E.M.E.D: 6µl 
 
For 5% stacking gel (6ml): 
H2O: 4.1ml  
30% acrylamide mix: 1ml 
1.5M Tris (pH 6.8): 750µl 
10% SDS: 60µl 
10% APS: 60µl 
T.E.M.E.D: 6µl 
 
10X Tris/glycine/SDS electrophoresis buffer: Running buffer (Cat. No. 161-
0732, Bio-Rad, CA, USA) 
2X Laemmli protein loading buffer (Cat. No. 161-0737, Bio-Rad, CA, USA) 




SDS-PAGE comprising of 10% resolving gel and 5% stacking gel was 
prepared. . 30 to 40μg of proteins from each sample was mixed with 6X 




protein samples were loaded onto the stacking gel alongside a protein marker 
and the SDS-PAGE was run at 100 volts for 2 hours. 
 
2.3.8.5 Semi-dry Electrophoretic Transfer 
2.3.8.5.1 Materials 
Blotting paper (Cat. No. 88605, Bio-Rad, CA, USA) 
Immunoblot PVDF membrane (Cat. No. 88520, Thermo Scientific, MA, USA) 
Trans blot SD semi-dry electrophoretic transfer cell (Bio-Rad, CA, USA) 
Tris/glycine electrophoresis buffer: Transfer buffer (Cat. No. 161-0734, Bio-
Rad, CA, USA) 
 
2.3.8.5.2 Procedure 
Once the proteins were separated on the SDS-PAGE, the stacking gel was cut-
out and discarded. PVDF membrane was activated by immersing in methanol 
for 1min and subsequently washed in 3 changes of distilled water. Blotting 
paper was placed on the transfer instrument over which the membrane was 
placed. The SDS-PAGE was placed on top of the membrane and finally 
covered with another blotting paper. Air bubbles trapped in between the SDS-
PAGE and membrane were pushed out and transfer buffer was added. The 
transfer process was carried out at 20 volts for 1h. 
 
2.3.8.6 Detection of protein on the membrane 
2.3.8.6.1 Materials 
Blotting Grade Blocker/nonfat dry milk (Cat. No.170-6404, Bio-Rad, CA, 
USA) 
Bovine serum albumin (BSA; W384A, Promega, WI, USA) 
Rabbit anti-Sirt3 antibody (1:1000; Cat. No. sc-99143, Santacruz 
Biotechnologies, CA, USA) 
Rabbit anti-Foxo3a antibody (1:1000; Cat. No. sc-11351, Santacruz 




Mouse anti-β-actin monoclonal antibody (1:5000; Cat. No. A1978, Sigma-
Aldrich, MO, USA) 
Rabbit anti-Lamin A antibody (1:1000; Cat. No. sc-20680, Santacruz 
Biotechnology, CA, USA) 
Restore
TM
 PLUS Western Blot Stripping Buffer: (Cat. No. 46430, Thermo 
Scientific, MA, USA) 
Goat anti-rabbit IgG (H+L) HRP-conjugated secondary antibody (1:3000; Cat. 
No. AP307P, Chemicon international, MA, USA) 
Goat anti-mouse IgG (H+L) HRP-conjugated secondary antibody (1:5000; 
Cat. No. AP308P, Chemicon international, MA, USA) 
SuperSignal West Pico Chemiluminescent Substrate: (Cat. No. 34087, Pierce 
Thermo Scientific, MA, USA) 
CL-XPosure Film: (Cat. No. 34091, Thermo Scientific, MA, USA) 
Densitometer (Model No. GS-800, Bio-Rad, CA, USA) 
1x TBS (pH7.6): 
Tris base: 2.42g 
NaCl: 8g 
Deinonized Water: 1000ml 
1x TBST: 
1x TBS: 900 ml 
10% Tween 20: 10ml 
 
2.3.8.6.2 Procedure 
The PVDF membrane containing the proteins transferred from SDS-PAGE 
was blocked overnight in 5% milk at 4ºC in the cold room. The following day, 
the membrane was washed 3 times in TBS-T (10 minutes per wash). The 
membrane was then incubated in primary antibody at room temperature for 1h 
with low-speed shaking. The membrane was washed again in TBS-T and 
incubated with HRP-conjugated secondary antibody for at room temperature 
for 1h with low-speed shaking. The membrane was washed with TBS-T once, 
then TBS twice and exposed to chemiluminiscent substrate for 3 to 5min in 




the signal intensity of protein bands was visualized and measured with 
Quantity One Software (Bio-rad, CA, USA) version 4.4.1. 
 
2.3.9 Chromatin immunoprecipitation (ChIP) Assay 
2.3.9.1 Principle 
Chromatin immunoprecipitation (CHIP) analysis is performed to study 
interactions between proteins and DNA. Specific regions on the DNA where 
proteins such as transcription factors and histones are bound can be 
determined. In this procedure, a protein-DNA complex is sheared and the 
protein of interest is pulled-down by immunoprecipitation method. 
Subsequently, the identity of the portion of DNA bound to this protein is 
determined by sequencing (CHIP-seq) or by PCR (Collas 2010).  
 
2.3.9.2 Materials and instrument 
Chromatin Immunoprecipitation Kit (EZ-ChIP, Cat No: 17-371, Millipore, 
Inc., USA) 
Sonication instrument (Bioruptor, Diagenode, NJ, USA) 
Rabbit anti-Foxo3a antibody (Cat No. ab12162, abcam, UK) 
Control Rabbit IgG antibody (Cat. No. sc-2027, Santacruz Biotechnology, CA, 
USA) 
Primers specific to promoter regions of catalase and mnSod 
Fast SYBR® green master mix (Cat. No. 4385612, Applied Biosystems, CA, 
USA) 
Fast real-time PCR system (Model No. 7900HT, Applied Biosystems, CA, 
USA) 
MicroAmp® Optical 96-Well Reaction Plate with Barcode (Cat. No. 4306737 
Applied Biosystems, CA, USA) 
 
2.3.9.3 Procedure 
The primers specific to promoter regions of catalase and mnSod genes were 




site (ATG) in Primer 3 software. The appropriate primers (listed in the table 
below) were selected and their specificity was confirmed by performing a 
nucleotide BLAST (http://blast.ncbi.nlm.nih.gov/).   
Chromatin immunoprecipitation was performed using the chromatin 
immunoprecipitation kit according to the manufacturer‘s instructions. BV-2 
microglial cells were pelleted and cross-linked with 1% formaldehyde for 
10min at room temperature and quenched with 0.125M glycine. The cells 
were then harvested and lysed with sonication. Sonicated chromatin was 
mixed with agarose protein G beads in order to eliminate non-specific binding 
of proteins to the agarose beads. 5% of the sonicated chromatin was used as 
the input DNA (control). The rest 95% of sonicated chromatin  was then 
immunoprecipitated with 8μg of either anti-Foxo3a antibody or IgG control 
antibody. After immunoprecipitation, the beads were washed, the 
protein/DNA complexes were eluted from the beads and crosslinks were 
reversed to free DNA. The DNA was then purified using DNA columns. 
Quantitative PCR was then performed using the Power SYBR Green PCR 
master mix using Applied Biosystems 7900HT thermal cycler with 2μl of 
immunoprecipitated DNA and input DNA with appropriate primers for either 
catalase promoter region, mnSod promoter region or control primers (mouse 
GAPDH). A common PCR thermal profile was set-up for all the primers 
according to the Fast SYBR® green master mix protocol. After pre-incubation 
at 95°C for 20s, 45 cycles of polymerase chain reaction (PCR) was performed 
as follows: denaturation at 95°C for 1s, annealing and extension at 60°C for 
20s. 
CHIP Primers Forward Primer Reverse Primer 
Cat gccaacaagattgccttctc actgtccgacatggtgtaggatt 






2.3.10 Knockdown and overexpression of Sirt3 in BV-2 microglia 
2.3.10.1 SiRNA-mediated knockdown of Sirt3 in BV-2 microglia 
2.3.10.1.1 Principle 
Short interfering RNAs (siRNAs) are short (~20 nucleotides) double stranded 
RNA molecules which mediate gene silencing by causing degradation of 
target mRNA. Once transfected into the cell, the two strands of the siRNA 
unwind and split. One strand is incorporated into the RNA-induced silencing 
complex (RISC) which guides the siRNA to its target mRNA. The siRNA 
binds to the target mRNA through complementarity leading to degradation of 
the target mRNA by the exonuclease activity of the RISC, eventually 
preventing the formation of proteins (Hannon 2002). 
 
2.3.10.1.2 Materials 
3 Silencer select pre-designed Sirt3 siRNA (Cat. No. 4390771, Ambion, CA, 
USA) – siRNA sequences provided in table below. 
Silencer select negative control siRNA (Cat. No. 4390843, Ambion, CA, 
USA) 
CY3-conjugated GAPDH siRNA (Part No. AM4649, Ambion, Inc. USA) 
Opti-MEM® I Reduced Serum Media (Cat. No. 31985070, Invitrogen, CA, 
USA) 
Lipofectamine RNAiMax transfection reagent (Cat. No. 13778-150, 
Invitrogen, CA, USA) 




ID Sense (5' to 3') Antisense (5' to 3') 
S1 
(s82219) GCAAGGUUCCUACUCCAUtt UAUGGAGUAGGAACCUUGCag 
S2 
(s82220) GGCCCAAUGUCACUCACUAtt UAGUGAGUGACAUUGGGCCtg 
S3 






BV-2 microglia to be transfected with siRNA were cultured in 75cm
2 
flasks 
until they reached 80% confluency. The cells were trypsinized with TE for 
5min at 37ºC. TE was inactivated by addition of complete medium (DMEM 
supplemented with 10% FBS) and the cell suspension was transferred to a 
50ml centrifuge tube. The cells were counted using a hemocytometer and an 
appropriate volume of cell suspension was pelleted by centrifugation at 
1000rpm for 5min at 4ºC. The cells were seeded on a 6-well plate (3 x 10
5 
cells per well). SiRNA-lipofectamine complexes were prepared before cells 
were transferred to the 6-well plate. In each well of a 6-well plate, 30nM of 
siRNA (7.5µl of 10µM siRNA stock) and 7.5µl of lipofectamine RNAiMax 
reagent were mixed in 500µl of opti-MEM medium and incubated at 37ºC for 
10min. This enables the binding of siRNA with the lipofectamine reagent, to 
facilitate the entry of siRNA into the cells. 3 x 10
5
 cells were seeded on top of 
the siRNA-lipofectamine complex and the volume was made up to 2.5ml with 
opti-MEM. After 8h of transfection, the medium was replaced with fresh 
complete medium. BV-2 microglia transfected with CY3-conjugated GAPDH 
siRNA were viewed under a fluorescence microscope to assess the 
transfection efficiency. Total RNA was extracted 24h after transfection and 
qRTPCR was performed to assess the percentage of target gene knockdown. 
ROS measurement and western blot analysis were performed after 48h of 
knockdown.    
 
2.3.10.2 Overexpression of long form of Sirt3 in BV-2 microglia 
2.3.10.2.1 Principle 
A gene to be overexpressed is cloned into an expression vector or plasmid and 
is transfected into the cell. The gene is introduced into the vector in a specific 
portion of the vector called the ‗multiple cloning site‘. The vector contains a 
promoter sequence for using the host cell‘s transcription machinery for protein 
synthesis from the gene cloned into the vector. One or more selection markers 




cells amongst those cells that are not transfected (Balbás et al. 1986). Further, 
a protein tag may be present in the vector for easy purification of the encoded 
protein. 
 
2.3.10.2.2 Materials and instrument 
pcDNA3.1(+) plasmid containing long form of Sirt3 fused with FLAG was 
kindly provided by  Dr. Michael N. Sack (NHLBI, NIH, MD, USA) (Bao et 
al. 2010)  
E.coli TOP10 cells (Cat. No. C4040-10, Invitrogen, CA, USA) 
Ampicillin (Cat. No. A0166, Sigma-Aldrich, MO, USA)   
Midiprep plasmid purification kit (Cat. No. K2100-04, Invitrogen, CA, USA) 
Isopropanol 
70% Ethanol 
SF cell line reagent (Cat. No. PBC2-00675, Lonza, Basel, Switzerland) 
Lonza 4-D nucleofector (Lonza, Basel, Switzerland) 
Luria Broth (LB) buffer (Cat. No. L3022, Sigma-Aldrich, MO, USA) 
LB agar plates (Cat. No. L2897, Sigma-Aldrich, MO, USA) 




Highly competent TOP10 E.coli cells were transformed with pcDNA3.1(+) 
vector with or without FLAG-tagged Sirt3 long form insert. TOP10 cells in 
each tube was mixed with 1µg plasmid and incubated on ice for 30min. The 
cells were then given a heat shock at 42ºC for 30sec and placed on ice for 
2min. The cells were added with super optimal broth (SOC) medium for 
recovery and incubated for 1h at 37ºC on an orbital shaker at approximately 
250rpm. The cells were spread on ampicillin plates which were incubated 
overnight at 37ºC for selection of colonies positive for ampicillin resistance. A 
few colonies were picked and grown in a 96-well plate for 3h at 37ºC in an 
orbital shaker at approximately 250rpm. A colony PCR was performed to 




transformed cells were mixed with 5µl of GoTaq PCR mix, 0.5µl each of 
forward and reverse primers for Sirt3. The presence of Sirt3 insert in the 
pcDNA3.1(+) vector was confirmed by performing agarose gel electrophoresis 
with the PCR product. The cells in the 96-well plate were scaled up to 50ml 
using LB broth containing ampicillin and the culture was grown overnight at 
37ºC in an orbital shaker at approximately 250rpm. 
 The following day, midiprep protocol was performed for the extraction 
of plasmid from the transformed cells according to the manufacturer‘s 
instructions. The columns were equilibrated by addition of 10ml of 
equilibration buffer and the solution was allowed to flow-through by gravity. 
The overnight culture of transformed cells was harvested by centrifuging the 
tube at 4000g for 5min. The pellet was resuspended in 4ml of resuspension 
buffer (supplemented with RNase A) until the mixture became homogenous. 
4ml of lysis buffer was added to this mixture and the tube was inverted until 
the mixture became homogenous and was incubated for 5min at room 
temperature. 4ml of precipitation buffer was added and the solution was 
thoroughly mixed and centrifuged at 12,000g for 10min at room temperature. 
The pellet was discarded and the supernatant was loaded onto the equilibrated 
column and allowed to flow down by gravity. The column was washed by 
addition of 10ml of wash buffer and the flow-through was discarded. A fresh 
15ml tube was placed under the column and 5ml of elution buffer was added 
and allowed to flow down by gravity. The flow-through contained the eluted 
plasmid DNA. 3.5ml of isopropanol was added to the elution tube and mixed 
well. The tube was centrifuged at 12,000g for 30min at 4ºC. The supernatant 
was discarded and the pellet was resuspended in 3ml of 70% ethanol. The tube 
was centrifuged at 12,000rpm for 5min at 4ºC. The pellet was air-dried and 
resuspended in 10µl of TE buffer and stored in -20ºC. The plasmid was 
sequenced, the sequence was analyzed using NCBI BLAST and the presence 
of Sirt3 long form insert in pcDNA3.1(+) backbone was ensured.  
 For overexpression of Sirt3 long form vector in BV-2 microglia, the 
cells were grown in 75cm
2 
to attain 80 to 90% confluency. The cells were 
trypsinized using TE for 5min at 37ºC. TE was inactivated by addition of 




suspension was added to a 50ml centrifuge tube. The cells were counted using 
a hemocytometer and pelleted at 1000 rpm for 5min at 4ºC. The cell pellet was 
re-suspended in an appropriate volume of culture media in order to seed 1 x 
10
6 
cells per well of a 6-well plate. The pellet was suspended in SF cell line 
reagent (100µl reagent per sample) and split into equal volumes in separate 
1.5ml tubes. Each tube of cells was added with either 5µg of empty vector or 
5µg of Sirt3 long form vector. The cell suspensions were added to cuvettes 
and transfection was carried out in LONZA nucleofector instrument using the 
DS-136 program. The cells were allowed to recover for 10min after 
transfection and mixed with 500µl of complete medium gently. The 
transfected cell suspension was transferred to a 6-well plate and the volume 
was topped-up to 1.6 ml using complete medium. The cells were harvested 
after 48h of Sirt3 overexpression and either RNA or protein was extracted for 
further analyses. The absence of FLAG protein tag in empty vector transfected 
cells and its presence in Sirt3 long form vector transfected cells following 
western blot analysis confirmed the overexpression of Sirt3 long form in BV-2 
microglia. 
 
2.4 Statistical analysis 
The data were presented as mean ± SD. Statistical significance was evaluated 













































3.1 Transcriptome analysis of amoeboid and ramified 
microglia isolated from the corpus callosum of rat brain 
3.1.1 Laser-capture microdissection (LCM) of microglial cells from the 
corpus callosum (CC) of 5-day and 4-week old rat brain 
To compare the gene expression profiles of AMC and RMC, both microglial 
cell types were stained with peroxidase-conjugated lectin and were isolated 
from the CC of 5-day and 4-week old rat brain, respectively. LCM of AMC 
and RMC from the CC has been shown in Figure 1A-F. Lectin staining has 
been widely used to selectively stain microglia in the CNS (Mannoji et al. 
1986; Streit and Kreutzberg 1987; Boya et al. 1991). The cells isolated by 
LCM were confirmed to be microglia since the mRNA expression of 
oligodendrocyte (CNPase), astrocyte (GFAP) and endothelial cell (Vimentin) 
specific genes was undetectable (Figure 1G). 
 
3.1.2 cDNA microarray and generation of gene lists specific to AMC and 
RMC 
The total RNA from AMC and RMC was extracted and cDNA microarray 
using Rat Genome 230 2.0 array (Affymetrix) was carried out to identify the 
genes that are differentially expressed between AMC and RMC. Each sample 
contained RNA from approximately six hundred laser-captured microglial 
cells. To ensure gene expression consistency between samples within the 
groups, the Pearson‘s rank correlation coefficient was determined after 
normalizing the raw expression data (Figure 2). The gene expression profile 
from the samples of same group showed a very high correlation of 0.97 ± 0.03 
while, a relatively lower correlation value of 0.87 ± 0.03 was observed 
between samples of different groups. A high correlation coefficient of above 
0.8 between the AMC and RMC may be due to the fact that the comparison is 
between the gene expression profiles of the same cell type, i.e. microglia 
regardless of the differences in age (5-day and 4-week rat brain) and 




hierarchical clustering was performed and genes showing over two-fold 
differential expression between AMC and RMC were identified using 
GeneSpring 7.3 (Figure 3A & B). About 800 genes were found to be 
differentially regulated in the two sample groups - 537 with upregulation and 
258 with downregulation in AMC. A high number of differentially expressed 
genes identified were either novel or did not have any functional annotation. 
In view of this, a list of genes with known functional annotations was 
generated using the statistical functions in the Bioinformatics Toolbox in 
MATLAB R2009a (Slonim and Yanai 2009). This list was generated using a 
less stringent filtering (p value < 0.05, in contrast to the GeneSpring list which 
has a p value < 0.01) and contained close to 1400 upregulated genes and 700 
downregulated genes in AMC compared to RMC (Figure 4). A few genes 
were selected from the microarray profile (Runx1t1, Septin 9, Septin 4 and 
MBP) based on their fold change values and known biological functions 
(proliferation, migration, morphological transformation and immune function) 
for validation by real time RT-PCR (Figure 5A). 
 
3.1.3 Functional categorization of AMC and RMC 
The genes with highest fold change values in AMC and RMC (Table 1 and 2) 
clearly delineate their functions and residing environment. The AMC express 
genes that are shown to be involved in nervous system development (such as 
Dpysl3, Crmp1 and Smarca1) (Wang and Strittmatter 1996; Barak et al. 
2003), immune system development (such as Hmgb3 and Sla) (Sosinowski et 
al. 2000; Nemeth et al. 2003; Nemeth et al. 2005; Dragone et al. 2009), cell 
migration during neurodevelopment (Dcx) (Bai et al. 2003) and the immune 
response as well in migration of microglia (Cxcr4, a chemokine receptor) 
(Lavi et al. 1997; Wang et al. 2008; Lu et al. 2009). The finding of 
expression of some genes that are known to be neuron-specific (such as Dcx), 
is interesting and has been further confirmed by qRTPCR which detected Dcx 
mRNA expression in murine BV-2 microglia cell line (Figure 5B). For the 
validation of highly expressed AMC and RMC genes, immunohistochemical 




6A). Immunohistochemical analysis also revealed the expression of Dcx by 
the AMC in the CC of 5 day old rat brain (Figure 6B-D).  
Interestingly, the RMC express genes involved in myelination (such as 
Mbp). Mbp-like proteins, also known as Golli proteins have previously been 
shown to be localized in human microglia at 22 weeks postnatally (Tosic et al. 
2002). MBP mRNA was found to be expressed by laser captured-RMC 
(Figure 5A) and BV-2 microglia (Figure 5B). Genes important for myelination 
such as Plp1 (Mikoshiba et al. 1991) and Lgi4 (Bermingham et al. 2006) 
were found with high expression values in the RMC (Table 2).  
On sorting the genes based on p values (Table 3 and 4), several genes involved 
in transcriptional repression (Mbd1 which binds to methylated sites on DNA) 
(Cross et al. 1997; Ng et al. 2000), vesicular trafficking (Snx6, a component 
of the retromer complex) (Wassmer et al. 2007), and microtubule 
depolymerization (Stmn1) (Belmont and Mitchison 1996) were found to be 
specific to AMC (Table 3). RMC expressed genes involved in immune 
functions such as RT1-A2, which is the MHC of rat and C1ql3, a protein of 
the complement system (Günther and Walter 2001; Iijima et al. 2010), 
calcium ion signaling pathway, i.e., Camk2 protein (Balla et al. 2002; House 
et al. 2007) (Table 4) and sodium dependent glucose transport, i.e., Slc5a11, a 
gene, known to interact with immune-related genes (Tsai et al. 2008) (Table 
2). Functional clusters of genes specific to AMC and RMC were derived using 
Database for Annotation, Visualization and Integrated Discovery (DAVID) 
v6.7. The functional groups in AMC involved in cell cycle, mRNA 
processing, ribosome activity, cytoskeleton (Table 5), and migration (CDC42-
RAC pathway) (Table 6) and those in RMC were cellular homeostasis, 
elongation of dendrites and other processes, glial cell development, axon 
ensheathment (Table 7), and regulation of synaptic transmission and plasticity 
(Table 8). It has been observed that genes which are involved in cell 
proliferation, migration, death, cytoskeletal organization and differentiation 
are highly expressed in AMC, whereas in RMC, genes that are mainly 
involved in cytoskeletal organization and cell differentiation are highly 
expressed (Figure 7 and 8, Refer Table 9 for entire list of AMC and RMC 





3.1.4 Expression of monocyte-specific genes by AMC and RMC 
Microglia have been shown to originate from the mesenchymal progenitor 
cells at the yolk sac (Ginhoux et al. 2010). Yet, microarray studies have 
revealed a close relationship between gene expression profiles of microglia 
and bone-marrow derived macrophages (Saijo and Glass 2011). The 
availability of gene expression profiles for bone-marrow derived circulating 
monocytes prompted us to compare and study the functional similarities of 
AMC and RMC with that of circulating monocytes (Liu et al. 2008). 
Monocytic genes highly expressed by AMC (Cxcr4, Csk and Rac1) (Table 10) 
are known to be involved in several disease pathways such as Parkinson‘s 
disease, Huntington‘s disease and HIV infection, phagocytosis and chemokine 
signaling pathways (Table 11). Further, the monocytic genes expressed by 
RMC (Hla-c, Cd74, Cd302, Lsp1 and Runx3) (Table 12) are involved in 
antigen presentation and lysosome-related functions (Table 13). 
 
3.1.5 Expression of neural, embryonic and hematopoietic stem cell specific 
genes by AMC and RMC 
Both AMC and RMC express a number of stem cell specific genes (Ramalho-
Santos et al. 2002) (Table 14 and 15). However, the RMC express a lesser 
number of genes specific for neural stem cell (NSC) and embryonic stem cell 
(ESC), compared with the AMC. In spite of this, higher percentage of 
hematopoietic stem cell specific genes (HSC) was found to be expressed in 
RMC (Figure 9). These findings suggest that microglia retain HSC specific 
properties even in the adult brain. 
 
3.1.6 Pathway analysis and validation of differentially expressed genes in 
AMC and RMC 
The pathway analysis (Figure 10) revealed novel molecular networks 
involving several signaling molecules and pathways within microglia. In order 




factors which are highly expressed in the AMC were selected. They are: Sox4 
and Sox11 which are SRY-related HMG-box family of transcription factors 
(Bowles et al. 2000) and Runt-related transcription factor 1; translocated to, 1 
(cyclinD-related) (Runx1t1), a member of the ETO gene family of 
transcriptional co-repressors (Davis et al. 2003). 
Runx1t1, by forming a fusion protein with Runx1, a member of RUNX 
family, leads to self-renewal of human monocytic cells thereby impairing 
differentiation of these cells (Tonks et al. 2004). Certain genes known to be 
downregulated by the Runx1-Runx1t1 transcription factor complex such as 
Socs1, Csf1, and Runx3 are highly expressed by RMC (Tonks et al. 2007) 
(Table 16). Further, this fusion protein was found to transactivate the 
expression of Sox4 in human progenitor cells (Tonks et al. 2007). In an 
earlier study, Sox4 deficient mice exhibited proliferation-defective pro-B cells 
(Schilham et al. 1996). Immunohistochemical analysis revealed that Sox4 
(Figure 11A-C) is expressed in the nucleus and cytoplasm of AMC in the CC 
of 5-day old rat brain. Similarly, Sox11 (Figure 12A-F) and Runx1t1 (Figure 
13A-F) are expressed in the AMC in the CC of 5-day old rat brain, but hardly 
detectable in the RMC of 4-week old rat  brain thus validating the microarray 
results. Further, quantitative real time RTPCR for Runx1t1 using RNA 
extracted from LCM-captured AMC and RMC showed that Runx1t1is 
expressed highly in AMC when compared to RMC (Figure 5A). 
 
3.1.7 Differential expression of Septin genes in AMC and RMC 
Septins are a family of multifunctional proteins involved in cytoskeletal 
organization and cell division (Hartwell 1971; Field and Kellogg 1999; 
Weirich et al. 2008). They have also been implicated in tumorigenesis and 
neurodegeneration (Kinoshita 2003). In the present study, Septin genes were 
found to be differentially expressed in AMC and RMC. Sept3, 6, 9 and 11 
were expressed in AMC whereas Sept4 and 8 expressed in RMC. The 
expression of some of these genes was further confirmed by 
immunohistochemical and quantitative real time RTPCR analysis which 




CC of 5-day old rat brain (Figure 14A-F and Figure 5A) and Sept4 expression 
in the RMC in the CC of 4-week old rat brain (Figure 15A-F and Figure 5A). 
Since the role of Septins in microglial functioning has not yet been 
investigated, studies on the Septin family may further the existing knowledge 
on the cytoskeletal dynamics involved in proliferation, migration and 
activation of AMC and RMC. 
 
3.1.8 Expression of inflammatory cytokines and chemokines by AMC and 
RMC 
Microglia in response to trauma or neurodegenerative stimuli exhibit 
upregulation of proinflammatory cytokines and chemokines (Dheen et al. 
2007). In the present study, both AMC and RMC exhibited relatively low 
expression intensities for most of the cytokine genes  such as TNF-α and 





3.2 The role of Sirtuin 3 (Sirt3) in regulation of ROS in 
microglia 
3.2.1 Sirt3 expression is specific to the AMC in the developing brain 
Sirt3 expression was examined immunohistochemically in vivo in the corpus 
callosum of postnatal day 1, 3, 5, 7, 14, 21 and 28-day rat brains. It was 
observed that Sirt3 expression is high in the microglial cells of postnatal day 1, 
3 and 5 (Figure 16A-I), thereafter the expression gradually diminishes over 
postnatal day 7 and 14 (Figure 16J-O) and becomes hardly detectable in the 
microglia of postnatal day 21 and 28 (Figure 16P-U). The difference in the 
morphology of microglial cells from amoeboid to ramified phenotype was 
evident in the different postnatal stages (Figure 16A, D, G, J, M, P, S). 
 
3.2.2 Sirt3 expression is upregulated in AMC in the corpus callosum of 
brain derived from 5-day old rat injected with LPS and in microglial cells in 
vitro following treatment with LPS 
Sirt3 expression was examined immunohistochemically in vivo in the corpus 
callosum of 5-day and 4-week old rat brains following intraperitoneal (i.p) 
injection of LPS. It was observed that the expression of Sirt3 markedly 
increased in the activated microglia in 5-day old rat brain following LPS 
treatment (Figure 17D-F) in comparison to its expression in control (Figure 
17A-C). In the 4-week old rat brain, injection of LPS resulted in a slight 
increase in the expression of Sirt3 in the microglial cells (Figure 17G-L). In 
vitro analysis further showed the upregulation of Sirt3 immunoexpression in 
microglia from primary culture treated with LPS (Figure 18D-F) in 
comparison to control (Figure 18A-C). This was further confirmed with 
western blot analysis using protein lysates obtained from the control and LPS-
treated BV-2 microglia. It can be observed that the expression of Sirt3 protein 
in BV2 microglia increased significantly by 1.69 folds at 3h following 





3.2.3 Mitochondrial ROS is increased following treatment of BV-2 
microglia with LPS 
Mitochondrial ROS (mitosox red indicator dye) expression was examined in 
BV-2 microglia following activation with LPS using confocal imaging. It was 
evident from the intensity of mitosox dye that mitochondrial ROS was 
increased in activated BV-2 microglia (Figure 20D-F) in comparison to 
control (Figure 20A-C). 
 
3.2.4 Activation of BV-2 microglia in vitro led to the nuclear translocation 
of Foxo3a 
Western blot analysis was performed using protein lysates of nuclear and 
cytosolic fractions of control and activated BV-2 microglia (treated with LPS 
for 1, 3 and 6h) (Figure 21A). Foxo3a protein expression significantly 
increased by 2.3 folds in the nuclear fraction upon treatment with LPS for 3h 
compared to control (Figure 21B). 
 
3.2.5 ChIP analysis reveals that Foxo3a binds to the promoters of anti-
oxidant genes Cat and mnSod 
In order to study if Foxo3a activates transcription of Cat and mnSod genes in 
microglia, a ChIP analysis was performed with chromatin (from BV-2 
microglial cells) pulled down using an antibody against Foxo3a protein. 
Quantitative real time RTPCR was performed using primers against promoter 
regions of Gapdh, Cat and mnSod. The PCR results indicated that Foxo3a 
protein has a strong binding affinity for the promoters of Cat and mnSod 
(Figure 22B,C). PCR result of Foxo3a protein binding onto GAPDH promoter 





3.2.6 SiRNA-mediated Sirt3 knockdown in BV-2 microglia resulted in the 
increase of both cellular and mitochondrial ROS with a concomitant 
decrease in the levels of antioxidant mnSod 
Knockdown of Sirt3 was performed in BV-2 microglia using three different 
siRNA constructs (S1, S2 and S3). The transfection efficiency in BV-2 
microglia was high as revealed by the fluorescence images of cy3-tagged 
GAPDH siRNA (Figure 23Aa-c). It was also confirmed that there was 
minimal cell death during siRNA transfection (Figure 23B). It was observed 
that the transfection of siRNA construct S1 significantly reduced the 
endogenous mRNA levels of Sirt3 by almost 80% in BV-2 microglia after 24h 
of knockdown in comparison to negative control siRNA (Figure 24A,B). 
Western blot analysis showed that the protein level of Sirt3 was reduced by 
40% in BV-2 microglia subjected to 48h of siRNA-mediated Sirt3 knockdown 
(Figure 24C,D). Immunohistochemical analysis also revealed the reduction in 
the levels of Sirt3 in both control and LPS-treated BV-2 microglia transfected 
with Sirt3 siRNA when compared to their respective controls (Figure 25A-L).  
 Mitochondrial ROS was imaged in both control and LPS-treated BV-2 
microglia following Sirt3 knockdown. As seen in the confocal images, Sirt3 
knockdown led to an increase in the levels of mitochondrial ROS (Figure 26D-
F) in comparison to its levels in negative control siRNA-treated BV-2 
microglia (Figure 26A-C). LPS treatment did not lead to any further induction 
of mitochondrial ROS in BV-2 microglia transfected with Sirt3 siRNA (Figure 
26G-L). Moreover, total cellular ROS was also significantly increased in BV2 
microglia following Sirt3 knockdown and this increase was equivalent to the 
increase in cellular ROS following activation of BV-2 microglia with LPS 
treatment for 6h (Figure 27A,B). In addition, the mRNA expression level of 
the antioxidant gene, mnSod was found to be significantly downregulated in 
BV-2 microglia following Sirt3 knockdown (Figure 27C). However, no 
significant difference was observed in the mRNA expression of mnSod in 





3.2.7 Overexpression of the long form of Sirt3 in BV-2 microglia led to 
upregulation of Foxo3a protein and increase in the levels of antioxidant 
gene Cat 
In order to study the mechanism by which Sirt3 regulates ROS in microglia, 
FLAG-tagged long form of Sirt3 was overexpressed in BV-2 microglia. The 
presence of Sirt3 insert in the plasmid was verified by performing a colony 
PCR with the transformed bacteria (Figure 28A) and sequencing the purified 
plasmid (Figure 28B). There was an upregulation in the protein levels of 
Foxo3a by 1.8 folds following Sirt3 overexpression in the control microglia 
(Figure 29A,B). In activated BV-2 microglia, the Foxo3a expression was 
found to be increased by 2.5 folds following Sirt3 overexpression (Figure 
29A,B). This was accompanied by an increase in the mRNA levels of 
antioxidant gene, Cat (Figure 29C). 
 
3.2.8 Sirt3 and Foxo3a expression is induced in the hippocampus of a 
brain in the traumatic brain injury (TBI) rat model 
Since, the upregulation of Sirt3 was observed in microglia following 
activation with LPS, its expression was examined in a traumatic brain injury 
rat model. TBI in the adult rat brain resulted in the transformation of ramified 
microglia into activated cells with a spherical morphology on the CA1 region 
of hippocampus on the ipsilateral side (Figure 30). A re-appearance of Sirt3 
expression was observed in the activated microglia in the hippocampus of the 
adult rat brain on the ipsilateral side 24 and 48h following TBI (Figure 
31G,H,I,M,N,O). On the other hand, the expression of Sirt3 in the ramified 
microglia was hardly detectable in sham-operated controls (Figure 31A-F) and 
on the contralateral side of TBI-induced rat brains (Figure 31J,K,L,P,Q,R). 
Quantification of immunofluorescence intensity revealed a significant 
upregulation of Sirt3 expression in the activated microglia following TBI in 
comparison to that in sham-operated controls (Figure 31S). Similarly, the 
expression of Foxo3a was markedly induced and was found to be localized in 




to sham-operated controls (Figure 32A-C). Quantification of 
immunofluorescence intensity revealed a significant upregulation of Foxo3a 
expression in the activated microglia following TBI in comparison to that in 
sham-operated controls (Figure 32G). 
 
3.2.9 Sirt3 is not induced in microglia of an Alzheimer’s disease (AD)-rat 
model 
Degeneration of neurons was observed in the hippocampal slices of AD-rat 
model as shown by the dark staining of the nissl bodies (Figure 33B,D) in 
comparison to that in controls which show lighter staining for Nissl bodies 
(Figure 33 A,C). Immunohistochemical analysis revealed that Sirt3 protein 
expression was hardly detectable in the microglia distributed in the 
hippocampus of AD-rat model (Figure 34A-F). On the other hand, Sirt3 was 
found to be induced in the neurons labeled with the neuronal marker neuN 




















































During CNS development, microglial cells have been classified as amoeboid 
and ramified (Ling and Wong 1993), and during inflammation as the M1 and 
M2 (Olah et al. 2011; Saijo and Glass 2011). Amoeboid microglia found in 
the developing CNS gradually transform into ramified microglia, which may 
in turn become reactive upon a detrimental insult to the CNS. In recent years, 
the change in phenotype of microglia during development and in 
neuropathological conditions has been associated with myriads of microglial 
functions in the CNS. The present study is the first of its kind to relate the 
morphological transformation of the microglia with the distinct changes in 





4.1 Microglia in the healthy brain express low levels of 
cytokines and chemokines 
The present study is a novel attempt to examine the global gene expression 
profile of microglia in situ and to functionally distinguish the two distinct 
microglial phenotypes, namely, AMC and RMC. A noteworthy feature of this 
transcriptome profile was that the expression of cytokines and chemokines in 
both AMC and RMC was hardly detectable, as reported in previous studies 
(Hurley et al. 1999). It has been widely shown that the untreated microglia in 
vitro produce some amount of proinflammatory cytokines and chemokines, 
indicating that culture media stimulate the microglial cells. In the present 
study, the low expression of cytokines and chemokines in both types of 
microglia isolated from the corpus callosum by laser capture microdissection 






4.2 AMC express genes involved in cell cycle process and 
migration whereas RMC express genes involved in synaptic 
integrity and neuronal maturation 
AMC from the first week of postnatal rat brains have a high proliferative 
capacity (Ling and Wong 1993). During development, about two-thirds of 
AMC undergo apoptosis and the rest transform into RMC (Imamoto and 
Leblond 1978; Wu et al. 1993). In accordance with this, microarray analysis 
in the present study revealed a high expression of cell proliferation/cell cycle-
related genes such as Myc and CyclinA2, CyclinB2 and CyclinD1 (Table 9) 
(Huang et al. 2005; He et al. 2008) and genes involved in cell death (Figure 8 
and Table 9) namely, Casp2, Casp3 (Kuida et al. 1996; Johnson et al. 2008) 
and Apaf1 (Glial apoptosis related gene) in the AMC (Bhattacharjee et al. 
2008). It is interesting to note that the AMC express Dcx, a protein known to 
be a marker for migrating neurons (Gleeson et al. 1999). It may be worth 
investigating the role of Dcx in migration of AMC in the early postnatal brain. 
On the other hand, the RMC, which have been shown to be involved in 
cell homeostasis and glial development, appear to contribute to synaptic 
transmission as they express genes such as Grin2c, S100b and Camk2a (Table 
8) (Nishiyama et al. 2002; Rossi et al. 2002; Hinds et al. 2003). This 
supports the recent experimental studies which demonstrated the role of 
microglia in the maintenance and modifications of synaptic integrity in the 
healthy brain (Graeber 2010; Tremblay et al. 2010). Further, Grin2c, a 
subunit of NMDA receptor complex is expressed by the microglial cells in the 
CC and has been shown to be functionally important in microglia-mediated 
neuroinflammation (Chen et al. 2006; Murugan et al. 2011). S100b, a 
calcium ion binding protein, is also expressed by microglia and relocates 
around phagosomes during microglial activation and phagocytosis (Smith and 
Shaw 1998; Adami et al. 2001). RMC has also been found to express myelin 
basic protein (Mbp) which encodes two families of proteins i.e., classic Mbps 
and Golli-Mbps. Classic Mbps serve as the major protein constituent of myelin 




known to be broadly distributed in the brain, particularly in the microglia 
during normal development and inflammation (Filipovic et al. 2002) and 
involved in the interaction between microglia and oligodendrocyte precursor 
cells during multiple sclerosis (Filipovic and Zecevic 2005). Taken together, 
these results reveal that microglia are not only involved in immune response 





4.3 Both AMC and RMC express cytoskeleton-related genes 
Regulation of cytoskeletal dynamics is important to both microglial migration 
and ramification (Ilschner and Brandt 1996; Rezaie and Male 2002; Stuart 
et al. 2007). It has been shown that the AMC express cytoskeleton-associated 
Crmp family proteins (Rosslenbroich et al. 2005) such as Crmp-1, Dpysl3 
and Dpysl5 and Septin family proteins such as Sept9 and 11 (Hanai et al. 
2004; Nagata et al. 2004). Septins are implicated in cytoskeletal processes 
such as vesicular trafficking (Kartmann and Roth 2001). These 
cytoskeleton-associated proteins may aid in the migration and phagocytosis of 
AMC during normal development and pathology. Further, AMC express Sept9 
but not Sept4 whereas, RMC express Sept4, but not Sept9, indicating 
differential roles of Septin family genes in AMC and RMC. Sept4 has been 
recently shown to be involved in cortical neuron migration (Shinoda et al. 
2010). Absence of Sept4 immunoexpression in the AMC and its high 
expression in the RMC is suggestive of an important role for this protein in 





4.4 Expression of monocyte- and stem cell-specific genes by 
AMC and RMC indicates their stemness and origin 
Recent studies have convincingly demonstrated that microglia originate from 
the mesenchymal progenitor cells at the yolk sac (Ginhoux et al. 2010). 
However, microarray studies of various hematopoetic and non-hematopoetic 
cell types revealed a close relationship between the gene expression profiles of 
microglia and bone-marrow derived macrophages (Saijo and Glass 2011) 
which are known to differentiate from circulating monocytes. The present 
study identified the monocyte-specific genes expressed by AMC and RMC. 
AMC express several monocyte-specific genes including Mcl1 and Id2. Mcl1 
is associated with cell viability and differentiation of myeloid cells which 
include monocytes and macrophages (Kozopas et al. 1993; Zhou et al. 1998) 
and Id2, a negative regulator of basic helix loop helix transcription factors, is 
involved in the differentiation of myeloid cells (Ishiguro et al. 1996). A 
recent study demonstrated that Id2 is required for bone morphogenic protein 
(Bmp)-mediated differentiation of microglia into Map2+ neurons and Gfap+ 
astrocytes (Niidome et al. 2008) suggesting that this gene may promote 
microglial trans-differentiation. Both Mcl1 and Id2 have been shown to be 
involved in cell differentiation and their high expression in AMC explains the 
role of these genes in promoting the maturation of AMC and its transformation 
into RMC.   
On the other hand, RMC exhibited increased expression of Lsp1, 
which is known to be a marker for leukocytes and binds to the cytoskeleton 
(Pulford et al. 1999). Overexpression of Lsp1 in neutrophils was associated 
with defective actin polymerization, which renders these cells immotile 
(Howard et al. 1994). Further, overexpression of Lsp1 in a highly motile 
melanoma cell line led to formation of hair-like projections. Thus, 
upregulation of Lsp1 in the RMC, compared to the AMC may explain the role 
of this gene in motility and ramification of RMC (Howard et al. 1998), which 
are the resident and quiescent population in the adult brain parenchyma.  
Both AMC and RMC express stem cell-specific (ESC, NSC and HSC) 




trans-differentiation. The RMC expressed a high percentage of HSC-specific 
genes in comparison to ESC- and NSC-specific genes, and this reinforces the 
monocytic nature of microglia. For example Mll1, a highly expressed HSC-
specific gene in the RMC, is a histone methyl transferase whose functional 
disruption is implicated in human leukemia (Guenther et al. 2005). 
Understanding the functions of monocytic- and HSC-specific genes may be 





4.5 AMC express proliferation- and differentiation-related 
genes, Sox4, Sox11 and Runx1t1 
In order to validate the microarray data, the expression patterns of SOX genes 
(Sox4 and Sox11), which are known to be involved in differentiation and 
Runx1t1, which is involved in the proliferation of hematopoietic lineage cells 
have been analyzed in the present study. These genes were highly expressed in 
the AMC and their expression and role have not been studied in microglia, so 
far. Initially, nuclear expression of the transcription factor, Sox11 was shown 
to be associated with embryonic neurogenesis (Hargrave et al. 1997; Chen et 
al. 2009). However, there are no data on the role of SOX genes in microglia in 
which Sox11 is expressed in the cytoplasm as reported in plasma myeloma 
cells and other B-cell lymphomas (Chen et al. 2009). According to previous 
studies, the overexpression of the fusion protein, Runx1-Runx1t1 causes the 
downregulation of Csf-1 (a hematopoietic cytokine known to induce 
proliferation of microglia) (Sawada et al. 1990) and Runx3 (a tumour 
suppressor) (Guo et al. 2002). The expression profile showed the increased 
expression of Runx1t1 in the AMC and downregulation of Csf-1 and Runx3 in 
AMC compared to RMC. Functional analysis of these transcription factors 





4.6 The role of Sirtuin 3 (Sirt3) in regulation of ROS in 
microglia 
Activation of microglia in response to injury or infection within the CNS 
parenchyma leads to release of various cytokines and growth factors which 
help in regeneration of damaged neural tissue (Kreutzberg 1996). In brain 
injury, activated microglia are useful in phagocytosing neurons that have been 
injured beyond repair (Streit 2000). Microglial cells also release neurotrophic 
factors such as BDNF and IGF-1 in order to promote repair and remodeling of 
the injured CNS tissue (Nagamoto-Combs et al. 2007; Thored et al. 2009). 
However, they also secrete excessive amounts of some noxious substances 
including nitric oxide (NO) and ROS, which may be detrimental to the neural 
tissue when microglia are chronically activated. 
The detrimental effect of the excessive production of ROS by activated 
microglia on the CNS is well documented (Block et al. 2007). Sirt3 has been 
shown to regulate ROS in several cell-types (Sundaresan et al. 2009; Chen 
et al. 2011; Kim et al. 2011). However, the role of Sirt3 in activated microglia 
has not yet been studied. The present study demonstrates for the first time that 
Sirt3 is developmentally regulated in microglial cells in the CNS being 
specifically expressed in the amoeboid microglia of the early postnatal rat 
brain. Sirt3 expression gradually decreases and becomes undetectable in the 
ramified microglia of the adult brain. The high expression of Sirt3 in 
amoeboid microglia in early postnatal rat brain may be associated with the 
neuroprotective mechanisms as the developing brain is highly vulnerable to 
ROS-induced oxidative stress (Blomgren and Hagberg 2006). Moreover, 
microglial cells are known to be highly active in phagocytosing dying neurons 
in the developing brain (Hristova et al. 2010) and therefore requiring high 
levels of Sirt3 for the attenuation of ROS produced by microglia.  
Activated microglia in response to inflammation in vitro and in vivo have 
been shown to produce a plethora of proinflammatory cytokines and reactive 
oxygen mediators including ROS (Dheen et al. 2007). In the present study, 
the upregulation of Sirt3 in activated microglia in response to LPS treatment 




microglia. This appears to be possible as a recent study showed that NMDA-
receptor mediated excitotoxicity led to increase in the levels of ROS in 
neurons and subsequently induced the expression of Sirt3 to neutralize ROS 
produced by neurons (Kim et al. 2011). Overall, this study indicates that Sirt3 
expression is increased in activated microglia, possibly to counter the 
production of ROS in microglia, which is known to mediate neurotoxicity. 
Foxo3a, the transcription factor implicated in ROS regulation was found to 
accumulate in the nuclei of activated microglia. This is in agreement with 
previous studies in cardiomyocytes wherein cellular stress results in the 
nuclear translocation of Foxo3a (Sundaresan et al. 2009). This study further 
demonstrates a direct link between Foxo3a and the anti-oxidant defense 
mechanism in microglia as Foxo3a has been shown to bind to promoter 
regions of Cat and mnSod by ChIP. These results indicate that Foxo3a 
translocates to the nucleus upon activation of microglia and transactivates the 
transcription of Cat and mnSod genes.  
To establish a causal link between Sirt3 and ROS in microglia, siRNA-
mediated knockdown of Sirt3 was carried out in microglia in vitro. There was 
a significant increase in both cellular and mitochondrial ROS and 
downregulation of mnSod in microglia after Sirt3 knockdown. MnSod belongs 
to the family of superoxide dismutases and is known to neutralize superoxides 
produced from the mitochondrial respiratory chain (Shen et al. 2006). Sirt3 
appeared to attenuate ROS by activating mnSod (Qiu et al. 2010). Sirt3 has 
also been shown to interact with mitochondrial Foxo3a and to increase 
Foxo3a-dependent gene expression (Jacobs et al. 2008; Tseng et al. 2013). In 
the present study, overexpression of the long form of Sirt3 in both control as 
well as activated microglia led to increase in the levels of Foxo3a and Cat 
when compared to their levels in empty vector-transfected microglia. These 
results show that Sirt3 increase directly activates Foxo3a, which transactivates 
the transcription of mnSod and Cat, both of which in turn mediate antioxidant 
defense mechanism in microglia.  
Traumatic brain injury (TBI) results in the activation of microglia which 
produce excessive quantities of neurotoxic molecules including ROS (Dohi et 




observed by their spherical appearance in the hippocampus of TBI rat model. 
In conjunction with the previous data relating to the increase of Sirt3 in LPS-
activated microglia in vivo and in vitro; a marked upregulation of Sirt3 in 
activated microglia was observed till 48h following the TBI. The Sirt3 
upregulation was associated with increased Foxo3a activity in activated 
microglia after TBI. However, Sirt3 expression remained undetectable in the 
resting microglia of the sham-operated controls and in the microglia of the 
non-injured side of the brain in TBI rat models. This clearly shows that an 
acute insult can lead to a surge of ROS in activated microglia which in turn 
upregulates Sirt3. The upregulation of Sirt3 facilitates the increase in Foxo3a 
activity to carry-out its antioxidant-mediated attenuation of ROS. 
An interesting finding in this study came from the analysis of Sirt3 
expression in AD rat models. In agreement with a previous study on the 
expression of Sirt3 in the CNS of an AD animal model (Weir et al. 2012), 
there was an increase in the expression of Sirt3 in the CNS of AD-rat model in 
comparison to controls. However, this increase of Sirt3 expression was not 
observed in the microglial cells of AD rat brain. The reason for the absence of 
Sirt3 induction in microglia in AD is not clear. Activated microglia in AD 
have been shown to be dysfunctional in clearance of toxic protein aggregates 
and neuroprotection, whereas it drives neurodegeneration by production of 
toxic pro-inflammatory factors and ROS (Block et al. 2007). As mentioned 
earlier, the excessive production of ROS by activated microglia may induce 
Sirt3, which in turn may neutralize it. However, in the case of AD, Sirt3 
expression was not induced despite the release of excessive amounts of ROS 
by activated microglia. Further studies are required to investigate the signaling 
pathways that function upstream of Sirt3 in activated microglia in aging-
associated neuropathologies such as AD. A recent study showed that 
peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), a 
transcriptional co-activator transactivates the expression of Sirt3 gene in 
muscle cells and hepatocytes (Kong et al. 2010). PGC-1α binds to, and 
increases the transcriptional activity of the nuclear recptor PPARγ 
(Puigserver et al. 1998). Further, induction of PPARγ using agonists has been 




from AD (Landreth et al. 2008). Investigating the interaction of PGC-1α with 
PPARγ in activated microglia in AD might offer some explanation for the lack 

































Microglial cells undergo morphological as well as functional transformation 
during development as well as in the event of an injury or disease. This 
transformation is believed to have functional importance and hence warrants 
the investigation of underlying gene expression changes. 
Although microglial cells have been broadly classified into amoeboid, 
ramified and activated, it has been shown that they exist in several 
intermediate phenotypes during development and in neurological disorders. 
Studies in the past have classified microglia based on their morphological 
heterogeneity displayed during different stages of development, regions in the 
brain and in disease states (Olah et al. 2011; Saijo and Glass 2011). 
However, a molecular catalogue of these different microglial forms is yet to be 
established although geneexpression profiles of in vitro microglia is available 
recently. These profiles do not entirely represent the gene expression profile of 
microglia in vivo (Hurley et al. 1999), since the microglia in vitro appear to 
be in stimulated state. One of the difficulties impeding the establishment of a 
precise molecular database for microglial cells is their rapid activation 
following isolation from their natural milieu. Hence it was necessary to 
compare the gene expression profiles of in vivo microglia isolated using 
techniques that will minimize their activation and hence, provide an accurate 
expression profile that reflects the physiology of microglia in the CNS. 
In the present study, laser-capture microdissection (LCM) was used to 
isolate microglia from thin frozen rat brain sections. Microarray analysis 
performed with the RNA extracted from these LCM-isolated cells confirms 
with previous studies (Hurley et al. 1999) asserting that resting-state 
microglia in the healthy brain express low to negligible levels of inflammatory 
cytokines. The gene expression profile agreed well with pre-existing 
knowledge on the functions of AMC (proliferation, phagocytosis, and 
migration) and RMC (antigen presentation, cytoskeletal processes). Further, 
the genes that carried out these functions have now been clearly recognized 
from the present study. Recent studies also associate microglia with synaptic 
transmission and maintenance. The present study has also identified the genes 
expressed by microglia (RMC) which were previously known to function at 




yolk sac macrophages, this study showed that both AMC and RMC are closely 
related to hematopoietic stem cells and circulating monocytes. 
Activated microglia are the prime cellular sources of reactive oxygen 
species (ROS) in the CNS. Chronic activation of microglia has been linked to 
aging-associated neurodegenerative diseases such as Alzheimer‘s disease 
(AD) and Parkinson‘s disease (PD) since they produce excessive amounts of 
ROS for a prolonged duration leading to oxidative stress. In the present study, 
Sirt3 was found to be highly specific to the AMC in comparison to the RMC. 
Further, this study has demonstrated the expression and function of microglial 
Sirt3 in context of development, inflammation, injury and aging-associated 
neurodegeneration. It is clear that the antioxidant machinery of microglia acts 
via Foxo3a which is regulated by Sirt3. Taken together, these results reveal an 
important antoxidant defense mechanism in microglia regulated by Sirt3. 
Targeting Sirt3 in activated microglia in a CNS disorder may prove to be a 
useful therapeutic strategy. Schematic figure summarizes the research findings 











































































































































































































































































































































































































































































































































































































































































































































































































































































Microarray analysis has been in use for over a decade and yet, a gene 
expression profile of microglia isolated from the healthy brain had not been 
elucidated. The present study is a novel approach to provide comprehensive 
gene expression profiles of two predominant phenotypes of microglia: AMC 
and RMC, which delineate the function of microglia in the healthy developing 
brain. Studies in chronic, aging associated neuropathologies such as 
Alzheimer‘s disease (AD) (McGeer et al. 1987; Combs et al. 2000; Qin et 
al. 2002), and Parkinson‘s disease (PD) (Zhang et al. 2005) indicate persistent 
microglial activation as the major causative factor for disease exacerbation. 
Further, chronic microglial activation has been shown to impair adult 
neurogenesis in hippocampus (Monje et al. 2003) and damage the 
periventricular white matter (PWMD) in the early postnatal brain (Kaur and 
Ling 2009). Hence, activated microglia in both postnatal and adult stages can 
have neurotoxic effects on the CNS by causing excessive inflammation. 
Identification of ways to attenuate microglia-mediated neuroinflammation, 
therefore, has been the primary consideration in therapeutic strategy. This calls 
for a need to understand the functional limitations that make activated 
microglia neurotoxic. Comparison of gene expression profiles of microglia 
from healthy developing brain identified in this study with those of activated 
microglia from various neuropathologies will aid in identification of drug 
targets in order to overcome the functional limitations of activated microglia 
and make them less neurotoxic and more neuroprotective. Recent studies have 
also shown that activated microglia exist in two phenotypes: the neurotoxic 
M1 (classically-activated) phenotype and neuroprotective M2 (alternatively-
activated) phenotype. Future studies evaluating the gene expression profiles of 
M1 and M2 activated microglia isolated from neuropathological conditions 
may be compared with the gene expression profiles from this study to identify 
candidate molecules for therapeutic intervention. Specific ablation of the M1 
phenotype and retention of M2 phenotype of activated microglia could be the 
focus for future research in neurodegenerative disease therapy.  
One of the most detrimental effects of microglial activation is the 
excessive release of ROS leading to neuronal death. The expression of Sirt3 in 




elucidated in the present study. Since, high levels of Sirt3 has been detected in 
individuals who age in a healthy manner, drugs that upregulate Sirt3 levels in 
activated microglia may aid in attenuating microglia-mediated ROS 
production in aging-associated neuropathologies. Sirtuin-activating 
antioxidant drugs such as resveratrol, found in red wine are currently being 
tested for treatment of cardiovascular disorders and cancer. Future studies may 
also evaluate the importance of Sirt3-mediated ROS regulation using 
transgenic mouse models. Conditional knockout of Sirt3 in activated microglia 
in acute and chronic neuropathological mouse models will help in 
understanding if Sirt3 is essential for attenuating microglia-mediated 
neurotoxicity. Therefore, development of drugs that specifically stimulate 
Sirt3 synthesis in activated microglia is believed to open new vistas in 
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Fig 1A-F. Identification and isolation of amoeboid microglial cells (AMC) 
and ramified microglial cells (RMC) from the corpus callosum (CC) of 5-
day and 4-week old rat brain respectively. AMC (A) and RMC (D) were 
stained with lectin and photographed under laser capture microscopy. These 
cells were laser-cut along their periphery and isolated (B, E). The isolated cells 
were collected in the cap of a microfuge vial. (C, F) Arrows indicate the same 
cells in all the three images. Scale bars: A-F 50 μm. G. Purity of LCM-
isolated cells. Agarose gel electrophoresis showed the expression of CD11b 
(microglia marker) and the absence of Gfap (astrocyte marker), Vimentin 
(endothelial cell marker) and CNPase (oligodendrocyte marker) confirming 
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Fig 2. Correlation plots. Correlation plots were generated in Affymetrix 
Expression Console 1.1 after RMA normalizing raw CEL files of AMC and 
RMC expression data. The color scale indicates the degree of correlation 

















































































Fig 3A. Cluster Analysis. Cluster analysis shows changes in gene expression 
profiles of AMC and RMC. Agglomerative average-linkage hierarchical 
clustering of the six independent samples was obtained for genes enriched in 
AMC (3 samples) and RMC (3 samples) using GeneSpring 7.3. Each colored 
box represents the normalized expression level of a given gene in each sample 
and is colored according to the fold change. B. Line Graph represents a two-
fold differential gene expression between the AMC and RMC. The lines in red 
represent genes upregulated and those in blue represent genes downregulated 



























































































Fig 4. Volcano Plot. Blue dots within the lateral quadrants (red and blue box) 
represent genes with two-fold differential expression and p < 0.05 in AMC and 





































































Fig 5A. Validation of genes from Microarray Profile. Histogram shows the 
real time RTPCR validation of two AMC-specific genes (Runx1t1 and Sept9) 
and two RMC-specific genes (Sept4 and Mbp) using RNA isolated from AMC 
and RMC laser-captured from 5-day and 4-week old rat brain tissue. B. 
Expression of Dcx and Mbp in BV-2 microglia. PCR was carried out using 
cDNA obtained from BV-2 microglia for Dcx and Mbp. Both Dcx and Mbp 
were found to be expressed by BV-2 microglia as identified by the PCR 
products in agarose gel electrophoresis. *p value < 0.05, **p value < 0.01, 















































































Fig 6A. Low magnification confocal image of the corpus callosum (CC, 
within dotted lines) showing OX42 (green) stained microglia. 6B-D. 
Immunoexpression of Dcx in AMC. Confocal images showing the 
immunoexpression of Dcx (C; red) in OX42 (B; green) labeled AMC of the 
corpus callosum in 5-day old rat brain tissue section (D). Nuclei are stained 





















































Fig 7. Functional clusters to highly-expressed AMC and RMC genes. Heat 
map shows the top 20 abundant genes in AMC and RMC (arranged according 
to fold change) and their involvement in major cellular functions. Red shading 



























































































Fig 8. Functional pathways. Graph shows the number of AMC and RMC 
genes enriched in different functions. It can be noted that the AMC express a 
high number of genes involved in cell proliferation, migration, death, 
cytoskeletal organization and differentiation whereas the RMC express a high 




































































Fig 9. Stemness of AMC and RMC. Venn diagrams represent the share of 
Embryonic (ESC), Neural (NSC) and Hematopoietic (HSC) stem cell genes in 
AMC and RMC. The AMC express a high number of stem cell genes 
compared to the RMC. The RMC express more HSC-specific genes than 





















































Fig 10. Pathway analysis. Novel molecular networks identified by inputting 
AMC and RMC gene expression data into Adriane Pathway Studio. Red 
colored shapes specify AMC genes and violet colored shapes specify RMC 
genes. Some AMC genes discussed in this study - Sox4, Sox11, Runx1t1 are 












































Fig 11A-C. Immunoexpression of Sox4 in AMC in the CC of 5-day old rat 
brain. Confocal images showing a high immunoexpression of Sox4 (B; red) in 
OX42 (A; green) labeled AMC (C) in the CC of 5-day old rat brain. Nuclei are 




















































Fig 12A-F. Differential immunoexpression of Sox11 in AMC and RMC. 
Immunoexpression of Sox11 (B, E; red) in OX42 (A, D; green) labeled AMC 
(C) and RMC (F) in the CC from 5-day (5D) and 4-week (4W) old rat brain 
was  observed. Sox11immuno expression is undetectable in RMC (F) 
compared to that in the AMC (C). Nuclei are stained with DAPI (blue). 


















































Fig 13A-F. Immunoexpression of Runx1t1 in AMC. Immunoexpression of 
Runx1t1 (B, E; red) in OX42 (A, D; green) labeled AMC (C) and RMC (F) in 
the CC from 5-day (5D) and 4-week (4W) old rat brain was observed. 
Runx1t1 immunoexpression is undetectable in RMC (F), but is evident in the 
AMC (C). Nuclei are stained with DAPI (blue). Arrows indicate the microglia. 

















































Fig 14A-F. Immunoexpression of Sept9 in AMC. Confocal images showing 
the immunoexpression of Sept9 (B, E; red) in OX42 (A, D; green) labeled 
AMC (C) and RMC (F) in the CC from 5-day (5D) and 4-week (4W) old rat 
brain. Sept9 immunoexpression is localized in the AMC (C) but is hardly 
detectable in RMC (F). Nuclei are stained with DAPI (blue). Arrows indicate 





















































Fig 15A-F. Immunoexpression of Sept4 in RMC. Confocal images showing 
the immunoexpression of Sept4 (B, E; red) in OX42 (A, D; green) labeled 
AMC (C) and RMC (F) in the CC from 5-day (5D) and 4-week (4W) old rat 
brain. Sept4 is undetectable in AMC (C), but is expressed in the RMC (F). 
Nuclei are stained with DAPI (blue). Arrows indicate the microglia.  Scale 



















































Fig 16. Temporal immunoexpression of Sirt3 in microglial cells of the 
developing rat brain. Confocal images showing the temporal expression 
pattern of Sirt3 (B, E, H, K, N, Q, T; red) in OX42 (A, D, G, J, M, P, S; green) 
labeled microglia in the corpus callosum of 1, 3, 5, 7, 14, 21 and 28 day old rat 
brain respectively. It is observed that Sirt3 is highly expressed in the amoeboid 
microglia until 7 day (7D) and its expression gradually reduces and becomes 
hardly detectable in the ramified microglia of 28 day (28D) rat brain. Nuclei 









































Fig 17. Increase in the immunoexpression of Sirt3 in microglia following 
LPS treatment in vivo. Confocal images showing the expression of Sirt3 (B, 
E, H, K; red) in OX42 (A, D, G, J; green) labeled microglia in the corpus 
callosum of 5day (5D) and 28 day (28D) old rat brain treated with LPS, 
respectively. It is observed that Sirt3 is highly expressed in the activated 
microglia at 5 day old rat brain following LPS treatment (E). A slight increase 
in the expression of Sirt3 can be observed in the microglia of 28 day rat brain 
following LPS treatment (K) when compared with control (H). Nuclei are 



















































Fig 18. Upregulation of Sirt3 in microglia following LPS treatment in 
vitro. A-F. Confocal images showing the expression of Sirt3 (B, E; red) in 
OX42 (A, D; green) labeled control (A, B, C) and activated (D, E, F) primary 
culture microglia. Upregulation of Sirt3 is evident in LPS activated microglia 
(E) compared to its expression in control (B). Nuclei are stained with DAPI 

















































Fig 19. Upregulation of Sirt3 protein expression in BV-2 microglia 
following LPS treatment. Western blot analysis reveals an upregulation of 

































































































Fig 20A-F. Increase in mitochondrial ROS in BV-2 microglia following 
LPS treatment. Confocal images showing the levels of mitochondrial ROS 
produced in control (A, B, C) and activated (D, E, F) BV-2 microglia. An 
increase in the intensity of mitochondrial ROS is observed in LPS activated 



















































Fig 21. Nuclear translocation of Foxo3a in BV-2 microglia following LPS 
treatment. A. Western blot analysis reveals the nuclear translocation of 
Foxo3a following LPS treatment for 1h, 3h and 6h in BV-2 microglia. B. 
Densitometry of western blots showed that increase of Foxo3a expression in 
the nuclear fraction following LPS treatment for 3h was significant when 














































Fig 22. Foxo3a binds to the promoters of Cat and mnSod. A. Histogram 
shows the weak binding of Foxo3a protein to the GAPDH promoter. B, C. 
Histogram shows that Foxo3a has a strong binding affinity to the promoters of 




























































































































Fig 23. Transfection and cell viability after Sirt3 siRNA treatment in BV-
2 microglia. A (a-c). Fluorescence microscopy images show a high 
transfection efficiency of cy3-tagged GAPDH siRNA into BV-2 microglia. B. 
MTS assay shows an insignificant cell death in Sirt3 siRNA treated BV-2 
microglia in comparison to negative control siRNA treated cells. NS = not 







































































Fig 24. siRNA-mediated knockdown of Sirt3 in BV-2 microglia. A. 
Histogram shows the efficiency of three different siRNA constructs (S1, S2, 
S3) used for the knockdown of Sirt3 mRNA. It is observed that siRNA 
construct S1 produced up to 80% knockdown of Sirt3 mRNA when analyzed 
by qRTPCR. B. The qRTPCR amplification curves depict the higher ct values 
for Sirt3 siRNA treated BV-2 microglia compared with negative control 
siRNA-treated cells ensuring that the knockdown efficiency is very high. C, 
D.  Western blot analysis shows the reduction in Sirt3 protein levels after Sirt3 






























































































































Fig 25. Sirt3 knockdown reduces Sirt3 immunoexpression in control and 
activated BV-2. Confocal images showing the expression of Sirt3 protein in 
control and activated BV-2 microglia treated with negative control (A, B, C 
and G, H, I) and Sirt3 siRNA (D, E, F and J, K, L). It is seen that Sirt3 protein 
expression level drasctically reduced in control and activated BV-2 microglia 
treated with Sirt3 siRNA (E, K) when compared to negative control (B, H). 
Nuclei are stained with DAPI (blue). Arrows indicate the microglia. Scale bars 





















































Fig 26. siRNA mediated knockdown of Sirt3 increases mitochondrial ROS 
production in BV-2 microglia. Confocal images showing the production of 
mitochondrial ROS (A, D, G, J; red) in control and LPS-activated microglia 
transfected with negative control and Sirt3 siRNA. Increased mitochondrial 
ROS production is observed in BV-2 microglia transfected with Sirt3 siRNA 
(D) in comparison to that transfected with negative control siRNA (A). Sirt3 
siRNA transfection in activated microglia (J) did not lead to further induction 
of mitochondrial ROS in comparison to activated microglia treated with 














































Fig 27. Total cellular ROS production and mRNA expression of 
antioxidant mnSod in BV-2 microglia transfected with Sirt3 siRNA. A. 
Flow cytometry analysis reveals the increase in the fluorescence intensity in 
BV-2 microglial cells transfected with Sirt3 siRNA and cells exposed to LPS. 
B. Histograms depict the relative cellular ROS produced in control and LPS-
activated microglia transfected with either negative control or Sirt3 siRNA. It 
was observed that cellular ROS increased upon Sirt3 knockdown when 
compared with negative control siRNA treated cells. Sirt3 knockdown in 
activated microglia did not lead to further increase in cellular ROS levels 
when compared to that in activated microglia treated with negative control 
siRNA. C. Real time qRT-PCR analysis shows that the anti-oxidant gene, 
mnSod was significantly down-regulated in BV-2 microglia transfected with 
Sirt3 siRNA. The mRNA levels of mnSod did not change significantly in 


































































































































Fig 28. Validation of Sirt3 insert in pcDNA 3.1 vector. A. Agarose gel 
photo shows the PCR amplification of Sirt3 insert present in the pcDNA3.1 
vector. B. Sequencing and nucleotide BLAST of purified plasmid DNA using 
primers against CMV promoter and BGH site confirms that the plasmid used 
















































Fig 29. Overexpression of long form of Sirt3 and mRNA expression of 
antioxidant Cat in BV-2 microglia. A. Western blot analysis shows the 
increase in the expression of Sirt3 labeled with FLAG tag following 
overexpression of the long form of Sirt3 in control and LPS activated BV-2 
microglia compared with the empty vector transfected cells. A, B. Western 
blot and densitometric analyses show the increase in the expression of Foxo3a 
protein in control and LPS-activated BV-2 microglia following overexpression 
of Sirt3 when compared with empty vector transfected cells. C. qRTPCR 
analysis shows the increase in the mRNA levels of antioxidant gene, catalase 
following overexpression of Sirt3 in LPS activated BV-2 microglia. n = 3, *p 































































































































Fig 30A. Low magnification confocal image of the hippocampus showing 
OX42 (green) stained microglia. 30B &C. Activation of microglia in the 
hippocampus of TBI-induced rat brain. Confocal images show OX42 
labeled activated microglia (green) co-localized with Sirt3 (red) on the 
hippocampal CA-1 region (area inside the dotted box in Fig 30A) on the 
ipsilateral side (B) and the resting microglia on the contralateral side (C). 
Nuclei are stained with DAPI (blue). Arrows indicate the microglia. Scale 














































Fig 31. Induction of Sirt3 immunoexpression in microglia of TBI-rat 
brain. Confocal images showing the induction of Sirt3 expression (B, H, N; 
red) in the OX42 labeled microglia (A, G, M; green) on the ipsilateral side of 
TBI-induced rat brain. The expression of Sirt3 (E, K, Q; red) remains hardly 
detectable in the microglia (D, J, P; green) on the contralateral side. Nuclei are 
stained with DAPI (blue). Arrows indicate the microglia. Scale bars A-R: 20 
µm. S. Graph indicates the increase in the fluorescence intensity of Sirt3 
staining in OX42 labeled microglia in rat brain 24 hours after traumatic brain 
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Fig 32. Induction of Foxo3a immunoexpression in microglia of TBI-
induced rat brain. Confocal images show the increased expression of Foxo3a 
protein (E; red) in OX42-labeled microglia (D; green) on the ipsilaterateral 
side (D-F) of the brain compared to its expression (B; red) in microglia (A; 
green) on the contralateral side (A-C). Nuclei are stained with DAPI (blue). 
Arrows indicate the microglia. Scale bars A-F: 20 µm. G. Graph indicates the 
increase in the fluorescence intensity of Foxo3a staining in OX42 labeled 
microglia in rat brain 24 hours after traumatic brain injury when compared 






























































Fig 33. Degeneration of neurons in AD-rat brain. Darkly Nissl-stained 
degenerating neurons are observed in the AD-rat brain sections (B, D) 
compared to lighter staining in healthy neurons in sham-operated controls (A, 


















































Fig 34. Sirt3 expression in the microglia of AD-rat brain. Confocal images 
show that Sirt3 expression is not detectable in microglia of both control (A-C) 
and AD-rat brains (D-F). Nuclei are stained with DAPI (blue). Arrows 



















































Fig 35. Sirt3 expression in the neurons of AD-rat brain. Confocal images 
show that Sirt3 expression is induced in neurons (labeled with NeuN, neuronal 
marker in green) of AD-rat brains (D-F) when compared to control (A-C). 











































































Table 1. Top 25 highly-expressed genes in AMC based on fold change. Both 
MATLAB and GeneSpring analysis are represented 
Genes from MATLAB analysis Genes from Genespring analysis 
Gene 
Symbol 

























Sox4 SRY (sex 
determining region 
Y)-box 4 












Rprm reprimo, TP53 
dependent G2 arrest 
mediator candidate 





























Crmp1 collapsin response 






















Cct8 chaperonin containing 
Tcp1, subunit 8 
(theta) 
13.53 protein folding Bmp2 bone 
morphogenet














Appbp2 amyloid beta 
precursor protein 
(cytoplasmic tail) 











Cxcr4 chemokine (C-X-C 
motif) receptor 4 













Ect2 epithelial cell 
transforming 









Hmgb3 high mobility group 
box 3 
12.47 negative 
regulation of B 
cell 
differentiation 




13.43 pro-B cell 
differentiati
on 
Hs3st5 heparan sulfate 
(glucosamine) 3-O-
sulfotransferase 5 
































Nap1l3 nucleosome assembly 
protein 1-like 3 
10.88 nucleosome 
assembly 
Zfml zinc finger, 
matrin-like 
12.20 nucleic acid 
binding 
Mex3b mex3 homolog B (C. 
elegans) 












































9.58 RNA splicing Mtus1 mitochondria
l tumor 
suppressor 1 
11.12 cell cycle 
Bex4 brain expressed gene 
4 








Fam164a family with sequence 
similarity 164, 
member A 




























Table 2. Top 25 genes in RMC based on fold change. Data from both 
MATLAB and GeneSpring analyses are represented. 
Genes from MATLAB analysis Genes from Genespring analysis 
Gene 
Symbol 

































Mbp myelin basic 
protein 









Cyp3a9 cytochrome P450, 
family 3, subfamily 
a, polypeptide 9 
19.31 sensory 
perception 





protein transport  
Opalin oligodendrocytic 
myelin paranodal 











Plp1 proteolipid protein 
1 
12.00 glial cell 
differentia
tion 

















Hapln2 hyaluronan and 
proteoglycan 
link protein 2 













of a branching 
structure  
Znf76 zinc finger protein 




Tnnc2 troponin C type 
2 (fast) 
8.60 skeletal muscle 
contraction  









8.12 cell adhesion Gng13 guanine nucleotide 
binding protein (G 





























































Akap8l A kinase 
(PRKA) anchor 
protein 8-like 






Cpne9 copine family 
member IX 

















Srpk3 SFRS protein 
kinase 3 





























































p value Function 
Dctn6 dynactin 6 2.3803 9.03E-06 transferase activity  
RGD13103
52 
similar to HTGN29 protein; 
keratinocytes associated 
transmembrane protein 2 
13.419 3.70E-05 --- 
Ppp1r14c 
protein phosphatase 1, 
regulatory (inhibitor) 
subunit 14c 
3.7916 4.32E-05 regulation of phosphorylation 
Nipsnap3a 
nipsnap homolog 3A (C. 
elegans) 
9.0179 6.17E-05 --- 
Mbd1 
methyl-CpG binding domain 
protein 1 
2.1202 6.78E-05   
Dync1h1 
dynein cytoplasmic 1 heavy 
chain 1 
2.6624 7.74E-05 microtubule-based movement  
Snx6 sorting nexin 6 6.3942 9.84E-05 cell communication  
Prkar2b 
protein kinase, cAMP 
dependent regulatory, type II 
beta 
2.7781 0.000135 
regulation of protein amino 
acid phosphorylation  
Ybx1 Y box binding protein 1 3.7191 0.00016 
negative regulation of 
transcription from RNA 
polymerase II promoter  
Mtvr2 
mammary tumor virus 
receptor 2 
5.7502 0.000182 receptor activity 
Crmp1 
collapsin response mediator 
protein 1 
15.498 0.000184 neuron development 
Sox4 
SRY (sex determining 
region Y)-box 4 
28.328 0.000221 response to hypoxia  






6.045 0.000245 signal transduction 
Bzw1 
basic leucine zipper and W2 
domains 1 
6.3039 0.000245 transcription  
RGD13055
37 
similar to RIKEN cDNA 
3110001I22 
6.8767 0.000258 --- 
Ube2d1 
ubiquitin-conjugating 
enzyme E2D 1, UBC4/5 
homolog (yeast) 
5.0533 0.000265 protein polyubiquitination  
Cldnd1 Claudin domain containing 1 2.2565 0.000271 --- 
Stmn1 stathmin 1 4.7384 0.000286 microtubule depolymerization  












p value Function 
Mobp 
myelin-associated 
oligodendrocyte basic protein 
623.18 1.23E-05 nervous system development 
RT1-A2 RT1 class Ia, locus A2 2.1753 3.09E-05 
antigen processing and 
presentation of peptide antigen 
via MHC class I  
Ccdc15
3 
coiled-coil domain containing 
153 
4.1465 8.61E-05 --- 
Shroom
1 
shroom family member 1 2.2842 0.00011 cell morphogenesis  
Zdhhc1 
zinc finger, DHHC-type 
containing 1 
2.2872 0.000132 protein palmitoylation  
Fgf6 fibroblast growth factor 6 2.1594 0.000147 cartilage condensation  
Taf1c 
TATA box binding protein 
(Tbp)-associated factor, RNA 
polymerase I, C 
2.3723 0.0002 transcription 
Zcchc17 
zinc finger, CCHC domain 
containing 17 
2.0382 0.000203 RNA binding  
Ccdc28a 
coiled-coil domain containing 
28A 
3.8307 0.000361 --- 
Akr1cl2 
aldo-keto reductase family 1, 
member C-like 2 
2.4959 0.000385 oxidation reduction 
Mbp myelin basic protein 4.7084 0.000396 myelination  
Hapln2 
hyaluronan and proteoglycan 
link protein 2 
9.8354 0.000399 cell adhesion 
Gpatch4 G patch domain containing 4 3.2975 0.000466 nucleic acid binding 
LOC304
903 
similar to Pappalysin-2 
precursor (Pregnancy-associated 
plasma protein-A2) (PAPP-A2) 
2.1139 0.000478 proteolysis  
Chn1 Chimerin (chimaerin) 1 5.3575 0.00057 signal transduction  
F12 
coagulation factor XII 
(Hageman factor) 
3.1552 0.000593 Factor XII activation  
Ctdspl 
CTD (carboxy-terminal domain, 
RNA polymerase II, 
polypeptide A) small 
phosphatase-like 




3.5115 0.000646 calcium ion binding  
Camk2a 
calcium/calmodulin-dependent 
protein kinase II alpha 
4.6656 0.000665 calcium ion transport 
C1ql3 
Complement component 1, q 
subcomponent-like 3 






Table 5. Functional clusters specific to AMC 
Annotation 
Cluster 1   
Enrichment 




p value   Benjamini 
  GOTERM_
CC_FAT  




bounded organelle  
196 7.10E-15 1.80E-12 
  GOTERM_
CC_FAT  
microtubule cytoskeleton  57 1.30E-09 1.70E-07 
  GOTERM_
CC_FAT  
cytoskeleton  105 1.00E-08 1.00E-06 
  GOTERM_
CC_FAT  
cytoskeletal part  78 9.80E-07 4.60E-05 
Annotation 
Cluster 2  
Enrichment 




p value  Benjamini 
  GOTERM_
CC_FAT  
nuclear lumen  111 5.30E-11 9.10E-09 
  GOTERM_
CC_FAT  
intracellular organelle lumen  124 1.20E-08 1.00E-06 
  GOTERM_
CC_FAT  
membrane-enclosed lumen  128 4.40E-08 3.20E-06 
  GOTERM_
CC_FAT  
organelle lumen  124 9.70E-08 6.20E-06 
  GOTERM_
CC_FAT  
nucleoplasm  78 9.80E-07 4.60E-05 
  GOTERM_
CC_FAT  
nucleoplasm part  44 2.20E-03 3.40E-02 
Annotation 
Cluster 3  
Enrichment 




p value Benjamini 
  GOTERM_
CC_FAT  
microtubule cytoskeleton  57 1.30E-09 1.70E-07 
  GOTERM_
CC_FAT  
microtubule  31 1.30E-07 7.70E-06 
  GOTERM_
CC_FAT  
cytoskeletal part  78 9.80E-07 4.60E-05 
  SP_PIR_KE
YWORDS  
microtubule  23 2.60E-04 4.80E-03 
  GOTERM_
BP_FAT  
microtubule-based process  27 4.90E-04 1.90E-02 
Annotation 
Cluster 4  
Enrichment 




p value Benjamini 
  GOTERM_
MF_FAT  
cytoskeletal protein binding  57 2.50E-08 1.20E-05 
  GOTERM_
MF_FAT  
actin binding  35 9.50E-06 1.10E-03 
  SP_PIR_KE
YWORDS  
actin-binding  24 8.20E-05 2.00E-03 
Annotation 
Cluster 5  
Enrichment 




p value Benjamini 
  SP_PIR_KE
YWORDS  
protein biosynthesis  42 2.10E-13 2.10E-11 
  GOTERM_
BP_FAT  
translational elongation  28 4.90E-11 1.50E-07 
  SP_PIR_KE
YWORDS  
ribonucleoprotein  38 5.90E-10 4.80E-08 
  KEGG_PAT
HWAY  
Ribosome  25 8.30E-10 1.40E-07 
  SP_PIR_KE
YWORDS  
ribosome  23 5.30E-08 3.60E-06 







translation  55 3.20E-06 2.80E-04 
  SP_PIR_KE
YWORDS  
ribosomal protein  27 8.40E-06 3.10E-04 
  GOTERM_
CC_FAT  
cytosolic part  21 1.60E-05 6.20E-04 
  GOTERM_
CC_FAT  
ribonucleoprotein complex  56 7.10E-05 2.30E-03 
  GOTERM_
CC_FAT  
cytosolic small ribosomal subunit  11 7.60E-05 2.30E-03 
  GOTERM_
CC_FAT  
small ribosomal subunit  12 1.70E-04 4.00E-03 
  GOTERM_
CC_FAT  
ribosomal subunit  16 2.10E-04 4.50E-03 
  GOTERM_
MF_FAT  
structural molecule activity  50 4.00E-02 5.10E-01 
  GOTERM_
CC_FAT  
ribosome  30 5.20E-02 3.40E-01 
  GOTERM_
MF_FAT  
structural constituent of ribosome  27 8.60E-02 7.10E-01 
Annotation 
Cluster 6  
Enrichment 




p value Benjamini 
  GOTERM_
BP_FAT  
cell cycle  70 8.90E-11 1.30E-07 
  GOTERM_
BP_FAT  
proteasomal protein catabolic 
process  




protein catabolic process  
24 1.80E-09 1.80E-06 
  GOTERM_
BP_FAT  




catabolic process  




macromolecule catabolic process  
47 1.30E-08 6.30E-06 
  GOTERM_
BP_FAT  





dependent protein catabolic process  
18 3.50E-08 1.30E-05 
  GOTERM_
BP_FAT  
cellular protein catabolic process  49 3.60E-08 1.20E-05 
  GOTERM_
BP_FAT  
proteolysis involved in cellular 
protein catabolic process  




catabolic process  
32 1.20E-07 3.30E-05 
  GOTERM_
BP_FAT  
regulation of ubiquitin-protein ligase 
activity during mitotic cell cycle  
18 1.50E-07 3.80E-05 
  GOTERM_
BP_FAT  
regulation of ligase activity  19 2.10E-07 4.60E-05 
  GOTERM_
BP_FAT  
negative regulation of ubiquitin-
protein ligase activity during mitotic 
cell cycle  
17 2.30E-07 4.30E-05 
  GOTERM_
BP_FAT  
positive regulation of ligase activity  18 2.60E-07 4.60E-05 
  GOTERM_
BP_FAT  
negative regulation of ligase activity  17 3.10E-07 4.80E-05 
  GOTERM_
BP_FAT  
negative regulation of ubiquitin-
protein ligase activity  
17 3.10E-07 4.80E-05 
  GOTERM_
BP_FAT  
positive regulation of ubiquitin-
protein ligase activity during mitotic 
cell cycle  






regulation of ubiquitin-protein ligase 
activity  
18 7.00E-07 9.20E-05 
  GOTERM_
BP_FAT  
positive regulation of ubiquitin-
protein ligase activity  
17 8.80E-07 1.10E-04 
  GOTERM_
BP_FAT  
cellular macromolecule catabolic 
process  
54 9.70E-07 1.10E-04 
  GOTERM_
BP_FAT  
macromolecule catabolic process  59 1.40E-06 1.60E-04 
  GOTERM_
BP_FAT  
cell cycle process  49 1.80E-06 1.90E-04 
  GOTERM_
BP_FAT  
negative regulation of protein 
ubiquitination  
17 1.80E-06 1.90E-04 
  GOTERM_
BP_FAT  
positive regulation of protein 
ubiquitination  
18 2.20E-06 2.10E-04 
  GOTERM_
BP_FAT  
regulation of protein ubiquitination  19 1.50E-05 1.10E-03 
  GOTERM_
BP_FAT  
negative regulation of protein 
modification process  
21 1.80E-05 1.20E-03 
  GOTERM_
CC_FAT  
proteasome complex  14 2.50E-05 8.60E-04 
  SP_PIR_KE
YWORDS  
proteasome  13 6.00E-05 1.80E-03 
  GOTERM_
BP_FAT  
positive regulation of protein 
metabolic process  
33 6.60E-05 3.70E-03 
  KEGG_PAT
HWAY  
Proteasome  13 1.20E-04 3.20E-03 
  GOTERM_
BP_FAT  
positive regulation of cellular 
protein metabolic process  
31 1.50E-04 7.40E-03 
  GOTERM_
BP_FAT  
positive regulation of catalytic 
activity  
51 1.50E-04 7.40E-03 
  GOTERM_
BP_FAT  
positive regulation of molecular 
function  
56 1.90E-04 8.70E-03 
  GOTERM_
BP_FAT  
negative regulation of cellular 
protein metabolic process  
25 2.60E-04 1.20E-02 
  GOTERM_
BP_FAT  
positive regulation of protein 
modification process  
26 2.80E-04 1.20E-02 
  GOTERM_
BP_FAT  
negative regulation of molecular 
function  
36 4.10E-04 1.60E-02 
  GOTERM_
BP_FAT  
negative regulation of protein 
metabolic process  
25 4.10E-04 1.60E-02 
  GOTERM_
BP_FAT  
regulation of cellular protein 
metabolic process  
46 7.60E-04 2.70E-02 
  GOTERM_
BP_FAT  
negative regulation of catalytic 
activity  
29 1.70E-03 5.40E-02 
  GOTERM_
BP_FAT  
regulation of protein modification 
process  
32 3.20E-03 8.80E-02 
  GOTERM_
BP_FAT  
cell cycle phase  26 1.20E-02 2.10E-01 
  SP_PIR_KE
YWORDS  
ubl conjugation pathway  21 4.00E-02 2.90E-01 
  GOTERM_
BP_FAT  
proteolysis  60 1.50E-01 8.00E-01 
Annotation 
Cluster 7  
Enrichment 




p value Benjamini 
  UP_SEQ_F
EATURE  
cross-link:Glycyl lysine isopeptide 
(Lys-Gly) (interchain with G-Cter in 
ubiquitin)  
24 4.10E-06 6.40E-03 
  SP_PIR_KE
YWORDS  
ubl conjugation  43 7.20E-05 1.80E-03 
  SP_PIR_KE
YWORDS  
isopeptide bond  28 8.80E-05 2.00E-03 




Cluster 8  Score: 4.44  of Genes 
  GOTERM_
BP_FAT  
protein transport  70 1.50E-07 3.60E-05 
  GOTERM_
BP_FAT  
establishment of protein localization  70 2.20E-07 4.40E-05 
  GOTERM_
BP_FAT  
protein localization  79 2.70E-07 4.50E-05 
  GOTERM_
BP_FAT  
intracellular transport  59 1.20E-05 9.00E-04 
  GOTERM_
BP_FAT  
cellular protein localization  39 3.10E-04 1.30E-02 
  GOTERM_
BP_FAT  
cellular macromolecule localization  39 3.50E-04 1.50E-02 
  GOTERM_
BP_FAT  
intracellular protein transport  35 6.50E-04 2.30E-02 
  GOTERM_
BP_FAT  
protein targeting  21 2.30E-03 6.90E-02 
  SP_PIR_KE
YWORDS  
protein transport  32 6.40E-03 7.70E-02 
Annotation 
Cluster 9  
Enrichment 




p value Benjamini 
  GOTERM_
BP_FAT  
mRNA processing  36 3.50E-07 5.20E-05 
  GOTERM_
BP_FAT  
mRNA metabolic process  39 5.80E-07 8.00E-05 
  GOTERM_
BP_FAT  
RNA splicing  31 2.10E-06 2.10E-04 
  GOTERM_
BP_FAT  
RNA processing  47 1.30E-05 9.40E-04 
  KEGG_PAT
HWAY  
Spliceosome  22 7.40E-05 2.50E-03 
  SP_PIR_KE
YWORDS  
mrna processing  21 1.30E-04 2.80E-03 
  SP_PIR_KE
YWORDS  
mrna splicing  18 2.00E-04 4.10E-03 
  GOTERM_
CC_FAT  
spliceosome  15 2.10E-04 4.60E-03 
  SP_PIR_KE
YWORDS  
Spliceosome  13 2.50E-04 5.00E-03 
  GOTERM_
BP_FAT  
RNA splicing, via transesterification 
reactions  
20 4.00E-04 1.70E-02 
  GOTERM_
BP_FAT  
nuclear mRNA splicing, via 
spliceosome  
20 4.00E-04 1.70E-02 
  GOTERM_
BP_FAT  
RNA splicing, via transesterification 
reactions with bulged adenosine as 
nucleophile  
20 4.00E-04 1.70E-02 
Annotation 
Cluster 10  
Enrichment 




p value Benjamini 
  GOTERM_
BP_FAT  
mitotic cell cycle  42 2.40E-09 1.80E-06 
  GOTERM_
BP_FAT  
cell cycle process  49 1.80E-06 1.90E-04 
  GOTERM_
BP_FAT  
cell division  27 3.60E-06 3.00E-04 
  SP_PIR_KE
YWORDS  
cell cycle  33 2.10E-05 7.30E-04 
  GOTERM_
BP_FAT  
mitosis  19 1.00E-04 5.40E-03 
  GOTERM_
BP_FAT  
nuclear division  19 1.00E-04 5.40E-03 
  GOTERM_
BP_FAT  






organelle fission  19 2.10E-04 9.80E-03 
  SP_PIR_KE
YWORDS  
cell division  21 3.80E-04 6.50E-03 
  GOTERM_
BP_FAT  
M phase  22 5.50E-03 1.30E-01 
  SP_PIR_KE
YWORDS  
mitosis  13 5.80E-03 7.50E-02 
  GOTERM_
BP_FAT  
cell cycle phase  26 1.20E-02 2.10E-01 
  GOTERM_
BP_FAT  






Table 6. Genes involved in CDC42-RAC pathway for migration were found 
to be specific to AMC 
Gene 
Symbol 
Gene Name Fold 
Change 
Rac1 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding 
protein Rac1) 
5.5863 
Cdc42 cell division cycle 42 (GTP binding protein, 25kDa) 5.1257 
Actr2 ARP2 actin-related protein 2 homolog (yeast) 4.6831 
Actr3 ARP3 actin-related protein 3 homolog (yeast) 3.8936 
Arpc5 actin related protein 2/3 complex, subunit 5, 16kDa 3.4395 
Pik3ca phosphoinositide-3-kinase, catalytic, alpha polypeptide 2.4225 






Table 7. Functional clusters specific to RMC 
Annotation 
Cluster 1   
Enrichment 




p value   Benjamini 
  GOTERM_
BP_FAT  
regulation of membrane 
potential  
18 2.20E-05 8.40E-03 
  GOTERM_
BP_FAT  
axon ensheathment  10 3.30E-05 1.10E-02 
  GOTERM_
BP_FAT  
ensheathment of neurons  10 3.30E-05 1.10E-02 
  GOTERM_
BP_FAT  
regulation of action 
potential in neuron  
11 9.50E-05 2.40E-02 
  GOTERM_
BP_FAT  
regulation of action 
potential  
12 1.20E-04 2.60E-02 
  GOTERM_
BP_FAT  
myelination  9 1.40E-04 2.80E-02 
  GOTERM_
BP_FAT  
transmission of nerve 
impulse  
23 3.50E-04 6.00E-02 
Annotation 
Cluster 2  
Enrichment 




p value   Benjamini 
  GOTERM_
CC_FAT  
cell projection  47 2.30E-05 8.80E-03 
  GOTERM_
CC_FAT  
neuron projection  30 3.60E-04 2.70E-02 
  GOTERM_
CC_FAT  
dendrite  17 5.70E-03 1.80E-01 
Annotation 
Cluster 3  
Enrichment 




p value   Benjamini 
  GOTERM_
BP_FAT  





36 9.10E-08 1.00E-04 
  GOTERM_
BP_FAT  
ion homeostasis  36 4.90E-07 3.70E-04 
  GOTERM_
BP_FAT  
cellular homeostasis  37 2.90E-06 1.70E-03 
  GOTERM_
BP_FAT  
chemical homeostasis  39 3.00E-06 1.40E-03 
  GOTERM_
BP_FAT  
regulation of membrane 
potential  
18 2.20E-05 8.40E-03 
  GOTERM_
BP_FAT  
homeostatic process  45 1.40E-04 2.60E-02 
  GOTERM_
BP_FAT  
cellular cation homeostasis  19 1.30E-03 1.60E-01 
  GOTERM_
BP_FAT  
cation homeostasis  19 4.50E-03 3.10E-01 
  GOTERM_
BP_FAT  
cellular metal ion 
homeostasis  
14 9.10E-03 4.10E-01 
  GOTERM_
BP_FAT  
metal ion homeostasis  14 1.20E-02 4.70E-01 
  GOTERM_
BP_FAT  
cellular di-, tri-valent 
inorganic cation 
homeostasis  
15 1.30E-02 4.60E-01 
  GOTERM_
BP_FAT  
di-, tri-valent inorganic 
cation homeostasis  
15 2.00E-02 4.90E-01 
  GOTERM_
BP_FAT  
cellular calcium ion 
homeostasis  
11 5.90E-02 7.30E-01 
  GOTERM_
BP_FAT  
calcium ion homeostasis  11 6.70E-02 7.60E-01 
  GOTERM_
BP_FAT  
cytosolic calcium ion 
homeostasis  






elevation of cytosolic 
calcium ion concentration  
6 2.80E-01 9.60E-01 
Annotation 
Cluster 4  
Enrichment 














5 3.00E-03 2.70E-01 
  GOTERM_
BP_FAT  
glial cell development  6 3.40E-03 2.80E-01 
  GOTERM_
BP_FAT  
glial cell differentiation  8 4.10E-03 3.00E-01 
  GOTERM_
BP_FAT  
ensheathment of axons in 
the central nervous system  
3 6.90E-03 3.80E-01 
  GOTERM_
BP_FAT  
myelination in the central 
nervous system  
3 6.90E-03 3.80E-01 
  GOTERM_
BP_FAT  
gliogenesis  8 1.40E-02 4.50E-01 
Annotation 
Cluster 5  
Enrichment 




p value   Benjamini 
  GOTERM_
MF_FAT  
ion binding  145 2.60E-05 1.60E-02 
  GOTERM_
MF_FAT  
cation binding  137 3.40E-04 3.00E-02 
  GOTERM_
MF_FAT  
metal ion binding  133 8.70E-04 6.00E-02 
  GOTERM_
MF_FAT  
transition metal ion binding  88 7.50E-03 2.60E-01 
  GOTERM_
MF_FAT  
zinc ion binding  71 8.30E-03 2.50E-01 
  SP_PIR_KE
YWORDS  
zinc  44 8.50E-02 7.20E-01 
  SP_PIR_KE
YWORDS  
zinc-finger  26 8.80E-02 7.10E-01 
  SP_PIR_KE
YWORDS  
metal-binding  65 1.00E-01 7.00E-01 
Annotation 
Cluster 6  
Enrichment 




p value   Benjamini 
  INTERPRO  Metallothionein 
superfamily, eukaryotic  
3 5.20E-03 8.90E-01 
  INTERPRO  Metallothionein, vertebrate, 
metal binding site  
3 5.20E-03 8.90E-01 
  INTERPRO  Metallothionein, vertebrate  3 5.20E-03 8.90E-01 
  SP_PIR_KE
YWORDS  
chelation  3 5.20E-03 2.10E-01 
  SP_PIR_KE
YWORDS  





3 5.30E-03 6.60E-01 
  UP_SEQ_F
EATURE  
region of interest:Alpha  3 5.70E-03 9.50E-01 
  UP_SEQ_F
EATURE  




site:Divalent metal cation; 
cluster A  




site:Divalent metal cation; 
cluster B  
3 5.70E-03 9.50E-01 
  SP_PIR_KE
YWORDS  





Cluster 7  
Enrichment 




p value   Benjamini 
  GOTERM_
CC_FAT  
synapse part  21 4.70E-04 2.90E-02 
  GOTERM_
CC_FAT  
postsynaptic membrane  14 7.10E-04 3.80E-02 
  GOTERM_
CC_FAT  




ion channel activity  
8 9.70E-03 2.70E-01 
  GOTERM_
CC_FAT  
cell junction  24 2.30E-02 3.30E-01 
  SP_PIR_KE
YWORDS  
postsynaptic cell membrane  10 3.00E-02 4.30E-01 
  SP_PIR_KE
YWORDS  
synapse  14 5.30E-02 5.70E-01 
  SP_PIR_KE
YWORDS  
cell junction  18 8.60E-02 7.10E-01 
Annotation 
Cluster 8  
Enrichment 




p value   Benjamini 
  GOTERM_
BP_FAT  
regulation of synaptic 
plasticity  
11 4.70E-04 7.40E-02 
  GOTERM_
BP_FAT  
regulation of neuronal 
synaptic plasticity  
8 1.40E-03 1.70E-01 
  GOTERM_
BP_FAT  
regulation of synaptic 
transmission  
13 1.20E-02 4.60E-01 
  GOTERM_
BP_FAT  
regulation of transmission 
of nerve impulse  
13 2.00E-02 5.00E-01 
  GOTERM_
BP_FAT  
regulation of neurological 
system process  
13 3.10E-02 5.90E-01 
  GOTERM_
BP_FAT  
regulation of system process  18 5.20E-02 7.00E-01 
Annotation 
Cluster 9  
Enrichment 




p value   Benjamini 
  GOTERM_
MF_FAT  
cytoskeletal protein binding  27 2.20E-03 1.10E-01 
  GOTERM_
CC_FAT  
actin cytoskeleton  15 1.20E-02 2.30E-01 
  GOTERM_
MF_FAT  
actin binding  16 2.30E-02 4.00E-01 
Annotation 
Cluster 10  
Enrichment 




p value   Benjamini 
  SP_PIR_KE
YWORDS  
ionic channel  28 1.20E-05 4.20E-03 
  GOTERM_
MF_FAT  
ion channel activity  29 3.60E-05 1.20E-02 
  GOTERM_
MF_FAT  
substrate specific channel 
activity  
29 6.10E-05 1.30E-02 
  GOTERM_
BP_FAT  
ion transport  44 6.30E-05 1.80E-02 
  GOTERM_
MF_FAT  




transporter activity  
29 1.20E-04 1.80E-02 
  GOTERM_
MF_FAT  
gated channel activity  24 1.20E-04 1.60E-02 
  GOTERM_
MF_FAT  
ligand-gated ion channel 
activity  





14 1.50E-04 1.60E-02 
  GOTERM_
CC_FAT  






ion transport  34 8.80E-04 7.60E-02 
  GOTERM_
MF_FAT  
cation channel activity  20 1.80E-03 1.00E-01 
  GOTERM_
MF_FAT  
metal ion transmembrane 
transporter activity  
21 5.50E-03 2.20E-01 
  INTERPRO  Potassium channel, voltage 
dependent, Kv3  





channel, alpha subunit  
3 1.00E-02 5.10E-01 
  GOTERM_
BP_FAT  
metal ion transport  24 1.30E-02 4.50E-01 
  SP_PIR_KE
YWORDS  




motif:Selectivity filter  
7 1.80E-02 9.30E-01 
  GOTERM_
BP_FAT  
cation transport  27 2.20E-02 5.10E-01 
  GOTERM_
CC_FAT  
cation channel complex  8 3.90E-02 4.00E-01 
  INTERPRO  Ion transport  9 4.00E-02 9.80E-01 
  GOTERM_
MF_FAT  




channel activity  
10 4.50E-02 5.50E-01 
  GOTERM_
BP_FAT  
monovalent inorganic cation 
transport  
17 4.50E-02 6.70E-01 
  GOTERM_
MF_FAT  
voltage-gated ion channel 
activity  





12 4.70E-02 5.60E-01 
  INTERPRO  Potassium channel, voltage 
dependent, Kv  
4 5.00E-02 9.80E-01 
  GOTERM_
CC_FAT  
T-tubule  4 5.60E-02 4.90E-01 
  INTERPRO  Voltage-dependent 
potassium channel  




channel activity  
7 9.20E-02 7.00E-01 
  GOTERM_
MF_FAT  
potassium ion binding  8 1.00E-01 7.20E-01 
  SP_PIR_KE
YWORDS  





voltage-gated channel, alpha 
subunit, subfamilies 
A/C/D/F/G/S  
3 1.00E-01 9.90E-01 
  SP_PIR_KE
YWORDS  
potassium channel  6 1.20E-01 6.90E-01 
  
INTERPRO  
Potassium channel, voltage 
dependent, Kv, 
tetramerisation  
4 1.30E-01 9.90E-01 
  GOTERM_
MF_FAT  
potassium channel activity  8 1.50E-01 8.10E-01 
  SP_PIR_KE
YWORDS  
potassium  8 1.50E-01 7.40E-01 
  GOTERM_
BP_FAT  
potassium ion transport  8 2.20E-01 9.40E-01 
  SP_PIR_KE
YWORDS  








channel complex  
4 3.00E-01 8.00E-01 
  GOTERM_
CC_FAT  
potassium channel complex  4 3.00E-01 8.00E-01 
  INTERPRO  BTB/POZ-like  6 3.10E-01 1.00E+00 






Table 8. Genes involved in synaptic transmission were found to be specific to 
RMC 
Gene Symbol Gene Name Fold Change 
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8)  6.3234 
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C  5.9695 
Cpeb1 cytoplasmic polyadenylation element binding protein 1  4.8865 
Camk2a calcium/calmodulin-dependent protein kinase II alpha  4.6656 
S100b S100 calcium binding protein B  3.3308 
Arc activity-regulated cytoskeleton-associated protein  3.3203 
Cabc1 presenilin 2; chaperone, ABC1 activity of bc1 complex homolog (S. pombe)  3.2619 
Egr1 early growth response 1  3.2473 
Rnf39 ring finger protein 39  3.2455 
Grm8 glutamate receptor, metabotropic 8  2.386 
Plk3 polo-like kinase 3 (Drosophila)  2.079 
Sipa1l1 signal-induced proliferation-associated 1 like 1  2.0713 






Table 9. AMC and RMC-specific genes involved in functional pathways 
 AMC specific genes involved in cell proliferation  
Gene 
Symbol 
Gene Title Fold 
Change 
Sox4 SRY (sex determining region Y)-box 4 28.328 
Cd24 CD24 molecule 9.2544 
Mycn v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) 8.6884 
Casp3 caspase 3, apoptosis related cysteine protease 5.3212 
Marcksl1 MARCKS-like 1 5.254 
Pax6 paired box 6 5.123 
Scye1 small inducible cytokine subfamily E, member 1 4.7907 
Eef1e1 eukaryotic translation elongation factor 1 epsilon 1 4.7568 
Smad2 SMAD family member 2 4.7514 
Myo16 myosin XVI 4.4391 
Nfib nuclear factor I/B 4.2932 
Crip2 cysteine-rich protein 2 4.1602 
Hmg1l1 high-mobility group (nonhistone chromosomal) protein 1-like 1 3.9596 
Myc myelocytomatosis oncogene 3.835 
Vash2 vasohibin 2 3.7308 
Ybx1 Y box binding protein 1 3.7191 
Dhcr7 7-dehydrocholesterol reductase 3.6913 
Cdh13 cadherin 13 3.5609 
Id2 inhibitor of DNA binding 2 3.524 
Frs2 fibroblast growth factor receptor substrate 2 3.4399 
Ccna2 cyclin A2 3.2889 
Ccnd1 cyclin D1 3.201 
Npm1 nucleophosmin (nucleolar phosphoprotein B23, numatrin) 3.1793 
Coro1a coronin, actin binding protein 1A 3.146 
Nup62 nucleoporin 62 3.128 
Xrcc4 X-ray repair complementing defective repair in Chinese hamster cells 4 3.0992 




Zmiz1 zinc finger, MIZ-type containing 1 3.044 
Jun Jun oncogene 3.0095 
Cd47 Cd47 molecule 2.843 
Bex1 brain expressed gene 1 2.7963 
Akr1b1 aldo-keto reductase family 1, member B1 (aldose reductase) 2.779 
Eid2 EP300 interacting inhibitor of differentiation 2 2.7084 
Etv4 ets variant 4 2.6701 
Bmp2 bone morphogenetic protein 2 2.6681 
Hmgn1 high-mobility group nucleosome binding domain 1 2.5724 
Pdgfra platelet derived growth factor receptor, alpha polypeptide 2.5694 
Nolc1 nucleolar and coiled-body phosphoprotein 1 2.4885 
Mif macrophage migration inhibitory factor 2.4869 
Id3 inhibitor of DNA binding 3 2.3788 
Cdk4 cyclin-dependent kinase 4 2.3458 
Rps9 ribosomal protein S9 2.3402 
Csk c-src tyrosine kinase 2.3096 
Tsg101 tumor susceptibility gene 101 2.2867 
Igfbp3 insulin-like growth factor binding protein 3 2.2773 
Chrna7 Cholinergic receptor, nicotinic, alpha 7 2.2716 
Aggf1 angiogenic factor with G patch and FHA domains 1 2.2678 
Stat1 signal transducer and activator of transcription 1 2.2596 
Nme2 non-metastatic cells 2, protein (NM23B) expressed in 2.2229 
Cfdp1 craniofacial development protein 1 2.194 
Arnt2 aryl hydrocarbon receptor nuclear translocator 2 2.1418 
Tp53 tumor protein p53 2.1165 
Cdc2 cell division cycle 2, G1 to S and G2 to M 2.0803 
Vash1 vasohibin 1 2.0244 
Foxp1 Forkhead box P1 2.0145 
 RMC specific genes involved in cell proliferation  
Gene Symbol Gene Title Fold  Change 




Tesc Tescalcin 5.6757 
Smarca2 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
3.663 
Hrh3 histamine receptor H3 3.5485 
Mll1 myeloid/lymphoid or mixed-lineage leukemia 1 2.9906 
Mitf microphthalmia-associated transcription factor 2.9697 
Dbp D site of albumin promoter (albumin D-box) binding protein 2.9682 
Csf1 colony stimulating factor 1 (macrophage) 2.8628 
Hsf4 heat shock transcription factor 4 2.5857 
Tnfsf13 tumor necrosis factor (ligand) superfamily, member 13 2.414 
Acvrl1 activin A receptor type II-like 1 2.4091 
Rogdi rogdi homolog (Drosophila) 2.2851 
Insl3 insulin-like 3 2.1941 
Bdkrb2 /// 
RGD1308470 
bradykinin receptor B2 /// similar to RIKEN cDNA 4933433P14 gene 2.1876 
Rxra retinoid X receptor alpha 2.1608 
Runx3 runt-related transcription factor 3 2.1139 
Tek TEK tyrosine kinase, endothelial 2.1025 
Esrra estrogen related receptor, alpha 2.1 
Syk spleen tyrosine kinase 2.0797 
Tgm2 transglutaminase 2, C polypeptide 2.0755 
Fbxo2 F-box protein 2 2.0622 
Cntfr ciliary neurotrophic factor receptor 2.0575 
Hdac1 histone deacetylase 1 2.0538 
Casr calcium-sensing receptor 2.0507 
Btg3 B-cell translocation gene 3 2.0372 
Il13 interleukin 13 2.0364 
Ptprv protein tyrosine phosphatase, receptor type, V 2.0303 
Serpinf1 serine (or cysteine) peptidase inhibitor, clade F, member 1 2.001 
 AMC specific genes involved in cell cycle  




Rprm reprimo, TP53 dependent G2 arrest mediator candidate  19.125 
Mcm6 minichromosome maintenance complex component 6  8.1985 
Anapc10 anaphase promoting complex subunit 10  8.066 
Tubb5 tubulin, beta 5  7.3307 
Tubb5 tubulin, beta 5  7.1734 
Mapre1 microtubule-associated protein, RP/EB family, member 1; similar to 
Microtubule-associated protein RP/EB family member 1 (APC-binding 
protein EB1) (End-binding protein 1) (EB1)  
7.0496 
Psme3 similar to proteaseome (prosome, macropain) 28 subunit, 3; proteasome 
(prosome, macropain) activator subunit 3  
7.0045 
Spast spastin  6.988 
Psmc6 proteasome (prosome, macropain) 26S subunit, ATPase, 6; similar to 
Psmc6 protein  
6.4896 
Nasp nuclear autoantigenic sperm protein (histone-binding); similar to 
nuclear autoantigenic sperm protein  
5.2995 
Ube2d1 ubiquitin-conjugating enzyme E2D 1, UBC4/5 homolog (yeast)  5.0533 
Nuf2 NUF2, NDC80 kinetochore complex component, homolog (S. 
cerevisiae)  
4.9688 
Npm1 nucleophosmin (nucleolar phosphoprotein B23, numatrin); similar to 
Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) 
(Nucleolar protein NO38)  
4.9399 
Dbc1 deleted in bladder cancer 1 (human)  4.8326 
Stmn1 stathmin 1  4.7384 
Racgap1 Rac GTPase-activating protein 1  4.6191 
Smc1a structural maintenance of chromosomes 1A  4.4069 
Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1  4.3134 
Ska2 hypothetical protein LOC691962; hypothetical protein LOC687897; 
family with sequence similarity 33, member A  
4.0094 
Khdrbs1 KH domain containing, RNA binding, signal transduction associated 1  3.9389 
Tubb3 tubulin, beta 3  3.8563 
Psme1 proteasome (prosome, macropain) activator subunit 1  3.6823 




Rrs1 RRS1 ribosome biogenesis regulator homolog (S. cerevisiae)  3.571 
Sept11 septin 11  3.5036 
Cdca8 cell division cycle associated 8  3.4068 
Ube2i transmembrane protein 215; similar to Ubiquitin-conjugating enzyme 
E2 I (Ubiquitin-protein ligase I) (Ubiquitin carrier protein I) (SUMO-1-
protein ligase) (SUMO-1-conjugating enzyme) (Ubiquitin-conjugating 
enzyme UbcE2A); ubiquitin-conjugating enzyme E2I  
3.3128 
Ccna2 cyclin A2  3.2889 
Ran RAN, member RAS oncogene family  3.2657 
Ccnb2 cyclin B2  3.2038 
Ccnd1 cyclin D1  3.201 
Psmb2 proteasome (prosome, macropain) subunit, beta type 2  3.1812 
Npm1 nucleophosmin (nucleolar phosphoprotein B23, numatrin); similar to 
Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) 
(Nucleolar protein NO38)  
3.1793 
Rnf2 ring finger protein 2  3.1366 
Psmd6 proteasome (prosome, macropain) 26S subunit, non-ATPase, 6  3.1318 
Msh2 mutS homolog 2 (E. coli)  3.1126 
Haus1 coiled-coil domain containing 5  3.0948 
Calm2 calmodulin pseudogene 2; calmodulin 3; calmodulin 2; calmodulin 1  3.0685 
Npm1 nucleophosmin (nucleolar phosphoprotein B23, numatrin); similar to 
Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) 
(Nucleolar protein NO38)  
3.0648 
Nek6 NIMA (never in mitosis gene a)-related kinase 6  2.9406 
Psma1 proteasome (prosome, macropain) subunit, alpha type 1  2.9127 
--- similar to spindlin; spindlin 1  2.8794 
Calm1 calmodulin pseudogene 2; calmodulin 3; calmodulin 2; calmodulin 1  2.8775 
Ppm1g protein phosphatase 1G (formerly 2C), magnesium-dependent, gamma 
isoform  
2.8138 
Rad17 RAD17 homolog (S. pombe)  2.8077 
LOC100361067 
/// Psma3 /// 
proteasome (prosome, macropain) subunit, alpha type 3; proteasome 





Psma3l (Proteasome component C8) (Macropain subunit C8) (Multicatalytic 
endopeptidase complex subunit C8) (Proteasome subunit K)  
Cdc25b cell division cycle 25 homolog B (S. pombe)  2.7607 
Nusap1 nucleolar and spindle associated protein 1  2.7393 
Uba3 ubiquitin-like modifier activating enzyme 3  2.7254 
Pelo pelota homolog (Drosophila)  2.7203 
Smc2 structural maintenance of chromosomes 2  2.7164 
Psmc6 proteasome (prosome, macropain) 26S subunit, ATPase, 6; similar to 
Psmc6 protein  
2.6092 
Zwint ZW10 interactor  2.5857 
Akt1 v-akt murine thymoma viral oncogene homolog 1  2.5848 
Psmb4 proteasome (prosome, macropain) subunit, beta type 4  2.5649 
Mapk6 mitogen-activated protein kinase 6  2.5004 
Anapc10 anaphase promoting complex subunit 10  2.4138 
Sept3 septin 3  2.3462 
Cdk4 cyclin-dependent kinase 4  2.3458 
Pdpn podoplanin  2.3404 
Kif3b kinesin family member 3B  2.3164 
Mad2l1 MAD2 (mitotic arrest deficient, homolog)-like 1 (yeast)  2.2948 
Tsg101 tumor susceptibility gene 101  2.2867 
Sept6 NF-KB repressing factor; septin 6  2.2675 
Cks1b similar to Cyclin-dependent kinases regulatory subunit 1 (CKS-1) (Sid 
1334); RGD1561797  
2.1804 
Ppp6c protein phosphatase 6, catalytic subunit  2.1596 
Psmd2 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2  2.1413 
Psma5 proteasome (prosome, macropain) subunit, alpha type 5  2.1221 
Tp53 tumor protein p53  2.1165 
Sept9 septin 9  2.1059 
Chtf8 CTF8, chromosome transmission fidelity factor 8 homolog (S. 
cerevisiae)  
2.1014 
Cdc2 cell division cycle 2, G1 to S and G2 to M  2.0803 




Psmd1 proteasome (prosome, macropain) 26S subunit, non-ATPase, 1  2.0534 
Chmp1a chromatin modifying protein 1A  2.0489 
Ube2i transmembrane protein 215; similar to Ubiquitin-conjugating enzyme 
E2 I (Ubiquitin-protein ligase I) (Ubiquitin carrier protein I) (SUMO-1-
protein ligase) (SUMO-1-conjugating enzyme) (Ubiquitin-conjugating 




similar to polyubiquitin; ubiquitin C; ubiquitin B  2.0076 
 RMC specific genes involved in cell cycle  
Gene Symbol Gene Name Fold Change 
Sept4 septin 4  6.0436 
Cpeb1 cytoplasmic polyadenylation element binding protein 1  4.8865 
Camk2a calcium/calmodulin-dependent protein kinase II alpha  4.6656 
--- septin 8  3.8265 
Sept8 septin 8  3.7375 
Camk2a calcium/calmodulin-dependent protein kinase II alpha  3.5972 
Camk2a calcium/calmodulin-dependent protein kinase II alpha  3.524 
Mapk12 mitogen-activated protein kinase 12  2.9091 
Mapre3 microtubule-associated protein, RP/EB family, member 3  2.894 
Numa1 nuclear mitotic apparatus protein 1  2.7358 
Plk5 polo-like kinase 5 pseudogene  2.5451 
Ddit3 DNA-damage inducible transcript 3  2.1394 
Plk3 polo-like kinase 3 (Drosophila)  2.079 
 AMC specific genes involved in cell death  
Gene Symbol Gene Name Fold Change 
Cd24 CD24 molecule  9.2544 
Apaf1 apoptotic peptidase activating factor 1  6.6501 
Ddah1 B-cell CLL/lymphoma 10; dimethylarginine dimethylaminohydrolase 1  6.1822 
Rac1 ras-related C3 botulinum toxin substrate 1  5.5863 
Casp3 caspase 3, apoptosis related cysteine protease  5.3212 




Casp2 caspase 2  4.1832 
Polb polymerase (DNA directed), beta  4.0578 
Mmd monocyte to macrophage differentiation-associated  3.9032 
Myc myelocytomatosis oncogene  3.835 
Ywhae tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, epsilon polypeptide  
3.2796 
Faim Fas apoptotic inhibitory molecule  3.1639 
Nup62 nucleoporin 62  3.128 
Msh2 mutS homolog 2 (E. coli)  3.1126 
Gapdh similar to glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) 
(EC 1.2.1.12)  
3.0318 
Ngfrap1 nerve growth factor receptor (TNFRSF16) associated protein 1  3.0174 
Jun Jun oncogene  3.0095 
Mapt microtubule-associated protein tau  2.9792 
Rac1 ras-related C3 botulinum toxin substrate 1  2.9728 
Nek6 NIMA (never in mitosis gene a)-related kinase 6  2.9406 
Mcl1 myeloid cell leukemia sequence 1  2.8383 
Pdcd6 programmed cell death 6  2.5972 
Luc7l3 cisplatin resistance-associated overexpressed protein  2.596 
Akt1 v-akt murine thymoma viral oncogene homolog 1  2.5848 
Aen apoptosis enhancing nuclease  2.4961 
Pdcd10 programmed cell death 10  2.434 
Madd MAP-kinase activating death domain  2.3363 
Aimp2 JTV1 gene  2.3333 
Smndc1 survival motor neuron domain containing 1  2.2793 
Sqstm1 sequestosome 1  2.2461 
Psmg2 proteasome (prosome, macropain) assembly chaperone 2  2.2433 
Tp53 tumor protein p53  2.1165 
Ift57 intraflagellar transport 57 homolog (Chlamydomonas)  2.0491 
Bre brain and reproductive organ-expressed protein  2.0428 
Mapt microtubule-associated protein tau  2.034 




protein, beta polypeptide  
LOC100360548 
/// Ubb 
similar to polyubiquitin; ubiquitin C; ubiquitin B  2.0076 
 RMC specific genes involved in cell death  
Gene Symbol Gene Name Fold Change 
Slc5a11 solute carrier family 5 (sodium/glucose cotransporter), member 11  12.343 
Gsn gelsolin  3.9717 
Aifm3 apoptosis-inducing factor, mitochondrion-associated 3  3.547 
Cabc1 presenilin 2; chaperone, ABC1 activity of bc1 complex homolog (S. 
pombe)  
3.2619 
Rtkn rhotekin  2.6178 
--- forkhead box L2  2.4773 
Tnfsf13 tumor necrosis factor (ligand) superfamily, member 13  2.414 
Sp110 SP110 nuclear body protein  2.3595 
Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a  2.3378 
Ube2z ubiquitin-conjugating enzyme E2Z  2.3277 
P2rx1 purinergic receptor P2X, ligand-gated ion channel, 1  2.3229 
Elmo3 engulfment and cell motility 3  2.2129 
Aatk apoptosis-associated tyrosine kinase  2.2009 
Ifnb1 interferon beta 1, fibroblast  2.1702 
Gata6 GATA binding protein 6  2.1637 
Hip1 huntingtin interacting protein 1  2.0956 
Aldoc aldolase C, fructose-bisphosphate  2.077 
 AMC specific genes involved in cell migration  
Gene Symbol Gene Name Fold Change 
--- SATB homeobox 2  18.049 
Dcx doublecortin  16.642 
Cxcr4 chemokine (C-X-C motif) receptor 4  12.759 
Cxcr4 chemokine (C-X-C motif) receptor 4  12.274 
--- cofilin 1, non-muscle; similar to Cofilin-1 (Cofilin, non-muscle isoform)  9.3235 




Pex13 peroxisomal biogenesis factor 13  8.4726 
Rac1 ras-related C3 botulinum toxin substrate 1  5.5863 
Pax6 paired box 6  5.123 
Aimp1 small inducible cytokine subfamily E, member 1  4.7907 
Reln reelin  4.568 
Ctnna2 catenin (cadherin associated protein), alpha 2  4.4094 
Ctgf connective tissue growth factor  4.374 
Nckap1 NCK-associated protein 1  4.268 
Cdh13 cadherin 13  4.2509 
Fyn FYN oncogene related to SRC, FGR, YES  4.249 
Pou3f3 POU class 3 homeobox 3  4.1031 
Fut8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase)  3.9358 
Cdh2 cadherin 2  3.7671 
Cdh13 cadherin 13  3.5609 
Ywhae tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, epsilon polypeptide  
3.2796 
Dclk1 doublecortin-like kinase 1  3.2522 
Coro1a coronin, actin binding protein 1A  3.146 
Rac1 ras-related C3 botulinum toxin substrate 1  2.9728 
Cd47 Cd47 molecule  2.843 
Cdh2 cadherin 2  2.8205 
Astn1 astrotactin 1  2.7225 
Nup85 nucleoporin 85kDa  2.718 
Dclk1 doublecortin-like kinase 1  2.6822 
Nrg1 neuregulin 1  2.5663 
Ndn necdin homolog (mouse)  2.5112 
Nrp1 neuropilin 1  2.4484 
Podxl podocalyxin-like  2.3518 
Nr2f1 nuclear receptor subfamily 2, group F, member 1  2.2851 
Vhl von Hippel-Lindau tumor suppressor  2.216 




Gene Symbol Gene Name Fold Change 
Robo3 roundabout homolog 3 (Drosophila)  17.393 
Acvrl1 activin A receptor type II-like 1  2.4091 
Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a  2.3378 
Plekhg5 pleckstrin homology domain containing, family G (with RhoGef domain) 
member 5  
2.3121 
Cntn2 contactin 2 (axonal)  2.1679 
Tlx3 T-cell leukemia, homeobox 3  2.0799 
Syk spleen tyrosine kinase  2.0797 
Barhl2 BarH-like homeobox 2  2.0607 
Apoa1 apolipoprotein A-I  2.0495 
 AMC specific genes involved in cytoskeleton  
Gene Symbol Gene Name Fold Change 
Dpysl3 dihydropyrimidinase-like 3  31.006 
Appbp2 amyloid beta precursor protein (cytoplasmic tail) binding protein 2  13.277 
--- cofilin 1, non-muscle; similar to Cofilin-1 (Cofilin, non-muscle 
isoform)  
9.3235 
Marcks myristoylated alanine rich protein kinase C substrate  8.5949 
Tubb5 tubulin, beta 5  7.3307 
Tubb5 tubulin, beta 5  7.1734 
Mapre1 microtubule-associated protein, RP/EB family, member 1; similar to 
Microtubule-associated protein RP/EB family member 1 (APC-binding 
protein EB1) (End-binding protein 1) (EB1)  
7.0496 
Spast spastin  6.988 




tubulin, alpha 1C  6.3695 
Ywhaz tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, zeta polypeptide  
6.0917 




cytoplasmic 2 (Gamma-actin); similar to actin-like  
Cttnbp2nl CTTNBP2 N-terminal like  5.6111 
Stau2 staufen, RNA binding protein, homolog 2 (Drosophila)  5.6094 
Pfn2 profilin 2  5.1856 
Mid1 midline 1  5.0901 
Npm1 nucleophosmin (nucleolar phosphoprotein B23, numatrin); similar to 
Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) 
(Nucleolar protein NO38)  
4.9399 
Dynlt1 dynein light chain Tctex-type 1  4.8568 
Stmn1 stathmin 1  4.7384 
Actr2 ARP2 actin-related protein 2 homolog (yeast)  4.6831 
Akap12 A kinase (PRKA) anchor protein 12  4.5495 
Tpm4 tropomyosin 4  4.5474 
Myo16 myosin XVI  4.4391 
Ctnna2 catenin (cadherin associated protein), alpha 2  4.4094 
Stau2 staufen, RNA binding protein, homolog 2 (Drosophila)  4.2722 
Vcl vinculin  4.2035 
Ckap2 similar to cytoskeleton associated protein 2; cytoskeleton associated 
protein 2  
4.1187 
Kif2a similar to hypothetical protein; kinesin family member 2A  4.0729 
Polb polymerase (DNA directed), beta  4.0578 
Ska2 hypothetical protein LOC691962; hypothetical protein LOC687897; 
family with sequence similarity 33, member A  
4.0094 
Lasp1 LIM and SH3 protein 1  3.953 
Actr3 ARP3 actin-related protein 3 homolog (yeast)  3.8936 
Tubb3 tubulin, beta 3  3.8563 
Myc myelocytomatosis oncogene  3.835 
--- myristoylated alanine rich protein kinase C substrate  3.7211 
Trim32 tripartite motif-containing 32  3.6942 
Actb actin, beta  3.6424 
Tbca tubulin folding cofactor A  3.5647 




Sept11 septin 11  3.5036 
Ap1g1 adaptor-related protein complex 1, gamma 1 subunit  3.4678 
Hsbp1 heat shock factor binding protein 1  3.4454 
Arpc5 actin related protein 2/3 complex, subunit 5  3.4395 
Cdca8 cell division cycle associated 8  3.4068 
Map1b microtubule-associated protein 1B  3.2594 
Cbx1 chromobox homolog 1 (HP1 beta homolog Drosophila )  3.2536 
Gabarap GABA(A) receptor-associated protein  3.2524 
Prkcb protein kinase C, beta  3.2509 
Arpc2 actin related protein 2/3 complex, subunit 2  3.2334 
Ccnb2 cyclin B2  3.2038 
Appbp2 amyloid beta precursor protein (cytoplasmic tail) binding protein 2  3.1876 
Nefl neurofilament, light polypeptide  3.1827 
Npm1 nucleophosmin (nucleolar phosphoprotein B23, numatrin); similar to 
Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) 
(Nucleolar protein NO38)  
3.1793 
Coro1a coronin, actin binding protein 1A  3.146 
H1f0 H1 histone family, member 0  3.1325 
Nup62 nucleoporin 62  3.128 
Dync1i1 dynein cytoplasmic 1 intermediate chain 1  3.124 
Arl8a ADP-ribosylation factor-like 8A  3.1143 
Haus1 coiled-coil domain containing 5  3.0948 
Lmnb1 lamin B1  3.0938 
Clip2 CAP-GLY domain containing linker protein 2  3.0825 
Calm2 calmodulin pseudogene 2; calmodulin 3; calmodulin 2; calmodulin 1  3.0685 
Npm1 nucleophosmin (nucleolar phosphoprotein B23, numatrin); similar to 
Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) 
(Nucleolar protein NO38)  
3.0648 
Mapt microtubule-associated protein tau  2.9792 
Cnn3 calponin 3, acidic  2.8817 
--- similar to spindlin; spindlin 1  2.8794 




Ndrg1 N-myc downstream regulated gene 1  2.8387 
Arhgap24 Rho GTPase activating protein 24  2.8244 
Actr1a ARP1 actin-related protein 1 homolog A, centractin alpha (yeast)  2.8046 
LOC100361067 
/// Psma3 /// 
Psma3l 
proteasome (prosome, macropain) subunit, alpha type 3; proteasome 
subunit alpha type 3-like; similar to Proteasome subunit alpha type 3 
(Proteasome component C8) (Macropain subunit C8) (Multicatalytic 
endopeptidase complex subunit C8) (Proteasome subunit K)  
2.7971 
Cdc25b cell division cycle 25 homolog B (S. pombe)  2.7607 
Map1b microtubule-associated protein 1B  2.7587 
Myo5a myosin Va  2.7463 
Nusap1 nucleolar and spindle associated protein 1  2.7393 
Actr10 actin-related protein 10 homolog (S. cerevisiae)  2.7331 
Nup85 nucleoporin 85kDa  2.718 
Tnks2 tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 2  2.6977 
Kif3c kinesin family member 3C  2.6881 
Dync1h1 dynein cytoplasmic 1 heavy chain 1  2.6624 
Tpm3 tropomyosin 3, gamma  2.6579 
Tmsb10 similar to thymosin, beta 10; thymosin, beta 10  2.6407 
Tbl1xr1 transducin (beta)-like 1 X-linked receptor 1  2.6107 
Dpysl2 dihydropyrimidinase-like 2  2.6079 
Akt1 v-akt murine thymoma viral oncogene homolog 1  2.5848 
Psmb4 proteasome (prosome, macropain) subunit, beta type 4  2.5649 
Tbl1xr1 transducin (beta)-like 1 X-linked receptor 1  2.5429 
Mtss1 metastasis suppressor 1  2.5385 
Ndn necdin homolog (mouse)  2.5112 
Ip6k2 inositol hexakisphosphate kinase 2  2.4902 
Tpm3 tropomyosin 3, gamma  2.4784 
Add2 adducin 2 (beta)  2.4619 
Pfn1 profilin 1  2.4598 
Rhoq ras homolog gene family, member Q  2.458 
Actr3 ARP3 actin-related protein 3 homolog (yeast)  2.4502 




Dctn6 dynactin 6  2.3803 
Kif18b /// 
LOC100363850 
kinesin family member 18B  2.3528 
Sept3 septin 3  2.3462 
Kif3b kinesin family member 3B  2.3164 
Ina internexin neuronal intermediate filament protein, alpha  2.3027 
Mad2l1 MAD2 (mitotic arrest deficient, homolog)-like 1 (yeast)  2.2948 
Wdr1 WD repeat domain 1  2.2916 
Chrna7 cholinergic receptor, nicotinic, alpha 7  2.2716 
Sept6 κ repressing factor; septin 6  2.2675 
Dctn3 similar to dynactin 3; dynactin 3  2.2652 
Nme2 non-metastatic cells 2, protein (NM23B) expressed in; non-metastatic 
cells 2, protein (NM23B) expressed in, pseudogene 1  
2.2229 
Sptbn1 spectrin, beta, non-erythrocytic 1  2.1942 
Gabarap GABA(A) receptor-associated protein  2.177 
Tpm1 tropomyosin 1, alpha  2.1674 
Cotl1 coactosin-like 1 (Dictyostelium)  2.1611 
Cttnbp2nl CTTNBP2 N-terminal like  2.1313 
Farp1 FERM, RhoGEF (Arhgef) and pleckstrin domain protein 1 
(chondrocyte-derived)  
2.1199 
Kif2a similar to hypothetical protein; kinesin family member 2A  2.1086 
Sept9 septin 9  2.1059 
Kif2a similar to hypothetical protein; kinesin family member 2A  2.0971 
Cdc2 cell division cycle 2, G1 to S and G2 to M  2.0803 
Ift57 intraflagellar transport 57 homolog (Chlamydomonas)  2.0491 
Chmp1a chromatin modifying protein 1A  2.0489 
Mapt microtubule-associated protein tau  2.034 
Stmn3 stathmin-like 3  2.0278 
Jakmip1 janus kinase and microtubule interacting protein 1  2.0262 
 RMC specific genes involved in cytoskeleton  




Asb14 dynein, axonemal, heavy polypeptide 12  12.772 
Ermn ermin, ERM-like protein  8.8241 
Tnnc2 troponin C type 2 (fast)  8.6024 
Sept4 septin 4  6.0436 
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C  5.9695 
Ttll9 tubulin tyrosine ligase-like family, member 9  5.7674 
Myh11 myosin, heavy chain 11, smooth muscle  5.2547 
Sptbn4 spectrin, beta, non-erythrocytic 4  5.1284 
Cnksr2 connector enhancer of kinase suppressor of Ras 2  5.1124 
Iqub IQ motif and ubiquitin domain containing; Wiskott-Aldrich syndrome-like  5.0687 
Cpeb1 cytoplasmic polyadenylation element binding protein 1  4.8865 
Tnnt1 troponin T type 1 (skeletal, slow)  4.4062 
Nefh neurofilament, heavy polypeptide  4.2066 
Ablim2 actin binding LIM protein family, member 2  4.1983 
Tnni3 troponin I type 3 (cardiac)  4.0048 
Dnah7 dynein, axonemal, heavy polypeptide 7  3.9824 
Gsn gelsolin  3.9717 
Dnah1 dynein, axonemal, heavy chain 1  3.858 
P2rx6 purinergic receptor P2X, ligand-gated ion channel, 6  3.8483 
--- septin 8  3.8265 
Camk2n1 calcium/calmodulin-dependent protein kinase II inhibitor 1  3.7875 
Sept8 septin 8  3.7375 
Arc activity-regulated cytoskeleton-associated protein  3.3203 
Cort cortistatin; kinesin family member 1B  3.2903 
Tmod1 tropomodulin 1  3.2862 
Fermt3 fermitin family homolog 3 (Drosophila)  3.0629 
Cdc42ep1 CDC42 effector protein (Rho GTPase binding) 1  3.0373 
Dnai1 dynein, axonemal, intermediate chain 1  3.0337 
Arhgap4 Rho GTPase activating protein 4  2.9998 
Wasl IQ motif and ubiquitin domain containing; Wiskott-Aldrich syndrome-like  2.9348 




Mapre3 microtubule-associated protein, RP/EB family, member 3  2.894 
Plekhh3 pleckstrin homology domain containing, family H (with MyTH4 domain) 
member 3  
2.8935 
Numa1 nuclear mitotic apparatus protein 1  2.7358 
Ints6 integrator complex subunit 6  2.6003 
Itpr1 inositol 1,4,5-triphosphate receptor, type 1  2.5019 
Fermt2 fermitin family homolog 2 (Drosophila)  2.3256 
Dnali1 dynein, axonemal, light intermediate chain 1  2.3126 
Pkp2 plakophilin 2  2.3106 
Shroom1 shroom family member 1  2.2842 
Pstpip1 proline-serine-threonine phosphatase-interacting protein 1  2.2798 
Ermn ermin, ERM-like protein  2.2732 
Tln1 talin 1  2.2627 
Lmna lamin A  2.2565 
Myh13 myosin, heavy chain 13, skeletal muscle  2.2529 
Ubr4 ZUBR1  2.2474 
Pxn paxillin  2.2373 
Freq frequenin homolog (Drosophila)  2.2311 
Elmo3 engulfment and cell motility 3  2.2129 
Tchp trichoplein, keratin filament binding  2.1749 
Myrip myosin VIIA and Rab interacting protein  2.1568 
Ptpn4 protein tyrosine phosphatase, non-receptor type 4  2.086 
Abca2 ATP-binding cassette, sub-family A (ABC1), member 2  2.0815 
 AMC specific genes involved in cell morphogenesis  
Gene Symbol Gene Name Fold Change 
Dpysl3 dihydropyrimidinase-like 3  31.006 
Dcx doublecortin  16.642 
Cxcr4 chemokine (C-X-C motif) receptor 4  12.759 
Ect2 epithelial cell transforming sequence 2 oncogene  12.498 
Cxcr4 chemokine (C-X-C motif) receptor 4  12.274 




Hnrnpab heterogeneous nuclear ribonucleoprotein A/B  8.8712 
Nrep neuronal regeneration related protein  7.4128 
Stradb amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 
2 (human)  
5.8947 
Rac1 ras-related C3 botulinum toxin substrate 1  5.5863 
Klf7 Kruppel-like factor 7 (ubiquitous)  5.4363 
Cdc42 cell division cycle 42 (GTP binding protein)  5.1257 
Pax6 paired box 6  5.123 
Vcan versican  4.9595 
Stmn1 stathmin 1  4.7384 
Bmp2 bone morphogenetic protein 2  4.5698 
Reln reelin  4.568 
Ctnna2 catenin (cadherin associated protein), alpha 2  4.4094 
Fat1 FAT tumor suppressor homolog 1 (Drosophila)  4.2863 
Hmg1l1 similar to high mobility group protein 1 (HMG-1)  3.9596 
Gap43 growth associated protein 43  3.9493 
Actb actin, beta  3.6424 
Map1b microtubule-associated protein 1B  3.2594 
Dclk1 doublecortin-like kinase 1  3.2522 
Nefl neurofilament, light polypeptide  3.1827 
RGD1311558 similar to 4930506M07Rik protein  3.0291 
Rac1 ras-related C3 botulinum toxin substrate 1  2.9728 
Epha4 Eph receptor A4  2.7895 
Vcan versican  2.7777 
Map1b microtubule-associated protein 1B  2.7587 
Plxna3 plexin A3  2.7048 
Dclk1 doublecortin-like kinase 1  2.6822 
Etv4 ets variant 4  2.6701 
Bmp2 bone morphogenetic protein 2  2.6681 
Robo2 roundabout, axon guidance receptor, homolog 2 (Drosophila)  2.6021 
L1cam L1 cell adhesion molecule  2.5785 




Ndn necdin homolog (mouse)  2.5112 
Nrp1 neuropilin 1  2.4484 
Robo2 roundabout, axon guidance receptor, homolog 2 (Drosophila)  2.3881 
Pdpn podoplanin  2.3404 
Hmgb1 similar to high mobility group protein; Rattus norvegicus high mobility 
group box 1, pseudogene 3; similar to Hmgb1 protein; similar to High 
mobility group protein 1 (HMG-1) 
2.1736 
Trim28 tripartite motif-containing 28  2.1465 
Sdc2 syndecan 2  2.0821 
  RMC specific genes involved in cell morphogenesis 
Gene Symbol Gene Name Fold Change 
Robo3 roundabout homolog 3 (Drosophila)  17.393 
Sptbn4 spectrin, beta, non-erythrocytic 4  5.1284 
Map7 microtubule-associated protein 7  3.263 
Shroom1 shroom family member 1  2.2842 
Cntn2 contactin 2 (axonal)  2.1679 
Rxra retinoid X receptor alpha  2.1608 
Runx3 runt-related transcription factor 3  2.1139 
Vax2 ventral anterior homeobox 2  2.0916 
Apoa1 apolipoprotein A-I  2.0495 
Onecut1 one cut homeobox 1  2.002 
 AMC specific genes involved in Neuron 
differentiation 
 
Gene Symbol Gene Name Fold Change 
Dpysl3 dihydropyrimidinase-like 3  31.006 
Dcx doublecortin  16.642 
Crmp1 collapsin response mediator protein 1  15.498 
Cxcr4 chemokine (C-X-C motif) receptor 4  12.759 
Cxcr4 chemokine (C-X-C motif) receptor 4  12.274 
Smarca1 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 1  
10.724 
Cd24 CD24 molecule  9.2544 




Nrep neuronal regeneration related protein  7.4128 
Gnao1 guanine nucleotide binding protein (G protein), alpha activating activity 
polypeptide O  
7.3973 
Gpc2 glypican 2  6.8796 
Rac1 ras-related C3 botulinum toxin substrate 1  5.5863 
Klf7 Kruppel-like factor 7 (ubiquitous)  5.4363 
Casp3 caspase 3, apoptosis related cysteine protease  5.3212 
Cdc42 cell division cycle 42 (GTP binding protein)  5.1257 
Pax6 paired box 6  5.123 
Vcan versican  4.9595 
Stmn1 stathmin 1  4.7384 
Reln reelin  4.568 
Bhlhe22 basic helix-loop-helix family, member e22  4.5657 
Ctnna2 catenin (cadherin associated protein), alpha 2  4.4094 
Gprin1 G protein-regulated inducer of neurite outgrowth 1  4.1506 
Gap43 growth associated protein 43  3.9493 
Tubb3 tubulin, beta 3  3.8563 
Atxn10 ataxin 10  3.8086 
Nkx2-2 NK2 homeobox 2  3.7815 
Nedd4 neural precursor cell expressed, developmentally down-regulated gene 4  3.6588 
Actb actin, beta  3.6424 
Nlgn1 neuroligin 1  3.5456 
Map1b microtubule-associated protein 1B  3.2594 
Dclk1 doublecortin-like kinase 1  3.2522 
Nefl neurofilament, light polypeptide  3.1827 
Cln8 ceroid-lipofuscinosis, neuronal 8  3.1431 
Hdac2 similar to Histone deacetylase 2 (HD2); histone deacetylase 2  3.0713 
RGD1311558 similar to 4930506M07Rik protein  3.0291 
Mapt microtubule-associated protein tau  2.9792 
Rac1 ras-related C3 botulinum toxin substrate 1  2.9728 
Rnd1 Rho family GTPase 1  2.9597 




Vcan versican  2.7777 
Map1b microtubule-associated protein 1B  2.7587 
Plxna3 plexin A3  2.7048 
Dclk1 doublecortin-like kinase 1  2.6822 
Etv4 ets variant 4  2.6701 
Robo2 roundabout, axon guidance receptor, homolog 2 (Drosophila)  2.6021 
L1cam L1 cell adhesion molecule  2.5785 
Nrg1 neuregulin 1  2.5663 
Ndn necdin homolog (mouse)  2.5112 
Nrp1 neuropilin 1  2.4484 
Agtpbp1 ATP/GTP binding protein 1   2.401 
Robo2 roundabout, axon guidance receptor, homolog 2 (Drosophila)  2.3881 
Id3 inhibitor of DNA binding 3  2.3788 
Stx3 syntaxin 3  2.2896 
Mtpn myotrophin  2.2567 
Sdc2 syndecan 2  2.0821 
Ptprk protein tyrosine phosphatase, receptor type, K, extracellular region  2.0808 
Trappc4 trafficking protein particle complex 4  2.0419 
Mapt microtubule-associated protein tau  2.034 
Stmn3 stathmin-like 3  2.0278 
 RMC specific genes involved in Neuron 
differentiation 
 
Gene Symbol Gene Name Fold Change 
Robo3 roundabout homolog 3 (Drosophila)  17.393 
Lgi4 leucine-rich repeat LGI family, member 4  8.1016 
Sptbn4 spectrin, beta, non-erythrocytic 4  5.1284 
--- kinase non-catalytic C-lobe domain (KIND) containing 1  4.2146 
Nkx6-2 NK6 homeobox 2  3.0395 
Lgi4 leucine-rich repeat LGI family, member 4  2.9917 
Ntrk1 neurotrophic tyrosine kinase, receptor, type 1  2.3371 




Cntn2 contactin 2 (axonal)  2.1679 
Rxra retinoid X receptor alpha  2.1608 
Runx3 runt-related transcription factor 3  2.1139 
Vax2 ventral anterior homeobox 2  2.0916 
Tlx3 T-cell leukemia, homeobox 3  2.0799 
Btg2 B-cell translocation gene 2, anti-proliferative  2.0761 
Barhl2 BarH-like homeobox 2  2.0607 
Hdac1 hypothetical gene supported by AF321129; similar to histone 
deacetylase 1; histone deacetylase 1; histone deacetylase 1-like  
2.0538 
Apoa1 apolipoprotein A-I  2.0495 
Olig2 oligodendrocyte lineage transcription factor 2  2.046 
Notch3 Notch homolog 3 (Drosophila)  2.0324 
Fscn2 fascin homolog 2, actin-bundling protein, retinal (Strongylocentrotus 
purpuratus)  
2.0267 
 AMC specific genes involved in Glial 
differentiation 
 
Gene Symbol Gene Name Fold Change 
Pax6 paired box 6  5.123 
Reln reelin  4.568 
Pou3f1 POU class 3 homeobox 1  4.5113 
Sox11 SRY (sex determining region Y)-box 11  4.5022 
Gap43 growth associated protein 43  3.9493 
Nkx2-2 NK2 homeobox 2  3.7815 
Nrg1 neuregulin 1  2.5663 
 RMC specific genes involved in Glial differentiation  
Gene Symbol Gene Name Fold Change 
Plp1 proteolipid protein 1  8.9996 
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8)  6.3234 
Aspa aspartoacylase  4.4382 
Gsn gelsolin  3.9717 




Nkx6-2 NK6 homeobox 2  3.0395 
Olig2 oligodendrocyte lineage transcription factor 2  2.046 
Metrn meteorin, glial cell differentiation regulator  2.0417 
 AMC specific genes involved in Myeloid 
differentiation 
 
Gene Symbol Gene Name Fold Change 
Hmgb3 high mobility group box 3; similar to High mobility group protein 4 
(HMG-4) (High mobility group protein 2a) (HMG-2a)  
12.466 
Hmg1l1 similar to high mobility group protein  3.9596 
Id2 inhibitor of DNA binding 2  3.524 
Jun Jun oncogene  3.0095 
Gnas GNAS complex locus   2.473 
Nme2 non-metastatic cells 2, protein (NM23B) expressed in; non-metastatic 
cells 2, protein (NM23B) expressed in, pseudogene 1  
2.2229 
Hmgb1 similar to high mobility group protein  2.1736 
 RMC specific genes involved in Myeloid 
differentiation 
 
Gene Symbol Gene Name Fold Change 
Tesc tescalcin  5.6757 
Car2 carbonic anhydrase II  3.7983 
Mitf microphthalmia-associated transcription factor  2.9697 
Csf1 colony stimulating factor 1 (macrophage)  2.8628 
Zbtb7a zinc finger and BTB domain containing 7a  2.1625 
Adipoq adiponectin, C1Q and collagen domain containing  2.1101 
Esrra estrogen related receptor, alpha  2.1 
Car2 carbonic anhydrase II  2.0443 
 AMC specific genes involved in Leukocyte 
differentiation 
 
Gene Symbol Gene Name Fold Change 




Cd24 CD24 molecule  9.2544 
Sox4 SRY (sex determining region Y)-box 4  6.6886 
Sstr1 somatostatin receptor 1  6.1777 
Cbfb core-binding factor, beta subunit  6.0758 
Sox4 SRY (sex determining region Y)-box 4  4.6399 
Bcl11a B-cell CLL/lymphoma 11A (zinc finger protein)   3.5046 
Coro1a coronin, actin binding protein 1A  3.146 
Msh2 mutS homolog 2 (E. coli)  3.1126 
Xrcc4 X-ray repair complementing defective repair in Chinese hamster cells 4  3.0992 
Tp53 tumor protein p53  2.1165 
Foxp1 forkhead box P1  2.0145 
 RMC specific genes involved in Leukocyte 
differentiation 
 
Gene Symbol Gene Name Fold Change 
Car2 carbonic anhydrase II  3.7983 
Cabc1 presenilin 2; chaperone, ABC1 activity of bc1 complex homolog 
(S. pombe)  
3.2619 
Egr1 early growth response 1  3.2473 
Mitf microphthalmia-associated transcription factor  2.9697 
Csf1 colony stimulating factor 1 (macrophage)  2.8628 
LOC687705 /// Mink1 similar to misshapen-like kinase 1 isoform 1; similar to Map4k6-
pending protein  
2.7585 
Ntrk1 neurotrophic tyrosine kinase, receptor, type 1  2.3371 
Cd74 Cd74 molecule, major histocompatibility complex, class II 
invariant chain  
2.1378 
Syk spleen tyrosine kinase  2.0797 
Car2 carbonic anhydrase II  2.0443 
Onecut1 one cut homeobox 1  2.002 






Gene Symbol Gene Name Fold Change 
Sox4 SRY (sex determining region Y)-box 4  28.328 
Cd24 CD24 molecule  9.2544 
Sox4 SRY (sex determining region Y)-box 4  6.6886 
Sstr1 somatostatin receptor 1  6.1777 
Cbfb core-binding factor, beta subunit  6.0758 
Sox4 SRY (sex determining region Y)-box 4  4.6399 
Bcl11a B-cell CLL/lymphoma 11A (zinc finger protein)   3.5046 
Coro1a coronin, actin binding protein 1A  3.146 
Msh2 mutS homolog 2 (E. coli)  3.1126 
Xrcc4 X-ray repair complementing defective repair in Chinese hamster cells 4  3.0992 
Tp53 tumor protein p53  2.1165 
Foxp1 forkhead box P1  2.0145 
 RMC specific genes involved in Lymphocyte 
differentiation 
 
Gene Symbol Gene Name Fold Change 
Egr1 early growth response 1  3.2473 
LOC687705 /// Mink1 similar to misshapen-like kinase 1 isoform 1; similar to 
Map4k6-pending protein  
2.7585 
Ntrk1 neurotrophic tyrosine kinase, receptor, type 1  2.3371 
Cd74 Cd74 molecule, major histocompatibility complex, class II 
invariant chain  
2.1378 
Syk spleen tyrosine kinase  2.0797 
Onecut1 one cut homeobox 1  2.002 
 AMC specific genes involved in Muscle cell 
differentiation 
 
Gene Symbol Gene Name Fold Change 
Actg1 actin, gamma 1; similar to put. type 5 nonmuscle actin; similar to Actin, 
cytoplasmic 2 (Gamma-actin); similar to actin-like  
5.8562 




Csrp2 cysteine and glycine-rich protein 2  2.641 
Nrg1 neuregulin 1  2.5663 
Mtpn myotrophin  2.2567 
Agrn agrin  2.1852 
Rcan1 regulator of calcineurin 1  2.0934 
Foxp1 forkhead box P1  2.0145 
 RMC specific genes involved in Muscle cell 
differentiation 
 
Gene Symbol Gene Name Fold Change 
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8)  6.3234 
Myh11 myosin, heavy chain 11, smooth muscle  5.2547 
Tmod1 tropomodulin 1  3.2862 
Mapk12 mitogen-activated protein kinase 12  2.9091 
Bin1 bridging integrator 1  2.4971 
Gata6 GATA binding protein 6   2.1637 
Rxra retinoid X receptor alpha  2.1608 
Fgf6 fibroblast growth factor 6  2.1594 
Sox15 SRY (sex determining region Y)-box 15  2.1253 
Syne1 spectrin repeat containing, nuclear envelope 1  2.0433 
 AMC specific genes involved in Leydig cell 
differentiation 
 
Gene Symbol Gene Name Fold Change 
Ccnd1 cyclin D1   3.201 
Hsd17b10 hydroxysteroid (17-beta) dehydrogenase 10  2.144 
 RMC specific genes involved in Leydig cell 
differentiation 
 
Gene Symbol Gene Name Fold Change 
Map7 microtubule-associated protein 7  3.263 




 AMC specific genes involved in Cell 
Adhesion 
 
Gene Symbol Gene Name Fold Change 
Cd24 CD24 molecule  9.2544 
Pcdh18 protocadherin 18  6.9746 
Fat4 FAT tumor suppressor homolog 4 (Drosophila); similar to FAT 
tumor suppressor homolog 4  
6.4558 
Rac1 ras-related C3 botulinum toxin substrate 1  5.5863 
Pcdha1 protocadherin alpha 4  5.4411 
Adam9 ADAM metallopeptidase domain 9 (meltrin gamma)  5.0154 
Vcan versican  4.9595 
Atp2c1 ATPase, Ca++ transporting, type 2C, member 1  4.6029 
Reln reelin  4.568 
Lyve1 lymphatic vessel endothelial hyaluronan receptor 1  4.5102 
Ctnna2 catenin (cadherin associated protein), alpha 2  4.4094 
Ctgf connective tissue growth factor  4.374 
Col3a1 collagen, type III, alpha 1  4.3557 
Pcdh21 protocadherin 21  4.3513 
Fat1 FAT tumor suppressor homolog 1 (Drosophila)  4.2863 
Cdh13 cadherin 13  4.2509 
Vcl vinculin  4.2035 
Nell2 NEL-like 2 (chicken); similar to protein kinase C-binding 
protein NELL2  
4.1415 
Negr1 neuronal growth regulator 1  3.9103 
Cdh2 cadherin 2  3.7671 
Cdh13 cadherin 13  3.5609 
Nlgn1 neuroligin 1  3.5456 
Col14a1 collagen, type XIV, alpha 1  3.2817 
Pcdh17 protocadherin 17  3.1805 
Coro1a coronin, actin binding protein 1A  3.146 




Rac1 ras-related C3 botulinum toxin substrate 1  2.9728 
Tspan5 tetraspanin 5  2.9458 
Nid1 nidogen 1  2.8619 
Cd47 Cd47 molecule  2.843 
Cdh2 cadherin 2  2.8205 
Vcan versican  2.7777 
Plcxd2 phosphatidylinositol-specific phospholipase C, X domain 
containing 2; CD96 molecule  
2.777 
Astn1 astrotactin 1  2.7225 
Rasa1 RAS p21 protein activator (GTPase activating protein) 1  2.6875 
Tspan5 tetraspanin 5  2.6418 
Robo2 roundabout, axon guidance receptor, homolog 2 (Drosophila)  2.6021 
L1cam L1 cell adhesion molecule  2.5785 
Ctnnd2 catenin (cadherin-associated protein), delta 2 (neural 
plakophilin-related arm-repeat protein)  
2.5246 
Sdc3 syndecan 3  2.4525 
Nrp1 neuropilin 1  2.4484 
Rpsa similar to 40S ribosomal protein SA (p40) (34/67 kDa laminin 
receptor); ribosomal protein SA  
2.3925 
Robo2 roundabout, axon guidance receptor, homolog 2 (Drosophila)  2.3881 
Pdpn podoplanin  2.3404 
Rpl29 ribosomal protein L29; similar to 60S ribosomal protein L29 
(P23); ribosomal protein L29, pseudogene 1; similar to 60S 
ribosomal protein L29  
2.2795 
Aggf1 angiogenic factor with G patch and FHA domains 1  2.2678 
Gpr56 G protein-coupled receptor 56  2.2564 
Cdh11 cadherin 11  2.2357 
Cfdp1 similar to craniofacial development protein 1; craniofacial 
development protein 1  
2.194 
Ptprk protein tyrosine phosphatase, receptor type, K, extracellular 
region  
2.0808 




 RMC specific genes involved in Cell Adhesion  
Gene Symbol Gene Name Fold Change 
Hapln2 hyaluronan and proteoglycan link protein 2  9.8354 
Mag myelin-associated glycoprotein  8.1186 
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8)  6.3234 
Col11a2 collagen, type XI, alpha 2  5.6344 
Cldn11 claudin 11  5.1628 
Col27a1 collagen, type XXVII, alpha 1  4.2993 
Cntnap1 contactin associated protein 1  3.3452 
Adam8 ADAM metallopeptidase domain 8  3.3285 
Hapln4 hyaluronan and proteoglycan link protein 4  3.0551 
Tnxb tenascin XA  2.4498 
Cldn3 claudin 3  2.4098 
Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a  2.3378 
Pkp2 plakophilin 2  2.3106 
Tln1 talin 1  2.2627 
Pxn paxillin  2.2373 
F8 coagulation factor VIII, procoagulant component  2.2221 
Ttyh1 tweety homolog 1 (Drosophila)  2.2184 
Cntn2 contactin 2 (axonal)  2.1679 
Fgf6 fibroblast growth factor 6  2.1594 
F8 coagulation factor VIII, procoagulant component  2.1392 
Tek TEK tyrosine kinase, endothelial  2.1025 






Table 10. Monocytic genes enriched in AMC 
Gene 
Symbol 
Gene Name   Signal intensity in 
monocytes 
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix 
protein  
873.6817 
MCL1 myeloid cell leukemia sequence 1 (BCL2-related)  1814.955 
CSK c-src tyrosine kinase  2521.708 
RAC1 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP 
binding protein Rac1)  
3980.139 






Table 11. Pathways involving monocytic genes expressed by AMC 
Pathway Nr. of 
Genes 
p value Benjamini 
corrected P-
value 
REACT_17015:Metabolism of proteins 37 2.00E-16 1.20E-14 
REACT_71:Gene Expression 42 3.30E-13 8.60E-12 
REACT_1762:3' -UTR-mediated translational 
regulation 
24 6.20E-13 1.10E-11 
Ribosome 17 1.30E-10 1.40E-08 
REACT_6167:Influenza Infection 24 1.90E-09 2.50E-08 
Proteasome 10 1.20E-06 6.90E-05 
Pathogenic Escherichia coli infection 10 6.70E-06 2.50E-04 
P00029:Huntington disease 16 7.20E-06 5.80E-04 
REACT_13635:Regulation of activated PAK-2p34 by 
proteasome mediated degradation 
10 1.50E-05 1.50E-04 
P00049:Parkinson disease 12 3.40E-05 1.40E-03 
REACT_9035:APC/C:Cdh1-mediated degradation of 
Skp2 
11 3.80E-05 3.30E-04 
REACT_6850:Cdc20:Phospho-APC/C mediated 
degradation of Cyclin A 
11 7.60E-05 5.70E-04 
REACT_6185:HIV Infection 18 1.70E-04 1.10E-03 
REACT_11045:Signaling by Wnt 10 2.20E-04 1.30E-03 
P00016:Cytoskeletal regulation by Rho GTPase 10 1.40E-03 3.70E-02 
Fc gamma R-mediated phagocytosis 9 1.90E-03 5.10E-02 
P00018:EGF receptor signaling pathway 11 2.40E-03 4.80E-02 
P00034:Integrin signalling pathway 14 2.70E-03 4.20E-02 
Neurotrophin signaling pathway 10 2.70E-03 6.00E-02 
P00060:Ubiquitin proteasome pathway 8 4.30E-03 5.70E-02 
REACT_578:Apoptosis 12 4.90E-03 2.50E-02 




REACT_1538:Cell Cycle Checkpoints 11 5.30E-03 2.50E-02 
P00021:FGF signaling pathway 10 5.80E-03 6.50E-02 






Table 12. Monocytic genes enriched in RMC 
Gene 
Symbol 
Gene Name   Signal intensity in 
monocytes 
HLA-C major histocompatibility complex, class I, C; major 
histocompatibility complex, class I, B  
21045.38 
CD74 CD74 molecule, major histocompatibility complex, class II 
invariant chain  
19329.63 
CD302 CD302 molecule; lymphocyte antigen 75  4356.911 
LSP1 lymphocyte-specific protein 1  3342.203 






Table 13. Pathways involving monocytic genes expressed by RMC 
Pathway Nr. of 
Genes 
p value Benjamini 
corrected P-value 
Lysosome 5 2.00E-03 1.00E-01 
Antigen processing and presentation 4 6.60E-03 1.60E-01 
70.Signal_peptides_(MHC)_class_I _molecules 2 3.30E-02 1.60E-01 
Other glycan degradation 2 7.30E-02 7.40E-01 






Table 14. Stem-cell genes enriched in AMC 
Gene 
Symbol 
Gene Title Fold 
Change 
Function 
Rprm reprimo, TP53 dependent G2 arrest mediator 
candidate 
19.125 cell cycle arrest  
Cct8 chaperonin containing Tcp1, subunit 8 (theta) 13.525 protein folding 
RGD13103
52 
similar to HTGN29 protein; keratinocytes 
associated transmembrane protein 2 
13.419 Unknown 
Ect2 epithelial cell transforming sequence 2 
oncogene 
12.498 cell morphogenesis  
Cfl2 cofilin 2, muscle 12.211 protein binding 
Sh3bgrl SH3 domain binding glutamic acid-rich 
protein like 
9.7435 Unknown 
Bex4 brain expressed gene 4 9.4991 Unknown 
Cfl1 cofilin 1, non-muscle 9.3235 cytokinesis  
Cd24 CD24 molecule 9.2544 response to hypoxia  
Ns5atp9 NS5A (hepatitis C virus) transactivated protein 
9 
9.1968 Unknown 
Hnrnpab heterogeneous nuclear ribonucleoprotein A/B 8.8712 epithelial to mesenchymal 
transition  
Mycn v-mycmyelocytomatosis viral related 
oncogene, neuroblastoma derived (avian) 




similar to Myristoylated alanine-rich C-kinase 
substrate (MARCKS) (ACAMP-81)  
8.5949 actin binding  
Pex13 peroxisomal biogenesis factor 13 8.4726 fatty acid alpha-oxidation  
Maoa monoamine oxidase A 7.8728 catecholamine metabolic 
process  
Tmeff1 transmembrane protein with EGF-like and two 
follistatin-like domains 1 
7.7994 multicellular organismal 
development 
Ube2e3 ubiquitin-conjugating enzyme E2E 3, UBC4/5 
homolog (yeast) 
7.5905 modification-dependent protein 




Rab10 RAB10, member RAS oncogene family 7.5637 regulation of transcription, 
DNA-dependent  
Arf4 ADP-ribosylation factor 4 7.3522 transport  
Mapre1 microtubule-associated protein, RP/EB family, 
member 1 
7.0496 cell cycle  
Psme3 proteasome (prosome, macropain) activator 
subunit 3 
7.0045 cell adhesion  
Tmem43 transmembrane protein 43 6.9166 Unknown 
Mar5 membrane-associated ring finger (C3HC4) 5 6.9148 zinc ion binding 
Sqle Squaleneepoxidase 6.7699 cellular aromatic compound 
metabolic process  






Table 15. Stem-cell genes enriched in RMC 
Gene 
Symbol 





similar to CG9346-PA 2.9758 RNA processing 
Mll1 myeloid/lymphoid or mixed-lineage 
leukemia 1 
2.9906 DNA repair  
Fermt3 fermitin family homolog 3 (Drosophila) 3.0629 protein binding  
Ppfibp2 PTPRF interacting protein, binding protein 
2 (liprin beta 2) 
3.2355 DNA integration 
Mtf1 metal-regulatory transcription factor 1 3.2416 regulation of transcription, 
DNA-dependent  
Egr1 early growth response 1 3.2473 negative regulation of 
transcription from RNA 
polymerase II promoter  
Map7 microtubule-associated protein 7 3.263 cell morphogenesis  
Sfrs11 splicing factor, arginine/serine-rich 11 3.3325 nuclear mRNA splicing, via 
spliceosome 
Cd302 CD302 molecule 3.3742 binding  
Ctnnal1 catenin (cadherin associated protein), 
alpha-like 1 
3.4127 Unknown 
Cyp4f6 cytochrome P450 4F6 3.4649 leukotriene metabolic process  
Mlec Malectin 3.5937 carbohydrate metabolic process 
Smarca2 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, 
subfamily a, member 2 
3.663 negative regulation of cell 
proliferation  
Scn1b sodium channel, voltage-gated, type I, beta 3.6699 transport  
Tmbim1 transmembrane BAX inhibitor motif 
containing 1 
3.7938 Unknown 
Pck2 phosphoenolpyruvatecarboxykinase 2 
(mitochondrial) 




Tnni3 troponin I type 3 (cardiac) 4.0048 Vasculogenesis 
Nefh neurofilament, heavy polypeptide 4.2066 microtubule cytoskeleton 
organization  
Prpf38b PRP38 pre-mRNA processing factor 38 
(yeast) domain containing B 
4.3721 mRNA processing  
Tnnt1 troponin T type 1 (skeletal, slow) 4.4062 skeletal muscle contraction  
Zranb2 zinc finger, RAN-binding domain 
containing 2 
4.598 mRNA processing  
Zrsr1 zinc finger (CCCH type), RNA binding 
motif and serine/arginine rich 1 
5.0348 nucleotide binding  
Lrrc23 leucine rich repeat containing 23 5.1395 protein binding 
Akap8l A kinase (PRKA) anchor protein 8-like 5.6932 DNA binding  






Table 16. Genes downregulated by the Runx1-Runx1t1 complex were found 
to be specific to RMC 
Gene Symbol Gene Name Fold Change 
Mbp myelin basic protein 21.571 
Nefh neurofilament, heavy polypeptide 200kDa 4.2066 
S100B S100 calcium binding protein B 3.3308 
Csf1 colony stimulating factor 1 (macrophage) 2.8628 
Bin2 bridging integrator 2 2.5676 
Prkcd protein kinase C, delta 2.432 
Tnfsf13 tumor necrosis factor (ligand) superfamily, member 13 2.414 
Egr3 early growth response 3 2.1875 
Runx3 runt-related transcription factor 3 2.1139 






Table 17. Expression of cytokines in AMC and RMC 
Gene 
Symbol 




Tgfbr2 transforming growth factor, beta 
receptor II 
2.433333333 10.6 
Ifng interferon gamma 5.9 50.93333333 
Cxcl3 chemokine (C-X-C motif) 
ligand 3 
6.233333333 54.33333333 
Tgfb1 transforming growth factor, beta 
1 
6.266666667 21.23333333 
Ifnb1 interferon beta 1, fibroblast 6.833333333 81.83333333 
Tnf tumor necrosis factor (TNF 
superfamily, member 2) 
8.733333333 44.96666667 
Cxcl3 chemokine (C-X-C motif) 
ligand 3 
8.733333333 19.6 
Cd40lg CD40 ligand 9.266666667 26.4 
Il1r1 interleukin 1 receptor, type I 11.33333333 54.06666667 
Ccl2 chemokine (C-C motif) ligand 2 12.36666667 38.3 
Tnf tumor necrosis factor (TNF 
superfamily, member 2) 
13.66666667 13.3 
Cxcl12 chemokine (C-X-C motif) 
ligand 12 (stromal cell-derived 
factor 1) 
15.1 102.3333333 
Mmp3 matrix metallopeptidase 3 15.36666667 60.4 
Il4ra interleukin 4 receptor, alpha 19.2 128.2666667 
Cxcl3 chemokine (C-X-C motif) 
ligand 3 
19.23333333 41.73333333 
Il6 interleukin 6 20.86666667 14.93333333 
Il1r1 interleukin 1 receptor, type I 21.26666667 115.5 
Il12a interleukin 12a 29.3 136.7333333 




Cd14 CD14 molecule 36.2 37.8 
Bdnf brain derived neurotrophic 
factor 
41.86666667 55.2 
Il12b interleukin 12b 45 67.23333333 
Tgfbr1 transforming growth factor, beta 
receptor 1 
45.16666667 82.6 
Cxcl3 chemokine (C-X-C motif) 
ligand 3 
45.73333333 104.7 
Il13ra2 interleukin 13 receptor, alpha 2 49.4 93.56666667 
Cxcl3 chemokine (C-X-C motif) 
ligand 3 
50.13333333 39.2 
Tgfbr3 transforming growth factor, beta 
receptor III 
52.86666667 173.1333333 
Ccl5 chemokine (C-C motif) ligand 5 53.63333333 87.33333333 
Tgfbr3 transforming growth factor, beta 
receptor III 
68.56666667 102.3 
Il1b interleukin 1 beta 71 115.0666667 
Bdnf brain derived neurotrophic 
factor 
72.13333333 313 
Ccl4 chemokine (C-C motif) ligand 4 83.76666667 119.4 
Ccl3 chemokine (C-C motif) ligand 3 90.8 144.3333333 
Csf1r colony stimulating factor 1 
receptor 
118.0333333 285.3 
Il18 interleukin 18 122.2333333 335.9666667 
Cd40 CD40 molecule, TNF receptor 
superfamily member 5 
227.8333333 109.2 
Cxcl12 chemokine (C-X-C motif) 
ligand 12 (stromal cell-derived 
factor 1) 
330.4666667 425.4666667 
Ifngr1 interferon gamma receptor 1 994.7666667 566.4666667 
Cxcl12 chemokine (C-X-C motif) 






Tgfbr1 transforming growth factor, beta 
receptor 1 
1346.966667 996.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
